[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBDdKcEag3JggoTgin5JRGYZID_XAd39I6w_09VPgnr8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of Maryland, Baltimore",[4,6],"University of Maryland, Baltimore County",683,false,164,21,701946,78,366,[15,18,21,24,27,29,32,34],{"name":16,"count":17},"Schizophrenia",57,{"name":19,"count":20},"Schizoaffective Disorder",16,{"name":22,"count":23},"Prostate Cancer",13,{"name":25,"count":26},"Breast Cancer",12,{"name":28,"count":26},"HIV",{"name":30,"count":31},"Opioid Use Disorder",10,{"name":33,"count":31},"Cardiovascular Diseases",{"name":35,"count":31},"Traumatic Brain Injury",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02891954","Genetics of Response to Canagliflozin","2023-09-25","Canagliflozin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04150900","1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck","2024-09-01","Bavituximab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03299426","Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","2025-01-30","Vi-Typhoid Conjugate Vaccine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03909737","Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali","2025-03-01","Azithromycin to pregnant women",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04851301","Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","2025-12-30","Naloxone",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04698564","Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging","2025-12-31","Hyperpolarized 13C-Pyruvate",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06993597","Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","2026-03","Prostaglandin Analogue -Containing IOP-Lowering Therapy",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07093281","Intranasal LAIV Mucosal Immunity Examination","2026-04","Live Attenuated Influenza Vaccine",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06199154","Induction of Labor in Morbidly Obese Patients","2026-05","Misoprostol",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06636227","Diclofenac Dose Response Study","2026-05-31","Diclofenac 100mg",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,145,207,236,259,283,311,329,355,373,399,424,452,475,493,519,553,579,604,622,647,699,769,810,841,875,893,911,929,956,980,1007,1025,1051,1077,1095,1118,1136,1160,1186,1204,1222,1240,1268,1292,1317,1342,1360,1386,1409,1442,1546,1574,1610,1635,1669,1687,1711,1735,1759,1782,1800,1818,1836,1874,1900,1926,1949,1967,1985,2018,2045,2063,2083,2101,2125,2151,2169,2196,2278,2320,2369,2414,2451,2473,2495,2533,2556,2584,2602,2620,2638,2656,2681,2705,2731,2755,2778,2802,2826,2852,2878,2896,2926,2944,2967,2985,3011,3036,3060,3083,3109,3127,3152,3179,3197,3215,3239,3263,3286,3314,3340,3358,3376,3401,3427,3454,3472,3495,3520,3538,3563,3581,3605,3629,3647,3672,3690,3715,3738,3763,3781,3806,3830,3856,3874,3899,3922,3947,3965,3983,4005,4029,4047,4072,4098,4116,4139,4172,4196,4214,4242,4260,4284,4309,4332,4350,4373,4396,4423,4441,4463,4513,4560,4602,4644,4683,4709,4731,4762,4801,4838,4860,4882,4917,4935,4959,4982,5008,5026,5044,5068,5086,5112,5136,5158,5176,5200,5224,5247,5273,5298,5316,5334,5352,5378,5403,5421,5444,5468,5493,5517,5542,5560,5583,5608,5626,5644,5668,5686,5711,5735,5761,5785,5811,5829,5847,5865,5892,5910,5934,5959,5977,5999,6017,6035,6065,6083,6111,6129,6155,6173,6203,6227,6252,6270,6288,6313,6338,6356,6374,6398,6416,6434,6452,6470,6494,6520,6538,6560,6578,6599,6623,6647,6671,6689,6707,6733,6758,6776,6798,6821,6845,6869,6887,6913,6937,6955,6978,7004,7022,7040,7058,7076,7094,7118,7142,7164,7190,7208,7233,7258,7276,7300,7326,7344,7367,7390,7408,7430,7452,7477,7495,7513,7538,7561,7585,7611,7629,7655,7673,7700,7718,7736,7761,7779,7803,7821,7839,7861,7887,7905,7923,7947,7971,7989,8007,8025,8043,8065,8087,8110,8134,8152,8170,8193,8216,8275,8313,8356,8399,8443,8481,8533,8562,8591,8613,8635,8664,8695,8720,8744,8769,8794,8824,8842,8860,8878,8896,8914,8936,8960,8982,9007,9025,9048,9071,9089,9112,9130,9154,9172,9196,9219,9237,9259,9284,9302,9328,9346,9367,9391,9409,9431,9457,9475,9493,9514,9537,9555,9578,9601,9623,9645,9667,9690,9712,9730,9753,9778,9800,9827,9845,9863,9885],{"intervention":96,"totalTrials":97,"cells":98},"Vivotif Typhoid Oral Vaccine",3,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":143},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110,121,133],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT03970304","CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults","ACTIVE_NOT_RECRUITING",[92],"2027-08-01","2013-10-24",87,[119],"Typhoid Vaccination",[96],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":131},"NCT03705585","CVD 38000: Study of Responses to Vaccination With Typhoid and\u002For Cholera","RECRUITING",[92],"2029-05-31","2018-11-05",240,[130],"Typhoid and\u002For Cholera Vaccination",[96,132],"Vaxchora",{"nctId":134,"briefTitle":135,"status":124,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"NCT03971669","Blood Donor CVD 5000",[92],"2030-06-30","2004-01-16",150,[141],"Risk Reduction",[96],{"trials":144,"activeCount":101},[],{"intervention":146,"totalTrials":147,"cells":148},"Varenicline",4,{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":167,"PHASE4":179,"NA":205},{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":101},[155],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"enrollment":20,"conditions":163,"interventions":165},"NCT00554840","Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia","COMPLETED",[90],"2010-12","2011-04","2007-11",[164,16],"Cigarette Smoking",[166],"varenicline",{"trials":168,"activeCount":101},[169],{"nctId":170,"briefTitle":171,"status":158,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT02460900","Optimizing Smoking Cessation for People With HIV\u002FAIDS Who Smoke",[91],"2021-04","2016-07",184,[177,28],"Smoking",[146],{"trials":180,"activeCount":204,"soonestReadout":196},[181,191],{"nctId":182,"briefTitle":183,"status":158,"phases":184,"primaryCompletion":185,"completion":161,"start":186,"enrollment":187,"conditions":188,"interventions":190},"NCT00492349","Varenicline Adjunctive Treatment in Schizophrenia",[92],"2010-05","2007-05",91,[16,19,189],"Schizophreniform Disorder",[146],{"nctId":192,"briefTitle":193,"status":194,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":203},"NCT05694637","Botswana Smoking and Abstinence Reinforcement Trial","ENROLLING_BY_INVITATION",[92],"2027-02-01","2027-08-31","2023-07-25",750,[201,202],"Smoking Cessation","Hiv",[146],1,{"trials":206,"activeCount":101},[],{"intervention":132,"totalTrials":208,"cells":209},2,{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":234},{"trials":211,"activeCount":101},[],{"trials":213,"activeCount":101},[],{"trials":215,"activeCount":101},[],{"trials":217,"activeCount":101},[],{"trials":219,"activeCount":204,"soonestReadout":126},[220,230],{"nctId":221,"briefTitle":222,"status":223,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":97,"conditions":227,"interventions":229},"NCT03724357","Blood Donor CVD 9000","TERMINATED",[92],"2021-10-28","2018-11-04",[228],"Cholera Vaccination",[132],{"nctId":122,"briefTitle":123,"status":124,"phases":231,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":232,"interventions":233},[92],[130],[96,132],{"trials":235,"activeCount":101},[],{"intervention":76,"totalTrials":204,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":257},{"trials":239,"activeCount":101},[],{"trials":241,"activeCount":101},[],{"trials":243,"activeCount":101},[],{"trials":245,"activeCount":101},[],{"trials":247,"activeCount":204,"soonestReadout":75},[248],{"nctId":73,"briefTitle":74,"status":249,"phases":250,"primaryCompletion":75,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NOT_YET_RECRUITING",[92],"2026-07","2026-02",25,[255],"Impact of Vaccination",[76],{"trials":258,"activeCount":101},[],{"intervention":260,"totalTrials":204,"cells":261},"Iodinated Contrast Agent",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":281},{"trials":263,"activeCount":101},[],{"trials":265,"activeCount":101},[],{"trials":267,"activeCount":101},[],{"trials":269,"activeCount":101},[],{"trials":271,"activeCount":204,"soonestReadout":276},[272],{"nctId":273,"briefTitle":274,"status":124,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":9,"conditions":278,"interventions":280},"NCT05758701","CT TAVR Abdomen Study",[92],"2027-03-01","2023-09-19",[279],"Transcatheter Aortic Valve Replacement",[260],{"trials":282,"activeCount":101},[],{"intervention":284,"totalTrials":204,"cells":285},"Mineral Trioxide Aggregate",{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":309},{"trials":287,"activeCount":101},[],{"trials":289,"activeCount":101},[],{"trials":291,"activeCount":101},[],{"trials":293,"activeCount":101},[],{"trials":295,"activeCount":204,"soonestReadout":300},[296],{"nctId":297,"briefTitle":298,"status":113,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":307},"NCT02298504","Vital Pulp Treatment in Primary Teeth",[92],"2026-12-01","2018-07-01",76,[304,305,306],"Vital Pulp Therapies","Indirect Pulp Cap","Pulpotomy",[284,308],"Biodentin",{"trials":310,"activeCount":101},[],{"intervention":308,"totalTrials":204,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":327},{"trials":314,"activeCount":101},[],{"trials":316,"activeCount":101},[],{"trials":318,"activeCount":101},[],{"trials":320,"activeCount":101},[],{"trials":322,"activeCount":204,"soonestReadout":300},[323],{"nctId":297,"briefTitle":298,"status":113,"phases":324,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":325,"interventions":326},[92],[304,305,306],[284,308],{"trials":328,"activeCount":101},[],{"intervention":330,"totalTrials":204,"cells":331},"Ceftriaxone 1 gram daily",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":353},{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":101},[],{"trials":337,"activeCount":101},[],{"trials":339,"activeCount":101},[],{"trials":341,"activeCount":204,"soonestReadout":197},[342],{"nctId":343,"briefTitle":344,"status":249,"phases":345,"primaryCompletion":197,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT07537413","Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia",[92],"2028-02-28","2026-09-01",430,[350],"Community Acquired Pneumonia (CAP)",[330,352],"Ceftriaxone 2 grams daily",{"trials":354,"activeCount":101},[],{"intervention":352,"totalTrials":204,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":371},{"trials":358,"activeCount":101},[],{"trials":360,"activeCount":101},[],{"trials":362,"activeCount":101},[],{"trials":364,"activeCount":101},[],{"trials":366,"activeCount":204,"soonestReadout":197},[367],{"nctId":343,"briefTitle":344,"status":249,"phases":368,"primaryCompletion":197,"completion":346,"start":347,"enrollment":348,"conditions":369,"interventions":370},[92],[350],[330,352],{"trials":372,"activeCount":101},[],{"intervention":374,"totalTrials":204,"cells":375},"IL-23",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":397},{"trials":377,"activeCount":101},[],{"trials":379,"activeCount":101},[],{"trials":381,"activeCount":101},[],{"trials":383,"activeCount":101},[],{"trials":385,"activeCount":204,"soonestReadout":390},[386],{"nctId":387,"briefTitle":388,"status":249,"phases":389,"primaryCompletion":390,"completion":391,"start":347,"enrollment":392,"conditions":393,"interventions":396},"NCT07615075","Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia",[92],"2029-09-01","2030-09-01",40,[16,394,395],"Schizo Affective Disorder","Healthy",[374],{"trials":398,"activeCount":101},[],{"intervention":400,"totalTrials":204,"cells":401},"Isocapnic Oxygen",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":422},{"trials":403,"activeCount":101},[],{"trials":405,"activeCount":101},[],{"trials":407,"activeCount":101},[],{"trials":409,"activeCount":101},[],{"trials":411,"activeCount":204,"soonestReadout":416},[412],{"nctId":413,"briefTitle":414,"status":124,"phases":415,"primaryCompletion":416,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},"NCT05344274","Retinal Blood Flow and Autoregulation",[92],"2027-09","2022-05-23",90,[420],"Glaucoma",[400],{"trials":423,"activeCount":101},[],{"intervention":425,"totalTrials":204,"cells":426},"Local anesthesia injections",{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":450},{"trials":428,"activeCount":101},[],{"trials":430,"activeCount":101},[],{"trials":432,"activeCount":101},[],{"trials":434,"activeCount":101},[],{"trials":436,"activeCount":204,"soonestReadout":441},[437],{"nctId":438,"briefTitle":439,"status":124,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":449},"NCT07217626","Pre-Incision Peripheral Nerve Blocks for Lower Extremity Fracture Surgery in Older Adults",[92],"2026-12-31","2026-02-24",34,[445,446,447,448],"Lower Extremity Fracture","Surgical Fracture Repair","Orthopaedic Trauma","Orthogeriatric Fractures",[425],{"trials":451,"activeCount":101},[],{"intervention":56,"totalTrials":204,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":473},{"trials":455,"activeCount":101},[],{"trials":457,"activeCount":101},[],{"trials":459,"activeCount":101},[],{"trials":461,"activeCount":101},[],{"trials":463,"activeCount":204,"soonestReadout":55},[464],{"nctId":53,"briefTitle":54,"status":113,"phases":465,"primaryCompletion":55,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},[92],"2026-03-31","2020-09-24",99700,[470],"Stillbirths and Infant Mortality",[56,472],"Azithromycin to infants",{"trials":474,"activeCount":101},[],{"intervention":472,"totalTrials":204,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":491},{"trials":478,"activeCount":101},[],{"trials":480,"activeCount":101},[],{"trials":482,"activeCount":101},[],{"trials":484,"activeCount":101},[],{"trials":486,"activeCount":204,"soonestReadout":55},[487],{"nctId":53,"briefTitle":54,"status":113,"phases":488,"primaryCompletion":55,"completion":466,"start":467,"enrollment":468,"conditions":489,"interventions":490},[92],[470],[56,472],{"trials":492,"activeCount":101},[],{"intervention":494,"totalTrials":204,"cells":495},"Zinc Gluconate 30 MG",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":517},{"trials":497,"activeCount":101},[],{"trials":499,"activeCount":101},[],{"trials":501,"activeCount":101},[],{"trials":503,"activeCount":101},[],{"trials":505,"activeCount":204,"soonestReadout":510},[506],{"nctId":507,"briefTitle":508,"status":124,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":516},"NCT05835037","Effect of Zinc on Glucose Homeostasis",[92],"2028-07","2024-02-16",200,[514,515],"Prediabetic State","Hyperglycemia",[494],{"trials":518,"activeCount":101},[],{"intervention":51,"totalTrials":208,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":539,"PHASE4":549,"NA":551},{"trials":522,"activeCount":101},[],{"trials":524,"activeCount":101},[],{"trials":526,"activeCount":101},[527],{"nctId":528,"briefTitle":529,"status":158,"phases":530,"primaryCompletion":531,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":537},"NCT03614533","Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso",[90],"2019-08-22","2024-08-22","2018-12-03",251,[536],"Typhoid",[51,538],"Inactivated Poliovirus Vaccine",{"trials":540,"activeCount":204,"soonestReadout":50},[541],{"nctId":48,"briefTitle":49,"status":113,"phases":542,"primaryCompletion":50,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},[91],"2027-01-30","2018-02-21",30000,[536],[51,548],"Meningococcal A Conjugate Vaccine",{"trials":550,"activeCount":101},[],{"trials":552,"activeCount":101},[],{"intervention":554,"totalTrials":204,"cells":555},"Antibiotic Cement Bead Pouch",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":575,"NA":577},{"trials":557,"activeCount":101},[],{"trials":559,"activeCount":101},[],{"trials":561,"activeCount":101},[],{"trials":563,"activeCount":204,"soonestReadout":568},[564],{"nctId":565,"briefTitle":566,"status":124,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT05615844","Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy",[91],"2027-03-31","2027-10-01","2023-11-05",312,[573],"Open tíbia Fracture",[554],{"trials":576,"activeCount":101},[],{"trials":578,"activeCount":101},[],{"intervention":580,"totalTrials":204,"cells":581},"Methadone",{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":600,"NA":602},{"trials":583,"activeCount":101},[],{"trials":585,"activeCount":101},[],{"trials":587,"activeCount":101},[],{"trials":589,"activeCount":204,"soonestReadout":594},[590],{"nctId":591,"briefTitle":592,"status":124,"phases":593,"primaryCompletion":594,"completion":595,"start":596,"enrollment":139,"conditions":597,"interventions":599},"NCT05459402","Divided or Single Exposure (DOSE) Study",[90,91],"2027-06-01","2028-06-01","2023-02-21",[30,598,580],"Chronic Pain",[580,580],{"trials":601,"activeCount":101},[],{"trials":603,"activeCount":101},[],{"intervention":548,"totalTrials":204,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":618,"NA":620},{"trials":607,"activeCount":101},[],{"trials":609,"activeCount":101},[],{"trials":611,"activeCount":101},[],{"trials":613,"activeCount":204,"soonestReadout":50},[614],{"nctId":48,"briefTitle":49,"status":113,"phases":615,"primaryCompletion":50,"completion":543,"start":544,"enrollment":545,"conditions":616,"interventions":617},[91],[536],[51,548],{"trials":619,"activeCount":101},[],{"trials":621,"activeCount":101},[],{"intervention":623,"totalTrials":204,"cells":624},"Vancomycin",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":643,"NA":645},{"trials":626,"activeCount":101},[],{"trials":628,"activeCount":101},[],{"trials":630,"activeCount":101},[],{"trials":632,"activeCount":204,"soonestReadout":637},[633],{"nctId":634,"briefTitle":635,"status":249,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":512,"conditions":639,"interventions":642},"NCT07221708","Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin",[90,91],"2027-12-31","2026-03-01",[640,641],"Clostridioides Difficile","Vancomycin Resistance Enterococcus Faecium",[623],{"trials":644,"activeCount":101},[],{"trials":646,"activeCount":101},[],{"intervention":66,"totalTrials":147,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":674,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":650,"activeCount":101},[],{"trials":652,"activeCount":208,"soonestReadout":657},[653,663],{"nctId":654,"briefTitle":655,"status":124,"phases":656,"primaryCompletion":657,"completion":637,"start":658,"enrollment":659,"conditions":660,"interventions":662},"NCT04772456","Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas",[89],"2026-08-31","2020-08-11",5,[661],"Glioma",[66],{"nctId":664,"briefTitle":665,"status":124,"phases":666,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT06103201","Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury",[89],"2026-11-26","2027-11-26","2023-10-26",15,[35,672],"Subarachnoid Hemorrhage",[66],{"trials":675,"activeCount":208,"soonestReadout":65},[676,682],{"nctId":63,"briefTitle":64,"status":124,"phases":677,"primaryCompletion":65,"completion":637,"start":678,"enrollment":679,"conditions":680,"interventions":681},[90],"2020-12-01",20,[22],[66],{"nctId":683,"briefTitle":684,"status":124,"phases":685,"primaryCompletion":300,"completion":686,"start":687,"enrollment":253,"conditions":688,"interventions":692},"NCT05697406","HP Pyruvate MRI in Cancers",[89,90],"2028-12-01","2024-06-24",[689,690,691],"Image","Warburg Effect","Tumors",[66],{"trials":694,"activeCount":101},[],{"trials":696,"activeCount":101},[],{"trials":698,"activeCount":101},[],{"intervention":700,"totalTrials":659,"cells":701},"Gemcitabine",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":719,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":204,"soonestReadout":710},[706],{"nctId":707,"briefTitle":708,"status":124,"phases":709,"primaryCompletion":710,"completion":711,"start":712,"enrollment":670,"conditions":713,"interventions":716},"NCT06546969","Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer",[89],"2027-12","2028-12","2024-10-29",[714,715],"Biliary Tract Cancer","Cholangiocarcinoma",[700,717,718],"Cisplatin","Durvalumab",{"trials":720,"activeCount":208,"soonestReadout":441},[721,730,742,753],{"nctId":722,"briefTitle":723,"status":124,"phases":724,"primaryCompletion":441,"completion":441,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT03652428","Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)",[89,90],"2019-04-02",24,[728],"Locally Advanced Pancreatic Cancer",[700],{"nctId":731,"briefTitle":732,"status":733,"phases":734,"primaryCompletion":735,"completion":736,"start":737,"enrollment":101,"conditions":738,"interventions":740},"NCT02538432","Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors","WITHDRAWN",[90],"2019-12","2021-12","2017-06",[22,739,25],"Non-Small Cell Lung Cancer",[741,700],"RQ-00000007",{"nctId":743,"briefTitle":744,"status":158,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":752},"NCT00390182","Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)",[89,90],"2011-05","2003-10",38,[750,751],"Gastrointestinal Neoplasms","Ovarian Neoplasms",[700],{"nctId":754,"briefTitle":755,"status":113,"phases":756,"primaryCompletion":757,"completion":637,"start":758,"enrollment":670,"conditions":759,"interventions":761},"NCT04098081","1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma",[90],"2027-02-17","2019-12-12",[760],"Advanced Pancreatic Cancer",[762,700],"galeterone",{"trials":764,"activeCount":101},[],{"trials":766,"activeCount":101},[],{"trials":768,"activeCount":101},[],{"intervention":770,"totalTrials":208,"cells":771},"Lofexidine",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":804,"PHASE4":806,"NA":808},{"trials":773,"activeCount":101},[],{"trials":775,"activeCount":101},[],{"trials":777,"activeCount":208,"soonestReadout":782},[778,793],{"nctId":779,"briefTitle":780,"status":124,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":789},"NCT05027919","Assessing a Clinically-meaningful Opioid Withdrawal Phenotype",[90],"2026-11-30","2027-02-28","2021-12-01",60,[787,30,788],"Opioid Withdrawal","Opioid Craving",[790,791,792,770],"Hydromorphone","Naloxone + lofexidine pretreatment","Naloxone + placebo pretreatment",{"nctId":794,"briefTitle":795,"status":124,"phases":796,"primaryCompletion":797,"completion":568,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT05511909","Evaluating Buspirone to Treat Opioid Withdrawal",[90],"2027-01-31","2023-03-15",100,[30,787,788,801],"Anxiety",[803,770],"Buspirone",{"trials":805,"activeCount":101},[],{"trials":807,"activeCount":101},[],{"trials":809,"activeCount":101},[],{"intervention":61,"totalTrials":208,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":101},[],{"trials":817,"activeCount":204,"soonestReadout":60},[818,828],{"nctId":58,"briefTitle":59,"status":113,"phases":819,"primaryCompletion":60,"completion":782,"start":820,"enrollment":821,"conditions":822,"interventions":827},[89,90],"2021-11-01",259,[823,824,825,826],"Pain","Virtual Reality","Placebo","Temporomandibular Disorder",[61],{"nctId":829,"briefTitle":830,"status":158,"phases":831,"primaryCompletion":65,"completion":65,"start":820,"enrollment":832,"conditions":833,"interventions":834},"NCT03897998","Neural Correlates of Hypoalgesia Driven by Observation",[90],211,[823,824,825],[61],{"trials":836,"activeCount":101},[],{"trials":838,"activeCount":101},[],{"trials":840,"activeCount":101},[],{"intervention":842,"totalTrials":208,"cells":843},"Neuromuscular Blocking Agents",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":101},[],{"trials":849,"activeCount":204,"soonestReadout":657},[850,860],{"nctId":851,"briefTitle":852,"status":124,"phases":853,"primaryCompletion":657,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":859},"NCT04545424","Trial of Therapeutic Hypothermia in Patients With ARDS",[90],"2026-10-31","2021-06-29",340,[858],"Respiratory Distress Syndrome, Adult",[842],{"nctId":861,"briefTitle":862,"status":733,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":101,"conditions":866,"interventions":868},"NCT03376854","Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS",[90],"2021-04-27","2018-05-01",[858,867],"Sars-CoV2",[842],{"trials":870,"activeCount":101},[],{"trials":872,"activeCount":101},[],{"trials":874,"activeCount":101},[],{"intervention":790,"totalTrials":204,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":878,"activeCount":101},[],{"trials":880,"activeCount":101},[],{"trials":882,"activeCount":204,"soonestReadout":782},[883],{"nctId":779,"briefTitle":780,"status":124,"phases":884,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":885,"interventions":886},[90],[787,30,788],[790,791,792,770],{"trials":888,"activeCount":101},[],{"trials":890,"activeCount":101},[],{"trials":892,"activeCount":101},[],{"intervention":791,"totalTrials":204,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":896,"activeCount":101},[],{"trials":898,"activeCount":101},[],{"trials":900,"activeCount":204,"soonestReadout":782},[901],{"nctId":779,"briefTitle":780,"status":124,"phases":902,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":903,"interventions":904},[90],[787,30,788],[790,791,792,770],{"trials":906,"activeCount":101},[],{"trials":908,"activeCount":101},[],{"trials":910,"activeCount":101},[],{"intervention":792,"totalTrials":204,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":914,"activeCount":101},[],{"trials":916,"activeCount":101},[],{"trials":918,"activeCount":204,"soonestReadout":782},[919],{"nctId":779,"briefTitle":780,"status":124,"phases":920,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":921,"interventions":922},[90],[787,30,788],[790,791,792,770],{"trials":924,"activeCount":101},[],{"trials":926,"activeCount":101},[],{"trials":928,"activeCount":101},[],{"intervention":930,"totalTrials":204,"cells":931},"Human papillomavirus (HPV) vaccine, 9-valent",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":933,"activeCount":101},[],{"trials":935,"activeCount":101},[],{"trials":937,"activeCount":204,"soonestReadout":942},[938],{"nctId":939,"briefTitle":940,"status":124,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":949},"NCT06624839","Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV",[90],"2027-01","2028-01","2025-03-15",120,[947,948,28],"Human Papilloma Virus","Anal Dysplasia",[930],{"trials":951,"activeCount":101},[],{"trials":953,"activeCount":101},[],{"trials":955,"activeCount":101},[],{"intervention":957,"totalTrials":204,"cells":958},"Semaglutide",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":101},[],{"trials":964,"activeCount":204,"soonestReadout":251},[965],{"nctId":966,"briefTitle":967,"status":124,"phases":968,"primaryCompletion":251,"completion":969,"start":970,"enrollment":392,"conditions":971,"interventions":973},"NCT06691243","Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV",[90],"2027-03","2025-08-07",[972,28],"Cocaine Use Disorder",[957],{"trials":975,"activeCount":101},[],{"trials":977,"activeCount":101},[],{"trials":979,"activeCount":101},[],{"intervention":981,"totalTrials":204,"cells":982},"niraparib\u002Fabiraterone acetate",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":984,"activeCount":101},[],{"trials":986,"activeCount":101},[],{"trials":988,"activeCount":204,"soonestReadout":993},[989],{"nctId":990,"briefTitle":991,"status":113,"phases":992,"primaryCompletion":993,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":999},"NCT06212583","High-Risk Metachronous Oligometastatic Prostate Cancer Trial",[90],"2028-12-31","2029-12-31","2024-04-17",88,[22,998],"Oligometastatic Disease",[981,1000],"Androgen deprivation therapy",{"trials":1002,"activeCount":101},[],{"trials":1004,"activeCount":101},[],{"trials":1006,"activeCount":101},[],{"intervention":1000,"totalTrials":204,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1010,"activeCount":101},[],{"trials":1012,"activeCount":101},[],{"trials":1014,"activeCount":204,"soonestReadout":993},[1015],{"nctId":990,"briefTitle":991,"status":113,"phases":1016,"primaryCompletion":993,"completion":994,"start":995,"enrollment":996,"conditions":1017,"interventions":1018},[90],[22,998],[981,1000],{"trials":1020,"activeCount":101},[],{"trials":1022,"activeCount":101},[],{"trials":1024,"activeCount":101},[],{"intervention":1026,"totalTrials":204,"cells":1027},"Daratumumab",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":101},[],{"trials":1033,"activeCount":204,"soonestReadout":1038},[1034],{"nctId":1035,"briefTitle":1036,"status":124,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1044},"NCT07075510","Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders",[89,90],"2030-10-01","2032-10-01","2025-10-23",30,[1043],"Plasma Cell Disorder",[1026],{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":101},[],{"trials":1050,"activeCount":101},[],{"intervention":1052,"totalTrials":204,"cells":1053},"TSCV",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1055,"activeCount":101},[],{"trials":1057,"activeCount":101},[],{"trials":1059,"activeCount":204,"soonestReadout":1064},[1060],{"nctId":1061,"briefTitle":1062,"status":124,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1069},"NCT05784701","Trivalent Salmonella Conjugate Vaccine (TSCV)",[90],"2027-01-05","2027-12-30","2023-04-05",800,[1062],[1052,1052,1070],"Typbar-TCV",{"trials":1072,"activeCount":101},[],{"trials":1074,"activeCount":101},[],{"trials":1076,"activeCount":101},[],{"intervention":1070,"totalTrials":204,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":101},[],{"trials":1082,"activeCount":101},[],{"trials":1084,"activeCount":204,"soonestReadout":1064},[1085],{"nctId":1061,"briefTitle":1062,"status":124,"phases":1086,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1087,"interventions":1088},[90],[1062],[1052,1052,1070],{"trials":1090,"activeCount":101},[],{"trials":1092,"activeCount":101},[],{"trials":1094,"activeCount":101},[],{"intervention":46,"totalTrials":204,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1098,"activeCount":101},[],{"trials":1100,"activeCount":101},[],{"trials":1102,"activeCount":204,"soonestReadout":45},[1103],{"nctId":43,"briefTitle":44,"status":113,"phases":1104,"primaryCompletion":45,"completion":1105,"start":1106,"enrollment":1107,"conditions":1108,"interventions":1110},[90],"2027-01-01","2020-01-13",7,[1109],"Squamous Cell Carcinoma",[46,1111],"Pembrolizumab",{"trials":1113,"activeCount":101},[],{"trials":1115,"activeCount":101},[],{"trials":1117,"activeCount":101},[],{"intervention":1111,"totalTrials":204,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1121,"activeCount":101},[],{"trials":1123,"activeCount":101},[],{"trials":1125,"activeCount":204,"soonestReadout":45},[1126],{"nctId":43,"briefTitle":44,"status":113,"phases":1127,"primaryCompletion":45,"completion":1105,"start":1106,"enrollment":1107,"conditions":1128,"interventions":1129},[90],[1109],[46,1111],{"trials":1131,"activeCount":101},[],{"trials":1133,"activeCount":101},[],{"trials":1135,"activeCount":101},[],{"intervention":1137,"totalTrials":204,"cells":1138},"Imdusiran",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":204,"soonestReadout":300},[1145],{"nctId":1146,"briefTitle":1147,"status":124,"phases":1148,"primaryCompletion":300,"completion":1149,"start":1150,"enrollment":31,"conditions":1151,"interventions":1153},"NCT06154278","Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B",[90],"2027-07-01","2024-07-25",[1152],"Chronic Hepatitis B",[1137],{"trials":1155,"activeCount":101},[],{"trials":1157,"activeCount":101},[],{"trials":1159,"activeCount":101},[],{"intervention":1161,"totalTrials":204,"cells":1162},"Treatment with Ketamine",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1164,"activeCount":101},[],{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":204,"soonestReadout":1173},[1169],{"nctId":1170,"briefTitle":1171,"status":124,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1178},"NCT06943859","Ketamine for Opioid Use Disorder",[90],"2028-08-31","2029-08-31","2026-02-04",50,[30],[1161,1179],"Treatment with Very Low Dose Ketamine",{"trials":1181,"activeCount":101},[],{"trials":1183,"activeCount":101},[],{"trials":1185,"activeCount":101},[],{"intervention":1179,"totalTrials":204,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1189,"activeCount":101},[],{"trials":1191,"activeCount":101},[],{"trials":1193,"activeCount":204,"soonestReadout":1173},[1194],{"nctId":1170,"briefTitle":1171,"status":124,"phases":1195,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1196,"interventions":1197},[90],[30],[1161,1179],{"trials":1199,"activeCount":101},[],{"trials":1201,"activeCount":101},[],{"trials":1203,"activeCount":101},[],{"intervention":803,"totalTrials":204,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":101},[],{"trials":1209,"activeCount":101},[],{"trials":1211,"activeCount":204,"soonestReadout":797},[1212],{"nctId":794,"briefTitle":795,"status":124,"phases":1213,"primaryCompletion":797,"completion":568,"start":798,"enrollment":799,"conditions":1214,"interventions":1215},[90],[30,787,788,801],[803,770],{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":101},[],{"trials":1221,"activeCount":101},[],{"intervention":762,"totalTrials":204,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1225,"activeCount":101},[],{"trials":1227,"activeCount":101},[],{"trials":1229,"activeCount":204,"soonestReadout":757},[1230],{"nctId":754,"briefTitle":755,"status":113,"phases":1231,"primaryCompletion":757,"completion":637,"start":758,"enrollment":670,"conditions":1232,"interventions":1233},[90],[760],[762,700],{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"trials":1239,"activeCount":101},[],{"intervention":1241,"totalTrials":204,"cells":1242},"Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1244,"activeCount":101},[],{"trials":1246,"activeCount":101},[],{"trials":1248,"activeCount":204,"soonestReadout":1253},[1249],{"nctId":1250,"briefTitle":1251,"status":124,"phases":1252,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1261},"NCT04050280","CLAG-GO for Patients With Persistent, Relapsed or Refractory AML",[90],"2026-06-30","2027-02","2019-11-01",39,[1258,1259,1260],"Acute Myeloid Leukemia, Adult","Acute Myeloid Leukemia Recurrent","Acute Myeloid Leukemia, Relapsed, Adult",[1241],{"trials":1263,"activeCount":101},[],{"trials":1265,"activeCount":101},[],{"trials":1267,"activeCount":101},[],{"intervention":1269,"totalTrials":204,"cells":1270},"Lebrikizumab",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1272,"activeCount":101},[],{"trials":1274,"activeCount":101},[],{"trials":1276,"activeCount":204,"soonestReadout":710},[1277],{"nctId":1278,"briefTitle":1279,"status":249,"phases":1280,"primaryCompletion":710,"completion":1281,"start":1282,"enrollment":670,"conditions":1283,"interventions":1285},"NCT07620561","Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients",[90],"2028-03","2026-06",[1284],"Prurigo Nodularis (PN)",[1269],{"trials":1287,"activeCount":101},[],{"trials":1289,"activeCount":101},[],{"trials":1291,"activeCount":101},[],{"intervention":1293,"totalTrials":204,"cells":1294},"Systemic Therapy",{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1296,"activeCount":101},[],{"trials":1298,"activeCount":101},[],{"trials":1300,"activeCount":204,"soonestReadout":1305},[1301],{"nctId":1302,"briefTitle":1303,"status":124,"phases":1304,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1310},"NCT05223803","TERPS Trial for de Novo Oligometastic Prostate Cancer",[90],"2026-07-31","2027-07-31","2022-10-18",122,[22,998],[1293],{"trials":1312,"activeCount":101},[],{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[],{"intervention":1318,"totalTrials":204,"cells":1319},"Ankle robot training group",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1336,"PHASE4":1338,"NA":1340},{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":204,"soonestReadout":1330},[1326],{"nctId":1327,"briefTitle":1328,"status":124,"phases":1329,"primaryCompletion":1330,"completion":441,"start":1331,"enrollment":785,"conditions":1332,"interventions":1334},"NCT04550728","Hybrid Robot+FES Stroke Rehabilitation",[89,90],"2026-10-01","2021-08-01",[1333],"Stroke",[1318,1335],"Ankle robot training and functional electrical stimulation(FES) group",{"trials":1337,"activeCount":101},[],{"trials":1339,"activeCount":101},[],{"trials":1341,"activeCount":101},[],{"intervention":1335,"totalTrials":204,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1345,"activeCount":101},[],{"trials":1347,"activeCount":101},[],{"trials":1349,"activeCount":204,"soonestReadout":1330},[1350],{"nctId":1327,"briefTitle":1328,"status":124,"phases":1351,"primaryCompletion":1330,"completion":441,"start":1331,"enrollment":785,"conditions":1352,"interventions":1353},[89,90],[1333],[1318,1335],{"trials":1355,"activeCount":101},[],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"intervention":1361,"totalTrials":204,"cells":1362},"Onvansertib",{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1380,"PHASE4":1382,"NA":1384},{"trials":1364,"activeCount":101},[],{"trials":1366,"activeCount":101},[],{"trials":1368,"activeCount":204,"soonestReadout":197},[1369],{"nctId":1370,"briefTitle":1371,"status":124,"phases":1372,"primaryCompletion":197,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1379},"NCT05450965","Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer",[90],"2027-11-30","2022-07-19",37,[1377,1378],"Small-cell Lung Cancer","Small Cell Lung Carcinoma",[1361],{"trials":1381,"activeCount":101},[],{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[],{"intervention":1387,"totalTrials":204,"cells":1388},"Arginine vasopressin",{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1390,"activeCount":101},[],{"trials":1392,"activeCount":101},[],{"trials":1394,"activeCount":204,"soonestReadout":1253},[1395],{"nctId":1396,"briefTitle":1397,"status":113,"phases":1398,"primaryCompletion":1253,"completion":441,"start":1399,"enrollment":392,"conditions":1400,"interventions":1402},"NCT03446456","Vasopressin and Pain Perception in the Brain",[89,90],"2018-09-17",[1401],"Acute Pain",[1387],{"trials":1404,"activeCount":101},[],{"trials":1406,"activeCount":101},[],{"trials":1408,"activeCount":101},[],{"intervention":41,"totalTrials":208,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1423,"PHASE3":1425,"PHASE4":1427,"NA":1440},{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":204,"soonestReadout":40},[1415],{"nctId":38,"briefTitle":39,"status":113,"phases":1416,"primaryCompletion":40,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},[89],"2026-12-25","2016-09",700,[1421],"Diabetes Mellitus, Type 2",[41],{"trials":1424,"activeCount":101},[],{"trials":1426,"activeCount":101},[],{"trials":1428,"activeCount":101},[1429],{"nctId":1430,"briefTitle":1431,"status":223,"phases":1432,"primaryCompletion":1433,"completion":1433,"start":1434,"enrollment":1041,"conditions":1435,"interventions":1439},"NCT02462421","Pharmacogenetics of SGLT2 Inhibitors",[92],"2021-12-31","2015-06-01",[1436,1437,1438],"Diabetes Mellitus","Gout","Hyperuricemia",[41],{"trials":1441,"activeCount":101},[],{"intervention":1443,"totalTrials":1444,"cells":1445},"cisplatin",9,{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1479,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1447,"activeCount":101},[],{"trials":1449,"activeCount":204,"soonestReadout":710},[1450,1463,1467],{"nctId":1451,"briefTitle":1452,"status":223,"phases":1453,"primaryCompletion":1454,"completion":1455,"start":1456,"enrollment":1457,"conditions":1458,"interventions":1461},"NCT01110226","Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies",[89],"2015-10-22","2015-10-27","2010-04-27",23,[1459,1460],"Non-Small Cell Lung Cancer, Small Cell Lung Cancer","Platinum Responsive Malignancies",[1462,717],"KML-001",{"nctId":707,"briefTitle":708,"status":124,"phases":1464,"primaryCompletion":710,"completion":711,"start":712,"enrollment":670,"conditions":1465,"interventions":1466},[89],[714,715],[700,717,718],{"nctId":1468,"briefTitle":1469,"status":1470,"phases":1471,"primaryCompletion":1254,"completion":1472,"start":1253,"enrollment":1176,"conditions":1473,"interventions":1475},"NCT05403723","Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","SUSPENDED",[89],"2027-08",[1474],"Extensive-stage Small-cell Lung Cancer",[1476,1477,717,1478],"Durvalumab 50 MG\u002F1 ML Intravenous Solution","Etoposide","Carboplatin",{"trials":1480,"activeCount":101},[1481,1496,1503,1513,1522,1532],{"nctId":1482,"briefTitle":1483,"status":158,"phases":1484,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":1487,"interventions":1489},"NCT00003399","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma",[90],"2002-09","1998-09",[1488],"Multiple Myeloma and Plasma Cell Neoplasm",[1490,1443,1491,1492,1493,1494,1495],"carmustine","cyclophosphamide","dexamethasone","etoposide","melphalan","paclitaxel",{"nctId":1497,"briefTitle":1483,"status":158,"phases":1498,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":1500,"interventions":1501},"NCT00003401",[90],"1999-01",[1488],[1490,1443,1491,1492,1493,1502,1494,1495],"gemcitabine hydrochloride",{"nctId":1504,"briefTitle":1505,"status":158,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1486,"enrollment":1508,"conditions":1509,"interventions":1510},"NCT00003400","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer",[90],"2000-03",45,[22],[1511,1490,1443,1494,1512],"filgrastim","vinorelbine tartrate",{"nctId":1514,"briefTitle":1515,"status":158,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1486,"enrollment":1518,"conditions":1519,"interventions":1521},"NCT00003413","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer",[90],"2001-02",32,[1520],"Ovarian Cancer",[1511,1490,1443,1494,1495],{"nctId":1523,"briefTitle":1524,"status":158,"phases":1525,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":1528,"interventions":1531},"NCT00003402","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[90],"2002-12",35,[1529,1530],"Leukemia","Lymphoma",[1490,1443,1491,1492,1493,1494,1495],{"nctId":1533,"briefTitle":1534,"status":158,"phases":1535,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":1536,"interventions":1537},"NCT00003397","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],"rituximab","sargramostim",{"trials":1541,"activeCount":101},[],{"trials":1543,"activeCount":101},[],{"trials":1545,"activeCount":101},[],{"intervention":718,"totalTrials":208,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1556,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1549,"activeCount":101},[],{"trials":1551,"activeCount":204,"soonestReadout":710},[1552],{"nctId":707,"briefTitle":708,"status":124,"phases":1553,"primaryCompletion":710,"completion":711,"start":712,"enrollment":670,"conditions":1554,"interventions":1555},[89],[714,715],[700,717,718],{"trials":1557,"activeCount":101},[1558],{"nctId":1559,"briefTitle":1560,"status":733,"phases":1561,"primaryCompletion":1562,"completion":1563,"start":1564,"enrollment":101,"conditions":1565,"interventions":1567},"NCT02885727","Durvalumab Plus \"Booster\" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)",[90],"2020-12","2022-12","2017-07",[1566],"Metastatic Pancreas Cancer",[718],{"trials":1569,"activeCount":101},[],{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"intervention":1575,"totalTrials":208,"cells":1576},"chemotherapy",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":204,"soonestReadout":1281},[1581,1591],{"nctId":1582,"briefTitle":1583,"status":158,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":1586,"enrollment":726,"conditions":1587,"interventions":1589},"NCT00002677","Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors",[89],"2003-03","1995-08",[22,1588],"Unspecified Adult Solid Tumor, Protocol Specific",[1575,1590],"tributyrin",{"nctId":1592,"briefTitle":1593,"status":124,"phases":1594,"primaryCompletion":1281,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT06800339","A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer",[89],"2030-03","2025-04-22",18,[739],[1600,1601],"Nivolumab","Chemotherapy",{"trials":1603,"activeCount":101},[],{"trials":1605,"activeCount":101},[],{"trials":1607,"activeCount":101},[],{"trials":1609,"activeCount":101},[],{"intervention":1611,"totalTrials":204,"cells":1612},"Semaglutide Pen Injector [Ozempic]",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1614,"activeCount":101},[],{"trials":1616,"activeCount":204,"soonestReadout":782},[1617],{"nctId":1618,"briefTitle":1619,"status":124,"phases":1620,"primaryCompletion":782,"completion":637,"start":1621,"enrollment":1622,"conditions":1623,"interventions":1626},"NCT05071898","Pharmacogenetics of Response to GLP1R Agonists",[89],"2022-04-11",600,[1624,1625],"Obesity","Diabetes Type 2",[1611],{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[],{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"intervention":1636,"totalTrials":204,"cells":1637},"CD19.20.22 CAR T cells",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1639,"activeCount":101},[],{"trials":1641,"activeCount":204,"soonestReadout":1149},[1642],{"nctId":1643,"briefTitle":1644,"status":194,"phases":1645,"primaryCompletion":1149,"completion":1646,"start":1647,"enrollment":670,"conditions":1648,"interventions":1659},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[89],"2028-07-01","2024-10-28",[1649,1650,1651,1652,1653,1654,1655,1656,1657,1658],"B-Cell Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Follicular Lymphoma","Transformed Follicular Lymphoma (tFL)","Mantle Cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Richter Transformation","Marginal Zone Lymphoma",[1636,1660],"Fludarabine and Cyclophosphamide",{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":101},[],{"trials":1666,"activeCount":101},[],{"trials":1668,"activeCount":101},[],{"intervention":1660,"totalTrials":204,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1672,"activeCount":101},[],{"trials":1674,"activeCount":204,"soonestReadout":1149},[1675],{"nctId":1643,"briefTitle":1644,"status":194,"phases":1676,"primaryCompletion":1149,"completion":1646,"start":1647,"enrollment":670,"conditions":1677,"interventions":1678},[89],[1649,1650,1651,1652,1653,1654,1655,1656,1657,1658],[1636,1660],{"trials":1680,"activeCount":101},[],{"trials":1682,"activeCount":101},[],{"trials":1684,"activeCount":101},[],{"trials":1686,"activeCount":101},[],{"intervention":1688,"totalTrials":204,"cells":1689},"glibenclamide",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1691,"activeCount":101},[],{"trials":1693,"activeCount":204,"soonestReadout":1698},[1694],{"nctId":1695,"briefTitle":1696,"status":249,"phases":1697,"primaryCompletion":1698,"completion":390,"start":347,"enrollment":31,"conditions":1699,"interventions":1702},"NCT07221799","OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis",[89],"2028-09-01",[1700,1701],"Multiple Sclerosis","Neuropathic Pain",[1688],{"trials":1704,"activeCount":101},[],{"trials":1706,"activeCount":101},[],{"trials":1708,"activeCount":101},[],{"trials":1710,"activeCount":101},[],{"intervention":1712,"totalTrials":204,"cells":1713},"PfSPZ Challenge",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1727,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1715,"activeCount":101},[],{"trials":1717,"activeCount":204,"soonestReadout":1722},[1718],{"nctId":1719,"briefTitle":1720,"status":249,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1518,"conditions":1724,"interventions":1726},"NCT07558122","Malaria CVD 36000; Gates INV090205",[89],"2026-08","2026-06-13",[1725],"Malaria (Plasmodium Falciparum)",[1712],{"trials":1728,"activeCount":101},[],{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":101},[],{"trials":1734,"activeCount":101},[],{"intervention":1736,"totalTrials":204,"cells":1737},"Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1751,"PHASE3":1753,"PHASE4":1755,"NA":1757},{"trials":1739,"activeCount":101},[],{"trials":1741,"activeCount":204,"soonestReadout":854},[1742],{"nctId":1743,"briefTitle":1744,"status":124,"phases":1745,"primaryCompletion":854,"completion":1746,"start":1747,"enrollment":31,"conditions":1748,"interventions":1750},"NCT04843852","TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B",[89],"2027-04-01","2025-10-16",[1749,1152],"Hepatitis B",[1736],{"trials":1752,"activeCount":101},[],{"trials":1754,"activeCount":101},[],{"trials":1756,"activeCount":101},[],{"trials":1758,"activeCount":101},[],{"intervention":86,"totalTrials":204,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1774,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1762,"activeCount":101},[],{"trials":1764,"activeCount":204,"soonestReadout":85},[1765],{"nctId":83,"briefTitle":84,"status":124,"phases":1766,"primaryCompletion":85,"completion":657,"start":1767,"enrollment":726,"conditions":1768,"interventions":1771},[89],"2024-12-01",[1769,1770],"Alcohol Use Disorder (AUD)","Alcohol-Related Disorders",[86,1772,1773],"Diclofenac 75mg","Diclofenac 50mg",{"trials":1775,"activeCount":101},[],{"trials":1777,"activeCount":101},[],{"trials":1779,"activeCount":101},[],{"trials":1781,"activeCount":101},[],{"intervention":1772,"totalTrials":204,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1792,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":101},[],{"trials":1787,"activeCount":204,"soonestReadout":85},[1788],{"nctId":83,"briefTitle":84,"status":124,"phases":1789,"primaryCompletion":85,"completion":657,"start":1767,"enrollment":726,"conditions":1790,"interventions":1791},[89],[1769,1770],[86,1772,1773],{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":101},[],{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[],{"intervention":1773,"totalTrials":204,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1810,"PHASE3":1812,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":204,"soonestReadout":85},[1806],{"nctId":83,"briefTitle":84,"status":124,"phases":1807,"primaryCompletion":85,"completion":657,"start":1767,"enrollment":726,"conditions":1808,"interventions":1809},[89],[1769,1770],[86,1772,1773],{"trials":1811,"activeCount":101},[],{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":101},[],{"intervention":1600,"totalTrials":204,"cells":1819},{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1821,"activeCount":101},[],{"trials":1823,"activeCount":204,"soonestReadout":1281},[1824],{"nctId":1592,"briefTitle":1593,"status":124,"phases":1825,"primaryCompletion":1281,"completion":1595,"start":1596,"enrollment":1597,"conditions":1826,"interventions":1827},[89],[739],[1600,1601],{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[],{"trials":1833,"activeCount":101},[],{"trials":1835,"activeCount":101},[],{"intervention":1837,"totalTrials":208,"cells":1838},"Fluoxetine",{"EARLY_PHASE1":1839,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1840,"activeCount":204,"soonestReadout":1845},[1841,1853],{"nctId":1842,"briefTitle":1843,"status":124,"phases":1844,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":785,"conditions":1848,"interventions":1850},"NCT03228732","The Effects of Fluoxetine and\u002For DHEA",[88],"2026-09-15","2026-12-15","2017-12-19",[1849],"Type 1 Diabetes Mellitus",[1837,1851,1852],"DHEA","Fluoxetine and DHEA",{"nctId":1854,"briefTitle":1855,"status":158,"phases":1856,"primaryCompletion":1857,"completion":1857,"start":1858,"enrollment":1859,"conditions":1860,"interventions":1863},"NCT01672255","Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)",[88],"2025-05","2012-10",64,[1861,1862],"Type 1 Diabetes","Hypoglycemia Associated Autonomic Failure",[1837],{"trials":1865,"activeCount":101},[],{"trials":1867,"activeCount":101},[],{"trials":1869,"activeCount":101},[],{"trials":1871,"activeCount":101},[],{"trials":1873,"activeCount":101},[],{"intervention":1875,"totalTrials":204,"cells":1876},"Glucagon-Like Peptide- 1 (GLP-1)",{"EARLY_PHASE1":1877,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1896,"NA":1898},{"trials":1878,"activeCount":204,"soonestReadout":1883},[1879],{"nctId":1880,"briefTitle":1881,"status":113,"phases":1882,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":1886,"conditions":1887,"interventions":1889},"NCT01858896","GLP-1 and Hypoglycemia",[88],"2026-09","2026-12","2013-07",28,[1888],"Type 2 Diabetes Mellitus",[1875],{"trials":1891,"activeCount":101},[],{"trials":1893,"activeCount":101},[],{"trials":1895,"activeCount":101},[],{"trials":1897,"activeCount":101},[],{"trials":1899,"activeCount":101},[],{"intervention":1901,"totalTrials":204,"cells":1902},"MRP and High Protein Supplement",{"EARLY_PHASE1":1903,"PHASE1":1916,"PHASE2":1918,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1904,"activeCount":204,"soonestReadout":1909},[1905],{"nctId":1906,"briefTitle":1907,"status":249,"phases":1908,"primaryCompletion":1909,"completion":1910,"start":276,"enrollment":12,"conditions":1911,"interventions":1915},"NCT05326633","Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors",[88],"2029-01-30","2029-10-30",[1912,1913,1914],"Critical Illness","Sarcopenia","ICU Acquired Weakness",[1901],{"trials":1917,"activeCount":101},[],{"trials":1919,"activeCount":101},[],{"trials":1921,"activeCount":101},[],{"trials":1923,"activeCount":101},[],{"trials":1925,"activeCount":101},[],{"intervention":1927,"totalTrials":204,"cells":1928},"Diclofenac",{"EARLY_PHASE1":1929,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1930,"activeCount":204,"soonestReadout":1722},[1931],{"nctId":1932,"briefTitle":1933,"status":113,"phases":1934,"primaryCompletion":1722,"completion":1722,"start":1935,"enrollment":26,"conditions":1936,"interventions":1938},"NCT06029296","Diclofenac as a KMO Inhibitor",[88],"2024-07-31",[1937],"Alcohol Use Disorder",[1927],{"trials":1940,"activeCount":101},[],{"trials":1942,"activeCount":101},[],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[],{"trials":1948,"activeCount":101},[],{"intervention":1851,"totalTrials":204,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1952,"activeCount":204,"soonestReadout":1845},[1953],{"nctId":1842,"briefTitle":1843,"status":124,"phases":1954,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":785,"conditions":1955,"interventions":1956},[88],[1849],[1837,1851,1852],{"trials":1958,"activeCount":101},[],{"trials":1960,"activeCount":101},[],{"trials":1962,"activeCount":101},[],{"trials":1964,"activeCount":101},[],{"trials":1966,"activeCount":101},[],{"intervention":1852,"totalTrials":204,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1975,"PHASE2":1977,"PHASE3":1979,"PHASE4":1981,"NA":1983},{"trials":1970,"activeCount":204,"soonestReadout":1845},[1971],{"nctId":1842,"briefTitle":1843,"status":124,"phases":1972,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":785,"conditions":1973,"interventions":1974},[88],[1849],[1837,1851,1852],{"trials":1976,"activeCount":101},[],{"trials":1978,"activeCount":101},[],{"trials":1980,"activeCount":101},[],{"trials":1982,"activeCount":101},[],{"trials":1984,"activeCount":101},[],{"intervention":81,"totalTrials":208,"cells":1986},{"EARLY_PHASE1":1987,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1988,"activeCount":204,"soonestReadout":80},[1989],{"nctId":78,"briefTitle":79,"status":124,"phases":1990,"primaryCompletion":80,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1997},[88],"2026-10","2024-07-15",162,[1995,1996],"Morbid Obesity","Pregnancy",[81],{"trials":1999,"activeCount":101},[],{"trials":2001,"activeCount":101},[],{"trials":2003,"activeCount":101},[],{"trials":2005,"activeCount":101},[],{"trials":2007,"activeCount":101},[2008],{"nctId":2009,"briefTitle":2010,"status":733,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":101,"conditions":2015,"interventions":2017},"NCT03796416","Obesity Study to Assess Induction of Labor",[93],"2022-01","2025-07","2019-12-01",[2016],"Induction of Labor Affected Fetus \u002F Newborn",[81],{"intervention":2019,"totalTrials":204,"cells":2020},"Topical Benzocaine",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2022,"activeCount":101},[],{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"trials":2032,"activeCount":204,"soonestReadout":1884},[2033],{"nctId":2034,"briefTitle":2035,"status":124,"phases":2036,"primaryCompletion":1884,"completion":2037,"start":2038,"enrollment":512,"conditions":2039,"interventions":2043},"NCT06691269","Photobiomodulation and Tooth Analgesia",[93],"2027-06","2025-07-07",[2040,2041,2042],"Dental Anaesthesia","Dental Pain","Dental Analgesia",[2019,2044],"Local Anesthesia",{"intervention":2044,"totalTrials":204,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2048,"activeCount":101},[],{"trials":2050,"activeCount":101},[],{"trials":2052,"activeCount":101},[],{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"trials":2058,"activeCount":204,"soonestReadout":1884},[2059],{"nctId":2034,"briefTitle":2035,"status":124,"phases":2060,"primaryCompletion":1884,"completion":2037,"start":2038,"enrollment":512,"conditions":2061,"interventions":2062},[93],[2040,2041,2042],[2019,2044],{"intervention":71,"totalTrials":204,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2066,"activeCount":101},[],{"trials":2068,"activeCount":101},[],{"trials":2070,"activeCount":101},[],{"trials":2072,"activeCount":101},[],{"trials":2074,"activeCount":101},[],{"trials":2076,"activeCount":204,"soonestReadout":70},[2077],{"nctId":68,"briefTitle":69,"status":124,"phases":2078,"primaryCompletion":70,"completion":1282,"start":2079,"enrollment":785,"conditions":2080,"interventions":2081},[],"2025-09-01",[420],[71,2082],"Beta Blocker",{"intervention":2082,"totalTrials":204,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2095},{"trials":2086,"activeCount":101},[],{"trials":2088,"activeCount":101},[],{"trials":2090,"activeCount":101},[],{"trials":2092,"activeCount":101},[],{"trials":2094,"activeCount":101},[],{"trials":2096,"activeCount":204,"soonestReadout":70},[2097],{"nctId":68,"briefTitle":69,"status":124,"phases":2098,"primaryCompletion":70,"completion":1282,"start":2079,"enrollment":785,"conditions":2099,"interventions":2100},[],[420],[71,2082],{"intervention":2102,"totalTrials":204,"cells":2103},"Ublituximab",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2105,"activeCount":101},[],{"trials":2107,"activeCount":101},[],{"trials":2109,"activeCount":101},[],{"trials":2111,"activeCount":101},[],{"trials":2113,"activeCount":101},[],{"trials":2115,"activeCount":204,"soonestReadout":1065},[2116],{"nctId":2117,"briefTitle":2118,"status":124,"phases":2119,"primaryCompletion":1065,"completion":2120,"start":2121,"enrollment":1041,"conditions":2122,"interventions":2124},"NCT06864936","Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis",[93],"2028-01-30","2026-05-01",[2123],"Multiple Sclerosis (MS) - Relapsing-remitting",[2102],{"intervention":2126,"totalTrials":204,"cells":2127},"Ginkgo App-based Exercise Training",{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2136,"NA":2138},{"trials":2129,"activeCount":101},[],{"trials":2131,"activeCount":101},[],{"trials":2133,"activeCount":101},[],{"trials":2135,"activeCount":101},[],{"trials":2137,"activeCount":101},[],{"trials":2139,"activeCount":204,"soonestReadout":1149},[2140],{"nctId":2141,"briefTitle":2142,"status":249,"phases":2143,"primaryCompletion":1149,"completion":115,"start":2144,"enrollment":785,"conditions":2145,"interventions":2149},"NCT07411339","Ginkgo Active App-Based Exercise Training",[93],"2026-07-01",[2146,2147,2148],"Healthy Adult Participants","Controlled Hypertension","Controlled Diabetes",[2126,2150],"NIA Booklet Exercise",{"intervention":2150,"totalTrials":204,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2154,"activeCount":101},[],{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":101},[],{"trials":2160,"activeCount":101},[],{"trials":2162,"activeCount":101},[],{"trials":2164,"activeCount":204,"soonestReadout":1149},[2165],{"nctId":2141,"briefTitle":2142,"status":249,"phases":2166,"primaryCompletion":1149,"completion":115,"start":2144,"enrollment":785,"conditions":2167,"interventions":2168},[93],[2146,2147,2148],[2126,2150],{"intervention":2170,"totalTrials":204,"cells":2171},"Tenofovir Alafenamide",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2173,"activeCount":101},[],{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[],{"trials":2179,"activeCount":101},[],{"trials":2181,"activeCount":101},[],{"trials":2183,"activeCount":204,"soonestReadout":2188},[2184],{"nctId":2185,"briefTitle":2186,"status":124,"phases":2187,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":2191,"conditions":2192,"interventions":2195},"NCT02995252","The HOPE Study: Characterizing Patients With Hepatitis B and C",[],"2034-07","2034-12","2014-12",550,[2193,2194],"Hepatitis B， Chronic","Hepatitis C",[2170],{"intervention":1491,"totalTrials":1444,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2212,"PHASE3":2262,"PHASE4":2264,"NA":2276},{"trials":2199,"activeCount":101},[],{"trials":2201,"activeCount":101},[2202],{"nctId":2203,"briefTitle":2204,"status":158,"phases":2205,"primaryCompletion":2206,"completion":2206,"start":2207,"conditions":2208,"interventions":2210},"NCT00005946","Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation",[89],"2002-06","2000-10",[1529,1530,1488,2209],"Myelodysplastic Syndromes",[1511,2211,1491,1493],"therapeutic allogeneic lymphocytes",{"trials":2213,"activeCount":101},[2214,2218,2222,2231,2235,2247,2258],{"nctId":1482,"briefTitle":1483,"status":158,"phases":2215,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":2216,"interventions":2217},[90],[1488],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1497,"briefTitle":1483,"status":158,"phases":2219,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":2220,"interventions":2221},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":2223,"briefTitle":2224,"status":158,"phases":2225,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":2226,"conditions":2227,"interventions":2228},"NCT00003396","Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[90],42,[1529,1530,1488,2209],[2229,2230,1491,1494],"anti-thymocyte globulin","graft-versus-tumor induction therapy",{"nctId":1523,"briefTitle":1524,"status":158,"phases":2232,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":2233,"interventions":2234},[90],[1529,1530],[1490,1443,1491,1492,1493,1494,1495],{"nctId":2236,"briefTitle":2237,"status":158,"phases":2238,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":2243,"interventions":2244},"NCT00003727","Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia",[90],"2005-03","2008-02","1999-03",22,[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],"recombinant interferon alfa","therapeutic autologous lymphocytes",{"nctId":2248,"briefTitle":2249,"status":158,"phases":2250,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":2253,"interventions":2255},"NCT00046852","Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma",[89,90],"2004-11","2001-12",[2254,1488],"Infection",[1511,2256,2246,2257,1490,1491,1494],"pneumococcal polyvalent vaccine","therapeutic tumor infiltrating lymphocytes",{"nctId":1533,"briefTitle":1534,"status":158,"phases":2259,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":2260,"interventions":2261},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":2263,"activeCount":101},[],{"trials":2265,"activeCount":101},[2266],{"nctId":2267,"briefTitle":2268,"status":158,"phases":2269,"primaryCompletion":2270,"completion":2270,"start":1486,"enrollment":1508,"conditions":2271,"interventions":2274},"NCT00003398","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",[92],"2000-05",[2272,2273,1529,1530,1488,2209],"Anemia","Graft Versus Host Disease",[2229,1511,1491,2275],"thiotepa",{"trials":2277,"activeCount":101},[],{"intervention":1511,"totalTrials":1107,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2288,"PHASE3":2310,"PHASE4":2312,"NA":2318},{"trials":2281,"activeCount":101},[],{"trials":2283,"activeCount":101},[2284],{"nctId":2203,"briefTitle":2204,"status":158,"phases":2285,"primaryCompletion":2206,"completion":2206,"start":2207,"conditions":2286,"interventions":2287},[89],[1529,1530,1488,2209],[1511,2211,1491,1493],{"trials":2289,"activeCount":101},[2290,2294,2298,2302,2306],{"nctId":1504,"briefTitle":1505,"status":158,"phases":2291,"primaryCompletion":1507,"completion":1507,"start":1486,"enrollment":1508,"conditions":2292,"interventions":2293},[90],[22],[1511,1490,1443,1494,1512],{"nctId":1514,"briefTitle":1515,"status":158,"phases":2295,"primaryCompletion":1517,"completion":1517,"start":1486,"enrollment":1518,"conditions":2296,"interventions":2297},[90],[1520],[1511,1490,1443,1494,1495],{"nctId":2236,"briefTitle":2237,"status":158,"phases":2299,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":2300,"interventions":2301},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":2248,"briefTitle":2249,"status":158,"phases":2303,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":2304,"interventions":2305},[89,90],[2254,1488],[1511,2256,2246,2257,1490,1491,1494],{"nctId":1533,"briefTitle":1534,"status":158,"phases":2307,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":2308,"interventions":2309},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":2311,"activeCount":101},[],{"trials":2313,"activeCount":101},[2314],{"nctId":2267,"briefTitle":2268,"status":158,"phases":2315,"primaryCompletion":2270,"completion":2270,"start":1486,"enrollment":1508,"conditions":2316,"interventions":2317},[92],[2272,2273,1529,1530,1488,2209],[2229,1511,1491,2275],{"trials":2319,"activeCount":101},[],{"intervention":2321,"totalTrials":97,"cells":2322},"Placebos",{"EARLY_PHASE1":2323,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2355,"NA":2367},{"trials":2324,"activeCount":101},[2325],{"nctId":2326,"briefTitle":2327,"status":733,"phases":2328,"primaryCompletion":2329,"completion":2329,"start":2330,"enrollment":101,"conditions":2331,"interventions":2333},"NCT04355832","Glucagon-like Peptide-1 in Type 1 Diabetes",[88],"2025-09-24","2020-06-24",[2332],"Type1 Diabetes Mellitus",[2334,2321],"Glucagon-like peptide-1",{"trials":2336,"activeCount":101},[],{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[2341],{"nctId":2342,"briefTitle":2343,"status":158,"phases":2344,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":2347,"conditions":2348,"interventions":2353},"NCT03126968","Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies",[90,91],"2021-07-02","2017-07-01",66,[2349,2350,2351,2352],"Lung Transplant; Complications, Mechanical","Lung Transplant; Complications","Bleeding","Hemoptysis",[2354,2321],"Topical epinephrine",{"trials":2356,"activeCount":101},[2357],{"nctId":2358,"briefTitle":2359,"status":733,"phases":2360,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":101,"conditions":2363,"interventions":2365},"NCT03631654","Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes",[92],"2021-08-31","2020-10-01",[2364],"Heart Failure NYHA Class IV",[2366,2321],"Ivabradine",{"trials":2368,"activeCount":101},[],{"intervention":2370,"totalTrials":208,"cells":2371},"Aspirin",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2412},{"trials":2373,"activeCount":101},[],{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":101},[],{"trials":2379,"activeCount":101},[],{"trials":2381,"activeCount":101},[2382,2394],{"nctId":2383,"briefTitle":2384,"status":158,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":2388,"conditions":2389,"interventions":2392},"NCT00799396","Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)",[92],"2012-02","2006-07",682,[2390,2391],"Platelet Aggregation Inhibitors","Coronary Heart Disease",[2393,2370],"Clopidogrel",{"nctId":2395,"briefTitle":2396,"status":158,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":2399,"enrollment":2400,"conditions":2401,"interventions":2411},"NCT03188705","CES1 Carriers in the PAPI Study",[92],"2020-01-17","2019-10-14",6,[2402,2403,2404,33,2405,2406,2407,2408,2409,2410],"Heart Diseases","Coronary Disease","Coronary Artery Disease","Myocardial Ischemia","Artery Occlusion","Aspirin Sensitivity","Clopidogrel, Poor Metabolism of","Platelet Dysfunction","Platelet Thrombus",[2393,2370],{"trials":2413,"activeCount":101},[],{"intervention":2415,"totalTrials":208,"cells":2416},"Dihydroartemisinin-Piperaquine",{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2449},{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[],{"trials":2422,"activeCount":101},[],{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[2427,2440],{"nctId":2428,"briefTitle":2429,"status":158,"phases":2430,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":2433,"conditions":2434,"interventions":2437},"NCT05980156","Comparing Chemoprevention Drugs for School-based Malaria Control",[92],"2023-07-28","2023-02-13",646,[2435,2436],"Malaria,Falciparum","Anemia in Children",[2415,2438,2439],"Chloroquine","Sulfadoxine pyrimethamine",{"nctId":2441,"briefTitle":2442,"status":158,"phases":2443,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2448},"NCT05244954","Comparing Chemoprevention Approaches for School-based Malaria Control",[92],"2022-08-26","2022-02-01",746,[2435,2436],[2415,2438],{"trials":2450,"activeCount":101},[],{"intervention":2438,"totalTrials":208,"cells":2452},{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2459,"PHASE4":2461,"NA":2471},{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[],{"trials":2458,"activeCount":101},[],{"trials":2460,"activeCount":101},[],{"trials":2462,"activeCount":101},[2463,2467],{"nctId":2428,"briefTitle":2429,"status":158,"phases":2464,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":2433,"conditions":2465,"interventions":2466},[92],[2435,2436],[2415,2438,2439],{"nctId":2441,"briefTitle":2442,"status":158,"phases":2468,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":2469,"interventions":2470},[92],[2435,2436],[2415,2438],{"trials":2472,"activeCount":101},[],{"intervention":2229,"totalTrials":208,"cells":2474},{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2485,"PHASE4":2487,"NA":2493},{"trials":2476,"activeCount":101},[],{"trials":2478,"activeCount":101},[],{"trials":2480,"activeCount":101},[2481],{"nctId":2223,"briefTitle":2224,"status":158,"phases":2482,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":2226,"conditions":2483,"interventions":2484},[90],[1529,1530,1488,2209],[2229,2230,1491,1494],{"trials":2486,"activeCount":101},[],{"trials":2488,"activeCount":101},[2489],{"nctId":2267,"briefTitle":2268,"status":158,"phases":2490,"primaryCompletion":2270,"completion":2270,"start":1486,"enrollment":1508,"conditions":2491,"interventions":2492},[92],[2272,2273,1529,1530,1488,2209],[2229,1511,1491,2275],{"trials":2494,"activeCount":101},[],{"intervention":2496,"totalTrials":208,"cells":2497},"Tacrolimus",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2515,"PHASE4":2517,"NA":2531},{"trials":2499,"activeCount":101},[],{"trials":2501,"activeCount":101},[],{"trials":2503,"activeCount":101},[2504],{"nctId":2505,"briefTitle":2506,"status":158,"phases":2507,"primaryCompletion":2508,"completion":2508,"start":2509,"conditions":2510,"interventions":2511},"NCT00006350","Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[90],"2001-11","2000-01",[1529,1530,1488,2209],[2512,2211,2513,2514],"daclizumab","mycophenolate mofetil","tacrolimus",{"trials":2516,"activeCount":101},[],{"trials":2518,"activeCount":101},[2519],{"nctId":2520,"briefTitle":2521,"status":223,"phases":2522,"primaryCompletion":2523,"completion":2524,"start":2525,"enrollment":1518,"conditions":2526,"interventions":2529},"NCT00931255","Tacrolimus to Sirolimus Conversion for Delayed Graft Function",[92],"2014-06","2014-07","2009-04",[2527,2528],"Kidney Transplant","Delayed Graft Function",[2496,2530],"Sirolimus",{"trials":2532,"activeCount":101},[],{"intervention":2534,"totalTrials":204,"cells":2535},"Elbasvir \u002F Grazoprevir Oral Tablet [Zepatier]",{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2542,"PHASE4":2544,"NA":2554},{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[],{"trials":2541,"activeCount":101},[],{"trials":2543,"activeCount":101},[],{"trials":2545,"activeCount":101},[2546],{"nctId":2547,"briefTitle":2548,"status":158,"phases":2549,"primaryCompletion":2550,"completion":2550,"start":2551,"enrollment":117,"conditions":2552,"interventions":2553},"NCT03823911","Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication",[92],"2022-12-31","2018-11-18",[33,2194,202],[2534],{"trials":2555,"activeCount":101},[],{"intervention":2557,"totalTrials":204,"cells":2558},"fast itraconazole",{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2567,"NA":2582},{"trials":2560,"activeCount":101},[],{"trials":2562,"activeCount":101},[],{"trials":2564,"activeCount":101},[],{"trials":2566,"activeCount":101},[],{"trials":2568,"activeCount":101},[2569],{"nctId":2570,"briefTitle":2571,"status":158,"phases":2572,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2576,"interventions":2578},"NCT04035187","Itraconazole Oral Absorption",[92],"2022-05-21","2020-02-10",17,[2577],"Fungal Infection",[2557,2579,2580,2581],"medium itraconazole","slow itraconazole","oral itraconazole solution",{"trials":2583,"activeCount":101},[],{"intervention":2579,"totalTrials":204,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2600},{"trials":2587,"activeCount":101},[],{"trials":2589,"activeCount":101},[],{"trials":2591,"activeCount":101},[],{"trials":2593,"activeCount":101},[],{"trials":2595,"activeCount":101},[2596],{"nctId":2570,"briefTitle":2571,"status":158,"phases":2597,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2598,"interventions":2599},[92],[2577],[2557,2579,2580,2581],{"trials":2601,"activeCount":101},[],{"intervention":2580,"totalTrials":204,"cells":2603},{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2618},{"trials":2605,"activeCount":101},[],{"trials":2607,"activeCount":101},[],{"trials":2609,"activeCount":101},[],{"trials":2611,"activeCount":101},[],{"trials":2613,"activeCount":101},[2614],{"nctId":2570,"briefTitle":2571,"status":158,"phases":2615,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2616,"interventions":2617},[92],[2577],[2557,2579,2580,2581],{"trials":2619,"activeCount":101},[],{"intervention":2581,"totalTrials":204,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2628,"PHASE4":2630,"NA":2636},{"trials":2623,"activeCount":101},[],{"trials":2625,"activeCount":101},[],{"trials":2627,"activeCount":101},[],{"trials":2629,"activeCount":101},[],{"trials":2631,"activeCount":101},[2632],{"nctId":2570,"briefTitle":2571,"status":158,"phases":2633,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2634,"interventions":2635},[92],[2577],[2557,2579,2580,2581],{"trials":2637,"activeCount":101},[],{"intervention":2439,"totalTrials":204,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2654},{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":101},[],{"trials":2647,"activeCount":101},[],{"trials":2649,"activeCount":101},[2650],{"nctId":2428,"briefTitle":2429,"status":158,"phases":2651,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":2433,"conditions":2652,"interventions":2653},[92],[2435,2436],[2415,2438,2439],{"trials":2655,"activeCount":101},[],{"intervention":2657,"totalTrials":204,"cells":2658},"Glecaprevir\u002Fpibrentasvir",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2679},{"trials":2660,"activeCount":101},[],{"trials":2662,"activeCount":101},[],{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":101},[],{"trials":2668,"activeCount":101},[2669],{"nctId":2670,"briefTitle":2671,"status":733,"phases":2672,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":101,"conditions":2676,"interventions":2678},"NCT04235049","Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)",[92],"2022-03-30","2024-10-30","2021-10-01",[2677],"HCV Infection",[2657],{"trials":2680,"activeCount":101},[],{"intervention":2682,"totalTrials":204,"cells":2683},"Drug: cimetidine",{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2690,"PHASE4":2692,"NA":2703},{"trials":2685,"activeCount":101},[],{"trials":2687,"activeCount":101},[],{"trials":2689,"activeCount":101},[],{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[2694],{"nctId":2695,"briefTitle":2696,"status":158,"phases":2697,"primaryCompletion":2698,"completion":2699,"start":2700,"enrollment":253,"conditions":2701,"interventions":2702},"NCT01256879","Cimetidine Biowaivers",[92],"2014-04","2014-05","2011-03",[395],[2682],{"trials":2704,"activeCount":101},[],{"intervention":2706,"totalTrials":204,"cells":2707},"Calcitonin",{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2714,"PHASE4":2716,"NA":2729},{"trials":2709,"activeCount":101},[],{"trials":2711,"activeCount":101},[],{"trials":2713,"activeCount":101},[],{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[2718],{"nctId":2719,"briefTitle":2720,"status":158,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":2725,"conditions":2726,"interventions":2728},"NCT03342001","Hypothyroidism Treated With Calcitonin",[92],"2019-06-30","2019-08-14","2018-06-18",11,[2727],"Hypothyroidism",[2706],{"trials":2730,"activeCount":101},[],{"intervention":2732,"totalTrials":204,"cells":2733},"Acthar gel",{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2742,"NA":2753},{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"trials":2739,"activeCount":101},[],{"trials":2741,"activeCount":101},[],{"trials":2743,"activeCount":101},[2744],{"nctId":2745,"briefTitle":2746,"status":223,"phases":2747,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":2400,"conditions":2750,"interventions":2752},"NCT02546492","Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar",[92],"2021-05-27","2016-08",[2751],"Transplant Glomerulopathy",[2732],{"trials":2754,"activeCount":101},[],{"intervention":2756,"totalTrials":204,"cells":2757},"prasugrel",{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2764,"PHASE4":2766,"NA":2776},{"trials":2759,"activeCount":101},[],{"trials":2761,"activeCount":101},[],{"trials":2763,"activeCount":101},[],{"trials":2765,"activeCount":101},[],{"trials":2767,"activeCount":101},[2768],{"nctId":2769,"briefTitle":2770,"status":223,"phases":2771,"primaryCompletion":1885,"completion":1885,"start":2386,"enrollment":1444,"conditions":2772,"interventions":2774},"NCT01452152","Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study",[92],[33,2773],"Acute Coronary Syndrome",[2775,2756],"clopidogrel",{"trials":2777,"activeCount":101},[],{"intervention":2779,"totalTrials":204,"cells":2780},"Silymarin",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2787,"PHASE4":2789,"NA":2800},{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[],{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[2791],{"nctId":2792,"briefTitle":2793,"status":158,"phases":2794,"completion":2795,"start":2796,"enrollment":512,"conditions":2797,"interventions":2799},"NCT00412763","Efficacy of Silymarin for Acute Hepatitis",[92],"2005-10","2003-07",[2798],"Hepatitis",[2779],{"trials":2801,"activeCount":101},[],{"intervention":2803,"totalTrials":204,"cells":2804},"H.P. Acthar Gel",{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2811,"PHASE4":2813,"NA":2824},{"trials":2806,"activeCount":101},[],{"trials":2808,"activeCount":101},[],{"trials":2810,"activeCount":101},[],{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[2815],{"nctId":2816,"briefTitle":2817,"status":158,"phases":2818,"primaryCompletion":2819,"completion":2819,"start":2820,"enrollment":147,"conditions":2821,"interventions":2823},"NCT02298491","Treatment of CNS Sarcoidosis With H.P. Acthar Gel",[92],"2020-11","2016-05",[2822],"CNS Sarcoidosis",[2803],{"trials":2825,"activeCount":101},[],{"intervention":2827,"totalTrials":204,"cells":2828},"Post-transplant Grazoprevir and Elbasvir",{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2850},{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":101},[],{"trials":2836,"activeCount":101},[],{"trials":2838,"activeCount":101},[2839],{"nctId":2840,"briefTitle":2841,"status":158,"phases":2842,"primaryCompletion":2843,"completion":2844,"start":2845,"enrollment":10,"conditions":2846,"interventions":2849},"NCT02902120","HCV Treatment Immune Response With Grazoprevir\u002FElbasvir Before or After Renal Transplant",[92],"2021-09-01","2022-06-08","2017-05-01",[2194,2847,2848],"Renal Insufficiency, Chronic","Disorder of Transplanted Kidney",[2827],{"trials":2851,"activeCount":101},[],{"intervention":2853,"totalTrials":204,"cells":2854},"Brand sodium ferric gluconate",{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2861,"PHASE4":2863,"NA":2876},{"trials":2856,"activeCount":101},[],{"trials":2858,"activeCount":101},[],{"trials":2860,"activeCount":101},[],{"trials":2862,"activeCount":101},[],{"trials":2864,"activeCount":101},[2865],{"nctId":2866,"briefTitle":2867,"status":158,"phases":2868,"primaryCompletion":2869,"completion":2870,"start":2871,"enrollment":2872,"conditions":2873,"interventions":2874},"NCT02399449","IV Iron Safety: Evaluation of Iron Species in Healthy Subjects",[92],"2019-03-22","2019-04-25","2017-09-15",110,[2272],[2853,2875],"Generic sodium ferric gluconate",{"trials":2877,"activeCount":101},[],{"intervention":2875,"totalTrials":204,"cells":2879},{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2894},{"trials":2881,"activeCount":101},[],{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[],{"trials":2887,"activeCount":101},[],{"trials":2889,"activeCount":101},[2890],{"nctId":2866,"briefTitle":2867,"status":158,"phases":2891,"primaryCompletion":2869,"completion":2870,"start":2871,"enrollment":2872,"conditions":2892,"interventions":2893},[92],[2272],[2853,2875],{"trials":2895,"activeCount":101},[],{"intervention":2897,"totalTrials":204,"cells":2898},"DuraPrep",{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2905,"PHASE4":2907,"NA":2924},{"trials":2900,"activeCount":101},[],{"trials":2902,"activeCount":101},[],{"trials":2904,"activeCount":101},[],{"trials":2906,"activeCount":101},[],{"trials":2908,"activeCount":101},[2909],{"nctId":2910,"briefTitle":2911,"status":158,"phases":2912,"primaryCompletion":798,"completion":2913,"start":2914,"enrollment":2915,"conditions":2916,"interventions":2922},"NCT03523962","Pre-operative Alcohol Skin Solutions in Fractured Extremities",[92],"2024-02-02","2018-08-21",8485,[2917,2918,2919,2920,2921],"Surgical Site Infection","Unplanned Fracture-Related Reoperation","Open Appendicular Fracture","Closed Lower Extremity Fracture","Pelvic Fracture",[2897,2923],"ChloraPrep",{"trials":2925,"activeCount":101},[],{"intervention":2923,"totalTrials":204,"cells":2927},{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2932,"PHASE3":2934,"PHASE4":2936,"NA":2942},{"trials":2929,"activeCount":101},[],{"trials":2931,"activeCount":101},[],{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[2938],{"nctId":2910,"briefTitle":2911,"status":158,"phases":2939,"primaryCompletion":798,"completion":2913,"start":2914,"enrollment":2915,"conditions":2940,"interventions":2941},[92],[2917,2918,2919,2920,2921],[2897,2923],{"trials":2943,"activeCount":101},[],{"intervention":2945,"totalTrials":204,"cells":2946},"rasagiline",{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2951,"PHASE3":2953,"PHASE4":2955,"NA":2965},{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[],{"trials":2952,"activeCount":101},[],{"trials":2954,"activeCount":101},[],{"trials":2956,"activeCount":101},[2957],{"nctId":2958,"briefTitle":2959,"status":158,"phases":2960,"primaryCompletion":2386,"completion":2386,"start":2961,"enrollment":2962,"conditions":2963,"interventions":2964},"NCT00492336","Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia",[92],"2007-01",84,[16],[2945],{"trials":2966,"activeCount":101},[],{"intervention":2275,"totalTrials":204,"cells":2968},{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2977,"NA":2983},{"trials":2970,"activeCount":101},[],{"trials":2972,"activeCount":101},[],{"trials":2974,"activeCount":101},[],{"trials":2976,"activeCount":101},[],{"trials":2978,"activeCount":101},[2979],{"nctId":2267,"briefTitle":2268,"status":158,"phases":2980,"primaryCompletion":2270,"completion":2270,"start":1486,"enrollment":1508,"conditions":2981,"interventions":2982},[92],[2272,2273,1529,1530,1488,2209],[2229,1511,1491,2275],{"trials":2984,"activeCount":101},[],{"intervention":2986,"totalTrials":204,"cells":2987},"Rivastigmine transdermal patch",{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":2994,"PHASE4":2996,"NA":3009},{"trials":2989,"activeCount":101},[],{"trials":2991,"activeCount":101},[],{"trials":2993,"activeCount":101},[],{"trials":2995,"activeCount":101},[],{"trials":2997,"activeCount":101},[2998],{"nctId":2999,"briefTitle":3000,"status":158,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":3004,"conditions":3005,"interventions":3008},"NCT03840837","Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease",[92],"2020-04-01","2019-05-02",31,[3006,3007],"Parkinson Disease","Parkinson Disease Dementia",[2986],{"trials":3010,"activeCount":101},[],{"intervention":3012,"totalTrials":204,"cells":3013},"Bupropion SR",{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3020,"PHASE4":3022,"NA":3034},{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":101},[],{"trials":3019,"activeCount":101},[],{"trials":3021,"activeCount":101},[],{"trials":3023,"activeCount":101},[3024],{"nctId":3025,"briefTitle":3026,"status":158,"phases":3027,"primaryCompletion":3028,"completion":3028,"start":3029,"enrollment":3030,"conditions":3031,"interventions":3033},"NCT00176449","A Comparison of Bupropion SR and Placebo for Smoking Cessation",[92],"2005-12","2001-04",52,[3032],"Tobacco Use Disorder",[3012],{"trials":3035,"activeCount":101},[],{"intervention":3037,"totalTrials":204,"cells":3038},"Platelet transfusion",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3058},{"trials":3040,"activeCount":101},[],{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":101},[3049],{"nctId":3050,"briefTitle":3051,"status":158,"phases":3052,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":139,"conditions":3055,"interventions":3057},"NCT06535360","Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion",[92],"2023-05-31","2020-09-01",[3056],"Cardiopulmonary Bypass Surgery",[3037],{"trials":3059,"activeCount":101},[],{"intervention":3061,"totalTrials":204,"cells":3062},"Acamprosate",{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3069,"PHASE4":3071,"NA":3081},{"trials":3064,"activeCount":101},[],{"trials":3066,"activeCount":101},[],{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[],{"trials":3072,"activeCount":101},[3073],{"nctId":3074,"briefTitle":3075,"status":158,"phases":3076,"primaryCompletion":2386,"completion":2386,"start":3077,"enrollment":3078,"conditions":3079,"interventions":3080},"NCT00688324","Biomarker Study of Acamprosate in Schizophrenia",[92],"2008-06",36,[16,19],[3061],{"trials":3082,"activeCount":101},[],{"intervention":3084,"totalTrials":204,"cells":3085},"Inactivated Influenza Vaccine Trivalent Types A and B",{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3092,"PHASE4":3094,"NA":3107},{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"trials":3095,"activeCount":101},[3096],{"nctId":3097,"briefTitle":3098,"status":158,"phases":3099,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":3103,"interventions":3105},"NCT01430689","Maternal Flu Vaccine Trial in Bamako, Mali",[92],"2014-01","2011-09-12",4193,[3104],"Influenza",[3084,3106],"Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine",{"trials":3108,"activeCount":101},[],{"intervention":3106,"totalTrials":204,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3117,"PHASE4":3119,"NA":3125},{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":101},[],{"trials":3120,"activeCount":101},[3121],{"nctId":3097,"briefTitle":3098,"status":158,"phases":3122,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":3123,"interventions":3124},[92],[3104],[3084,3106],{"trials":3126,"activeCount":101},[],{"intervention":3128,"totalTrials":204,"cells":3129},"Digoxin Antibodies Fab Fragments",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3136,"PHASE4":3138,"NA":3150},{"trials":3131,"activeCount":101},[],{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[],{"trials":3137,"activeCount":101},[],{"trials":3139,"activeCount":101},[3140],{"nctId":3141,"briefTitle":3142,"status":158,"phases":3143,"primaryCompletion":3144,"completion":3144,"start":3145,"enrollment":3146,"conditions":3147,"interventions":3149},"NCT03810417","Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI",[92],"2024-04-30","2019-07-22",267,[3148],"Acute Kidney Injury",[3128],{"trials":3151,"activeCount":101},[],{"intervention":3153,"totalTrials":204,"cells":3154},"Duragesic reference fentanyl TDS",{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3177},{"trials":3156,"activeCount":101},[],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[],{"trials":3164,"activeCount":101},[3165],{"nctId":3166,"briefTitle":3167,"status":158,"phases":3168,"primaryCompletion":3169,"completion":3170,"start":3171,"enrollment":31,"conditions":3172,"interventions":3174},"NCT02486016","Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy Adults",[92],"2017-08-08","2017-08-09","2015-07-09",[3173],"Peer Review, Research",[3153,3175,3176],"Apotex generic fentanyl TDS","Mylan generic fentanyl TDS",{"trials":3178,"activeCount":101},[],{"intervention":3175,"totalTrials":204,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3187,"PHASE4":3189,"NA":3195},{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":101},[],{"trials":3188,"activeCount":101},[],{"trials":3190,"activeCount":101},[3191],{"nctId":3166,"briefTitle":3167,"status":158,"phases":3192,"primaryCompletion":3169,"completion":3170,"start":3171,"enrollment":31,"conditions":3193,"interventions":3194},[92],[3173],[3153,3175,3176],{"trials":3196,"activeCount":101},[],{"intervention":3176,"totalTrials":204,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3205,"PHASE4":3207,"NA":3213},{"trials":3200,"activeCount":101},[],{"trials":3202,"activeCount":101},[],{"trials":3204,"activeCount":101},[],{"trials":3206,"activeCount":101},[],{"trials":3208,"activeCount":101},[3209],{"nctId":3166,"briefTitle":3167,"status":158,"phases":3210,"primaryCompletion":3169,"completion":3170,"start":3171,"enrollment":31,"conditions":3211,"interventions":3212},[92],[3173],[3153,3175,3176],{"trials":3214,"activeCount":101},[],{"intervention":3216,"totalTrials":204,"cells":3217},"Prebiotin",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3224,"PHASE4":3226,"NA":3237},{"trials":3219,"activeCount":101},[],{"trials":3221,"activeCount":101},[],{"trials":3223,"activeCount":101},[],{"trials":3225,"activeCount":101},[],{"trials":3227,"activeCount":101},[3228],{"nctId":3229,"briefTitle":3230,"status":158,"phases":3231,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":3234,"conditions":3235,"interventions":3236},"NCT03617783","Prebiotic Treatment in People With Schizophrenia - Pilot Study",[92],"2022-04-05","2019-07-18",26,[16,19],[3216],{"trials":3238,"activeCount":101},[],{"intervention":3240,"totalTrials":204,"cells":3241},"Nevirapine, FTC, and Tenofovir",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3248,"PHASE4":3250,"NA":3261},{"trials":3243,"activeCount":101},[],{"trials":3245,"activeCount":101},[],{"trials":3247,"activeCount":101},[],{"trials":3249,"activeCount":101},[],{"trials":3251,"activeCount":101},[3252],{"nctId":3253,"briefTitle":3254,"status":158,"phases":3255,"primaryCompletion":3256,"completion":3256,"start":3257,"enrollment":3258,"conditions":3259,"interventions":3260},"NCT00344461","A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine",[92],"2008-07","2004-03",54,[28],[3240],{"trials":3262,"activeCount":101},[],{"intervention":3264,"totalTrials":204,"cells":3265},"Atenolol",{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3284},{"trials":3267,"activeCount":101},[],{"trials":3269,"activeCount":101},[],{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":101},[],{"trials":3275,"activeCount":101},[3276],{"nctId":3277,"briefTitle":3278,"status":223,"phases":3279,"primaryCompletion":3280,"completion":2699,"start":3281,"enrollment":3004,"conditions":3282,"interventions":3283},"NCT00925119","Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes",[92],"2013-06","2009-12",[1421],[3264],{"trials":3285,"activeCount":101},[],{"intervention":3287,"totalTrials":204,"cells":3288},"Oritavancin",{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3293,"PHASE3":3295,"PHASE4":3297,"NA":3312},{"trials":3290,"activeCount":101},[],{"trials":3292,"activeCount":101},[],{"trials":3294,"activeCount":101},[],{"trials":3296,"activeCount":101},[],{"trials":3298,"activeCount":101},[3299],{"nctId":3300,"briefTitle":3301,"status":223,"phases":3302,"primaryCompletion":3303,"completion":3304,"start":1992,"enrollment":208,"conditions":3305,"interventions":3311},"NCT05521880","Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use",[92],"2025-05-22","2025-05-23",[3306,3307,3308,3309,3310],"Substance Use Disorders","Infection, Soft Tissue","Bacteremia","Osteomyelitis Acute","Septic Arthritis",[3287],{"trials":3313,"activeCount":101},[],{"intervention":3315,"totalTrials":204,"cells":3316},"10% povidone-iodine (1% free iodine) in purified water",{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3338},{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[],{"trials":3322,"activeCount":101},[],{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[3327],{"nctId":3328,"briefTitle":3329,"status":158,"phases":3330,"primaryCompletion":3331,"completion":3332,"start":3333,"enrollment":3334,"conditions":3335,"interventions":3336},"NCT03385304","Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures",[92],"2021-10-19","2022-06-27","2018-04-08",1638,[2917,2918,2919],[3315,3337],"4% chlorhexidine gluconate (CHG) in purified water",{"trials":3339,"activeCount":101},[],{"intervention":3337,"totalTrials":204,"cells":3341},{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3348,"PHASE4":3350,"NA":3356},{"trials":3343,"activeCount":101},[],{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":101},[],{"trials":3349,"activeCount":101},[],{"trials":3351,"activeCount":101},[3352],{"nctId":3328,"briefTitle":3329,"status":158,"phases":3353,"primaryCompletion":3331,"completion":3332,"start":3333,"enrollment":3334,"conditions":3354,"interventions":3355},[92],[2917,2918,2919],[3315,3337],{"trials":3357,"activeCount":101},[],{"intervention":2530,"totalTrials":204,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3374},{"trials":3361,"activeCount":101},[],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[],{"trials":3369,"activeCount":101},[3370],{"nctId":2520,"briefTitle":2521,"status":223,"phases":3371,"primaryCompletion":2523,"completion":2524,"start":2525,"enrollment":1518,"conditions":3372,"interventions":3373},[92],[2527,2528],[2496,2530],{"trials":3375,"activeCount":101},[],{"intervention":3377,"totalTrials":204,"cells":3378},"lamotrigine",{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3387,"NA":3399},{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"trials":3384,"activeCount":101},[],{"trials":3386,"activeCount":101},[],{"trials":3388,"activeCount":101},[3389],{"nctId":3390,"briefTitle":3391,"status":158,"phases":3392,"primaryCompletion":3393,"completion":3394,"start":3395,"enrollment":147,"conditions":3396,"interventions":3398},"NCT02404168","BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients",[92],"2016-01-18","2016-04-06","2015-07-07",[3397],"Epilepsy",[3377,3377],{"trials":3400,"activeCount":101},[],{"intervention":3402,"totalTrials":204,"cells":3403},"Ticagrelor",{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3410,"PHASE4":3412,"NA":3425},{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"trials":3409,"activeCount":101},[],{"trials":3411,"activeCount":101},[],{"trials":3413,"activeCount":101},[3414],{"nctId":3415,"briefTitle":3416,"status":158,"phases":3417,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":3420,"conditions":3421,"interventions":3424},"NCT03161678","CES1 Crossover Trial of Clopidogrel and Ticagrelor",[92],"2022-12-12","2017-08-22",111,[3422,3423,2409],"Myocardial Infarction","Thrombosis",[2393,3402],{"trials":3426,"activeCount":101},[],{"intervention":3428,"totalTrials":204,"cells":3429},"Entresto",{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3452},{"trials":3431,"activeCount":101},[],{"trials":3433,"activeCount":101},[],{"trials":3435,"activeCount":101},[],{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[3440],{"nctId":3441,"briefTitle":3442,"status":733,"phases":3443,"primaryCompletion":3444,"completion":3445,"start":3446,"enrollment":101,"conditions":3447,"interventions":3450},"NCT03279861","Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD",[92],"2018-11","2019-11","2017-11",[3448,3449],"Congestive Heart Failure","Hypertension",[3428,3451],"Valsartan",{"trials":3453,"activeCount":101},[],{"intervention":3451,"totalTrials":204,"cells":3455},{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3470},{"trials":3457,"activeCount":101},[],{"trials":3459,"activeCount":101},[],{"trials":3461,"activeCount":101},[],{"trials":3463,"activeCount":101},[],{"trials":3465,"activeCount":101},[3466],{"nctId":3441,"briefTitle":3442,"status":733,"phases":3467,"primaryCompletion":3444,"completion":3445,"start":3446,"enrollment":101,"conditions":3468,"interventions":3469},[92],[3448,3449],[3428,3451],{"trials":3471,"activeCount":101},[],{"intervention":3473,"totalTrials":204,"cells":3474},"Metoprolol",{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3479,"PHASE3":3481,"PHASE4":3483,"NA":3493},{"trials":3476,"activeCount":101},[],{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[],{"trials":3484,"activeCount":101},[3485],{"nctId":3486,"briefTitle":3487,"status":223,"phases":3488,"primaryCompletion":3489,"completion":3489,"start":3256,"enrollment":670,"conditions":3490,"interventions":3492},"NCT00806390","Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol",[92],"2012-06",[3491],"Cardiomyopathy",[3473],{"trials":3494,"activeCount":101},[],{"intervention":3496,"totalTrials":204,"cells":3497},"Enfuvirtide",{"EARLY_PHASE1":3498,"PHASE1":3500,"PHASE2":3502,"PHASE3":3504,"PHASE4":3506,"NA":3518},{"trials":3499,"activeCount":101},[],{"trials":3501,"activeCount":101},[],{"trials":3503,"activeCount":101},[],{"trials":3505,"activeCount":101},[],{"trials":3507,"activeCount":101},[3508],{"nctId":3509,"briefTitle":3510,"status":158,"phases":3511,"primaryCompletion":3512,"completion":3512,"start":3513,"enrollment":208,"conditions":3514,"interventions":3516},"NCT00344760","A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy",[92],"2007-03","2005-01",[3515],"HIV Infections",[3496,3517],"Efavirenz, lamivudine, and tenofovir",{"trials":3519,"activeCount":101},[],{"intervention":3517,"totalTrials":204,"cells":3521},{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3536},{"trials":3523,"activeCount":101},[],{"trials":3525,"activeCount":101},[],{"trials":3527,"activeCount":101},[],{"trials":3529,"activeCount":101},[],{"trials":3531,"activeCount":101},[3532],{"nctId":3509,"briefTitle":3510,"status":158,"phases":3533,"primaryCompletion":3512,"completion":3512,"start":3513,"enrollment":208,"conditions":3534,"interventions":3535},[92],[3515],[3496,3517],{"trials":3537,"activeCount":101},[],{"intervention":3539,"totalTrials":204,"cells":3540},"Pasireotide",{"EARLY_PHASE1":3541,"PHASE1":3543,"PHASE2":3545,"PHASE3":3547,"PHASE4":3549,"NA":3561},{"trials":3542,"activeCount":101},[],{"trials":3544,"activeCount":101},[],{"trials":3546,"activeCount":101},[],{"trials":3548,"activeCount":101},[],{"trials":3550,"activeCount":101},[3551],{"nctId":3552,"briefTitle":3553,"status":733,"phases":3554,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":101,"conditions":3557,"interventions":3559},"NCT02779257","Pasireotide Treatment for Neuroendocrine Tumor",[92],"2016-06","2016-04",[3558],"Gastro-enteropancreatic Neuroendocrine Tumor",[3539,3560],"Diazoxide",{"trials":3562,"activeCount":101},[],{"intervention":3560,"totalTrials":204,"cells":3564},{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3571,"PHASE4":3573,"NA":3579},{"trials":3566,"activeCount":101},[],{"trials":3568,"activeCount":101},[],{"trials":3570,"activeCount":101},[],{"trials":3572,"activeCount":101},[],{"trials":3574,"activeCount":101},[3575],{"nctId":3552,"briefTitle":3553,"status":733,"phases":3576,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":101,"conditions":3577,"interventions":3578},[92],[3558],[3539,3560],{"trials":3580,"activeCount":101},[],{"intervention":3582,"totalTrials":204,"cells":3583},"Sirolimus + Maraviroc",{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3590,"PHASE4":3592,"NA":3603},{"trials":3585,"activeCount":101},[],{"trials":3587,"activeCount":101},[],{"trials":3589,"activeCount":101},[],{"trials":3591,"activeCount":101},[],{"trials":3593,"activeCount":101},[3594],{"nctId":3595,"briefTitle":3596,"status":733,"phases":3597,"primaryCompletion":3598,"completion":3598,"start":2845,"enrollment":101,"conditions":3599,"interventions":3602},"NCT02990312","Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients",[92],"2019-07-17",[202,2527,3600,3601],"HIV Reservoir","CCR5",[3582],{"trials":3604,"activeCount":101},[],{"intervention":3606,"totalTrials":204,"cells":3607},"Brand lamotrigine",{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3627},{"trials":3609,"activeCount":101},[],{"trials":3611,"activeCount":101},[],{"trials":3613,"activeCount":101},[],{"trials":3615,"activeCount":101},[],{"trials":3617,"activeCount":101},[3618],{"nctId":3619,"briefTitle":3620,"status":158,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":1527,"conditions":3624,"interventions":3625},"NCT01995825","Lamotrigine Bioequivalence",[92],"2013-10","2012-05",[3397],[3606,3626],"Generic lamotrigine",{"trials":3628,"activeCount":101},[],{"intervention":3626,"totalTrials":204,"cells":3630},{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3635,"PHASE3":3637,"PHASE4":3639,"NA":3645},{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":101},[],{"trials":3636,"activeCount":101},[],{"trials":3638,"activeCount":101},[],{"trials":3640,"activeCount":101},[3641],{"nctId":3619,"briefTitle":3620,"status":158,"phases":3642,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":1527,"conditions":3643,"interventions":3644},[92],[3397],[3606,3626],{"trials":3646,"activeCount":101},[],{"intervention":3648,"totalTrials":204,"cells":3649},"simvastatin",{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3656,"PHASE4":3658,"NA":3670},{"trials":3651,"activeCount":101},[],{"trials":3653,"activeCount":101},[],{"trials":3655,"activeCount":101},[],{"trials":3657,"activeCount":101},[],{"trials":3659,"activeCount":101},[3660],{"nctId":3661,"briefTitle":3662,"status":158,"phases":3663,"primaryCompletion":3664,"completion":3664,"start":3665,"enrollment":670,"conditions":3666,"interventions":3668},"NCT00819403","Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment",[92],"2011-11","2009-01",[3667],"Metabolic Syndrome",[3648,3669],"ezetimibe\u002Fsimvastatin",{"trials":3671,"activeCount":101},[],{"intervention":3669,"totalTrials":204,"cells":3673},{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3680,"PHASE4":3682,"NA":3688},{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":101},[],{"trials":3679,"activeCount":101},[],{"trials":3681,"activeCount":101},[],{"trials":3683,"activeCount":101},[3684],{"nctId":3661,"briefTitle":3662,"status":158,"phases":3685,"primaryCompletion":3664,"completion":3664,"start":3665,"enrollment":670,"conditions":3686,"interventions":3687},[92],[3667],[3648,3669],{"trials":3689,"activeCount":101},[],{"intervention":3691,"totalTrials":204,"cells":3692},"Pseudoephedrine 60 MG",{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3699,"PHASE4":3701,"NA":3713},{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[],{"trials":3700,"activeCount":101},[],{"trials":3702,"activeCount":101},[3703],{"nctId":3704,"briefTitle":3705,"status":158,"phases":3706,"primaryCompletion":3707,"completion":3707,"start":3708,"enrollment":3709,"conditions":3710,"interventions":3712},"NCT04332211","Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy",[92],"2023-07-12","2021-05-01",105,[3711],"Barotrauma;Ear",[3691],{"trials":3714,"activeCount":101},[],{"intervention":3716,"totalTrials":204,"cells":3717},"Elbasvir\u002FGrazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]",{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3736},{"trials":3719,"activeCount":101},[],{"trials":3721,"activeCount":101},[],{"trials":3723,"activeCount":101},[],{"trials":3725,"activeCount":101},[],{"trials":3727,"activeCount":101},[3728],{"nctId":3729,"briefTitle":3730,"status":733,"phases":3731,"primaryCompletion":3732,"completion":3732,"start":2014,"enrollment":101,"conditions":3733,"interventions":3735},"NCT03381859","Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4",[92],"2020-06-01",[3734],"Hepatitis C Virus Infection, Response to Therapy of",[3716],{"trials":3737,"activeCount":101},[],{"intervention":3739,"totalTrials":204,"cells":3740},"pravastatin and chenodeoxycholic acid, after metformin and placebo",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3747,"PHASE4":3749,"NA":3761},{"trials":3742,"activeCount":101},[],{"trials":3744,"activeCount":101},[],{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":101},[3751],{"nctId":3752,"briefTitle":3753,"status":158,"phases":3754,"primaryCompletion":820,"completion":820,"start":3755,"enrollment":1597,"conditions":3756,"interventions":3759},"NCT04640571","Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition",[92],"2021-04-01",[3757,3758],"Bile Salt Export Pump (BSEP) Transporter","Polysorbate 80",[3739,3760],"valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo",{"trials":3762,"activeCount":101},[],{"intervention":3760,"totalTrials":204,"cells":3764},{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3771,"PHASE4":3773,"NA":3779},{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":101},[],{"trials":3774,"activeCount":101},[3775],{"nctId":3752,"briefTitle":3753,"status":158,"phases":3776,"primaryCompletion":820,"completion":820,"start":3755,"enrollment":1597,"conditions":3777,"interventions":3778},[92],[3757,3758],[3739,3760],{"trials":3780,"activeCount":101},[],{"intervention":3782,"totalTrials":204,"cells":3783},"Intranasal Mupirocin and Topical Chlorhexidine",{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3790,"PHASE4":3792,"NA":3804},{"trials":3785,"activeCount":101},[],{"trials":3787,"activeCount":101},[],{"trials":3789,"activeCount":101},[],{"trials":3791,"activeCount":101},[],{"trials":3793,"activeCount":101},[3794],{"nctId":3795,"briefTitle":3796,"status":158,"phases":3797,"primaryCompletion":3798,"completion":3798,"start":3799,"enrollment":3800,"conditions":3801,"interventions":3803},"NCT04218799","Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans",[92],"2015-09-22","2014-08-12",19,[3802],"Human Microbiome",[3782],{"trials":3805,"activeCount":101},[],{"intervention":3807,"totalTrials":204,"cells":3808},"Maraviroc",{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3813,"PHASE3":3815,"PHASE4":3817,"NA":3828},{"trials":3810,"activeCount":101},[],{"trials":3812,"activeCount":101},[],{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":101},[],{"trials":3818,"activeCount":101},[3819],{"nctId":3820,"briefTitle":3821,"status":158,"phases":3822,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":31,"conditions":3825,"interventions":3827},"NCT02881762","Maraviroc Efficacy for Hepatitis C",[92],"2019-03-27","2017-06-01",[2194,3826],"Human Immunodeficiency Virus",[3807],{"trials":3829,"activeCount":101},[],{"intervention":3831,"totalTrials":204,"cells":3832},"Primaquine",{"EARLY_PHASE1":3833,"PHASE1":3835,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3854},{"trials":3834,"activeCount":101},[],{"trials":3836,"activeCount":101},[],{"trials":3838,"activeCount":101},[],{"trials":3840,"activeCount":101},[],{"trials":3842,"activeCount":101},[3843],{"nctId":3844,"briefTitle":3845,"status":158,"phases":3846,"primaryCompletion":3847,"completion":3847,"start":3848,"enrollment":3849,"conditions":3850,"interventions":3852},"NCT04706130","Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure",[92],"2024-10-01","2021-04-15",160,[3851],"Vivax Malaria",[3831,3853],"Artesunate",{"trials":3855,"activeCount":101},[],{"intervention":3853,"totalTrials":204,"cells":3857},{"EARLY_PHASE1":3858,"PHASE1":3860,"PHASE2":3862,"PHASE3":3864,"PHASE4":3866,"NA":3872},{"trials":3859,"activeCount":101},[],{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[],{"trials":3865,"activeCount":101},[],{"trials":3867,"activeCount":101},[3868],{"nctId":3844,"briefTitle":3845,"status":158,"phases":3869,"primaryCompletion":3847,"completion":3847,"start":3848,"enrollment":3849,"conditions":3870,"interventions":3871},[92],[3851],[3831,3853],{"trials":3873,"activeCount":101},[],{"intervention":3875,"totalTrials":204,"cells":3876},"B\u002FF\u002FTAF",{"EARLY_PHASE1":3877,"PHASE1":3879,"PHASE2":3881,"PHASE3":3883,"PHASE4":3885,"NA":3897},{"trials":3878,"activeCount":101},[],{"trials":3880,"activeCount":101},[],{"trials":3882,"activeCount":101},[],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[3887],{"nctId":3888,"briefTitle":3889,"status":158,"phases":3890,"primaryCompletion":3891,"completion":3892,"start":3893,"enrollment":1886,"conditions":3894,"interventions":3896},"NCT03797014","B\u002FF\u002FTAF Switch Study for HIV-HBV Coinfection",[92],"2022-11-22","2023-05-05","2019-04-30",[3895,1749],"HIV-1-infection",[3875],{"trials":3898,"activeCount":101},[],{"intervention":3900,"totalTrials":204,"cells":3901},"Seasonal Trivalent Influenza Vaccine",{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3906,"PHASE3":3908,"PHASE4":3910,"NA":3920},{"trials":3903,"activeCount":101},[],{"trials":3905,"activeCount":101},[],{"trials":3907,"activeCount":101},[],{"trials":3909,"activeCount":101},[],{"trials":3911,"activeCount":101},[3912],{"nctId":3913,"briefTitle":3914,"status":158,"phases":3915,"primaryCompletion":185,"completion":185,"start":3916,"enrollment":785,"conditions":3917,"interventions":3919},"NCT00987350","Safety Study of Seasonal Influenza Vaccine by Jet Injection",[92],"2010-01",[3918],"Healthy Adults",[3900],{"trials":3921,"activeCount":101},[],{"intervention":3923,"totalTrials":204,"cells":3924},"Intravenous fentanyl citrate",{"EARLY_PHASE1":3925,"PHASE1":3927,"PHASE2":3929,"PHASE3":3931,"PHASE4":3933,"NA":3945},{"trials":3926,"activeCount":101},[],{"trials":3928,"activeCount":101},[],{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":101},[],{"trials":3934,"activeCount":101},[3935],{"nctId":3936,"briefTitle":3937,"status":158,"phases":3938,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":726,"conditions":3941,"interventions":3942},"NCT02531971","Fentanyl Patch Pharmacokinetics in Healthy Adults",[92],"2018-10-16","2016-01-14",[3173],[3923,3943,3944],"Duragesic®","Mylan generic fentanyl",{"trials":3946,"activeCount":101},[],{"intervention":3943,"totalTrials":204,"cells":3948},{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3955,"PHASE4":3957,"NA":3963},{"trials":3950,"activeCount":101},[],{"trials":3952,"activeCount":101},[],{"trials":3954,"activeCount":101},[],{"trials":3956,"activeCount":101},[],{"trials":3958,"activeCount":101},[3959],{"nctId":3936,"briefTitle":3937,"status":158,"phases":3960,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":726,"conditions":3961,"interventions":3962},[92],[3173],[3923,3943,3944],{"trials":3964,"activeCount":101},[],{"intervention":3944,"totalTrials":204,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3971,"PHASE3":3973,"PHASE4":3975,"NA":3981},{"trials":3968,"activeCount":101},[],{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[3977],{"nctId":3936,"briefTitle":3937,"status":158,"phases":3978,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":726,"conditions":3979,"interventions":3980},[92],[3173],[3923,3943,3944],{"trials":3982,"activeCount":101},[],{"intervention":3984,"totalTrials":204,"cells":3985},"nesiritide",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3992,"PHASE4":3994,"NA":4003},{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[],{"trials":3993,"activeCount":101},[],{"trials":3995,"activeCount":101},[3996],{"nctId":3997,"briefTitle":3998,"status":223,"phases":3999,"primaryCompletion":2961,"completion":2961,"start":3028,"enrollment":208,"conditions":4000,"interventions":4002},"NCT00270829","Renal Effects of Intrarenal Nesiritide",[92],[4001],"Heart Failure, Congestive",[3984],{"trials":4004,"activeCount":101},[],{"intervention":4006,"totalTrials":204,"cells":4007},"Nicoderm patch first, then Aveva patch",{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4012,"PHASE3":4014,"PHASE4":4016,"NA":4027},{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[4018],{"nctId":4019,"briefTitle":4020,"status":158,"phases":4021,"primaryCompletion":4022,"completion":4023,"start":4024,"enrollment":31,"conditions":4025,"interventions":4026},"NCT02371850","Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers",[92],"2015-04","2015-06","2014-10",[177],[4006],{"trials":4028,"activeCount":101},[],{"intervention":2366,"totalTrials":204,"cells":4030},{"EARLY_PHASE1":4031,"PHASE1":4033,"PHASE2":4035,"PHASE3":4037,"PHASE4":4039,"NA":4045},{"trials":4032,"activeCount":101},[],{"trials":4034,"activeCount":101},[],{"trials":4036,"activeCount":101},[],{"trials":4038,"activeCount":101},[],{"trials":4040,"activeCount":101},[4041],{"nctId":2358,"briefTitle":2359,"status":733,"phases":4042,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":101,"conditions":4043,"interventions":4044},[92],[2364],[2366,2321],{"trials":4046,"activeCount":101},[],{"intervention":4048,"totalTrials":204,"cells":4049},"Hydrochlorothiazide",{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4070},{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":101},[],{"trials":4055,"activeCount":101},[],{"trials":4057,"activeCount":101},[],{"trials":4059,"activeCount":101},[4060],{"nctId":4061,"briefTitle":4062,"status":158,"phases":4063,"primaryCompletion":4064,"completion":4065,"start":4066,"enrollment":4067,"conditions":4068,"interventions":4069},"NCT00896389","Salt Loading and Thiazide Intervention Study",[92],"2012-12","2013-03","2009-10",124,[3449],[4048],{"trials":4071,"activeCount":101},[],{"intervention":4073,"totalTrials":204,"cells":4074},"Metolazone 60 minutes prior to furosemide",{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4081,"PHASE4":4083,"NA":4096},{"trials":4076,"activeCount":101},[],{"trials":4078,"activeCount":101},[],{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[],{"trials":4084,"activeCount":101},[4085],{"nctId":4086,"briefTitle":4087,"status":223,"phases":4088,"primaryCompletion":4089,"completion":4089,"start":4090,"enrollment":97,"conditions":4091,"interventions":4094},"NCT03746002","Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing",[92],"2020-01-10","2019-01-01",[4092,4093],"Fluid Overload","Heart Failure Acute",[4073,4095],"Metolazone concurrently with furosemide",{"trials":4097,"activeCount":101},[],{"intervention":4095,"totalTrials":204,"cells":4099},{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4106,"PHASE4":4108,"NA":4114},{"trials":4101,"activeCount":101},[],{"trials":4103,"activeCount":101},[],{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[],{"trials":4109,"activeCount":101},[4110],{"nctId":4086,"briefTitle":4087,"status":223,"phases":4111,"primaryCompletion":4089,"completion":4089,"start":4090,"enrollment":97,"conditions":4112,"interventions":4113},[92],[4092,4093],[4073,4095],{"trials":4115,"activeCount":101},[],{"intervention":4117,"totalTrials":204,"cells":4118},"Risperdal",{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4125,"PHASE4":4127,"NA":4137},{"trials":4120,"activeCount":101},[],{"trials":4122,"activeCount":101},[],{"trials":4124,"activeCount":101},[],{"trials":4126,"activeCount":101},[],{"trials":4128,"activeCount":101},[4129],{"nctId":4130,"briefTitle":4131,"status":158,"phases":4132,"primaryCompletion":4133,"completion":4133,"start":2252,"enrollment":4134,"conditions":4135,"interventions":4136},"NCT00056498","Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine",[92],"2007-12",65,[16],[4117],{"trials":4138,"activeCount":101},[],{"intervention":4140,"totalTrials":208,"cells":4141},"Tryptophan",{"EARLY_PHASE1":4142,"PHASE1":4144,"PHASE2":4146,"PHASE3":4157,"PHASE4":4168,"NA":4170},{"trials":4143,"activeCount":101},[],{"trials":4145,"activeCount":101},[],{"trials":4147,"activeCount":101},[4148],{"nctId":4149,"briefTitle":4150,"status":158,"phases":4151,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":996,"conditions":4154,"interventions":4155},"NCT04013555","The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia",[89,90],"2024-08-14","2020-01-20",[16,19,189],[4156,4140],"N-acetylcysteine",{"trials":4158,"activeCount":101},[4159],{"nctId":4160,"briefTitle":4161,"status":158,"phases":4162,"primaryCompletion":4163,"completion":4163,"start":4164,"enrollment":4165,"conditions":4166,"interventions":4167},"NCT02067975","Tryptophan MRI in People With Schizophrenia and Healthy Controls",[90,91],"2019-12-31","2014-08-14",93,[16],[4140],{"trials":4169,"activeCount":101},[],{"trials":4171,"activeCount":101},[],{"intervention":4173,"totalTrials":204,"cells":4174},"Macitentan 10mg",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4192,"NA":4194},{"trials":4176,"activeCount":101},[],{"trials":4178,"activeCount":101},[],{"trials":4180,"activeCount":101},[],{"trials":4182,"activeCount":101},[4183],{"nctId":4184,"briefTitle":4185,"status":733,"phases":4186,"primaryCompletion":4187,"completion":595,"start":4188,"enrollment":101,"conditions":4189,"interventions":4191},"NCT05946811","Macitentan to Prevent PRVO",[91],"2028-01-01","2024-05-01",[4190],"Pulmonary Embolism",[4173],{"trials":4193,"activeCount":101},[],{"trials":4195,"activeCount":101},[],{"intervention":2354,"totalTrials":204,"cells":4197},{"EARLY_PHASE1":4198,"PHASE1":4200,"PHASE2":4202,"PHASE3":4204,"PHASE4":4210,"NA":4212},{"trials":4199,"activeCount":101},[],{"trials":4201,"activeCount":101},[],{"trials":4203,"activeCount":101},[],{"trials":4205,"activeCount":101},[4206],{"nctId":2342,"briefTitle":2343,"status":158,"phases":4207,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":2347,"conditions":4208,"interventions":4209},[90,91],[2349,2350,2351,2352],[2354,2321],{"trials":4211,"activeCount":101},[],{"trials":4213,"activeCount":101},[],{"intervention":4215,"totalTrials":204,"cells":4216},"Kcentra",{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4221,"PHASE3":4223,"PHASE4":4238,"NA":4240},{"trials":4218,"activeCount":101},[],{"trials":4220,"activeCount":101},[],{"trials":4222,"activeCount":101},[],{"trials":4224,"activeCount":101},[4225],{"nctId":4226,"briefTitle":4227,"status":223,"phases":4228,"primaryCompletion":4229,"completion":4230,"start":4231,"enrollment":4232,"conditions":4233,"interventions":4236},"NCT03341156","Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During\u002FAfter Heart Transplantation",[91],"2020-09-18","2025-02-20","2018-07-11",14,[4234,4235],"Heart Disease End Stage","Heart Failure，Congestive",[4215,4237],"Frozen Plasma Product, Human",{"trials":4239,"activeCount":101},[],{"trials":4241,"activeCount":101},[],{"intervention":4237,"totalTrials":204,"cells":4243},{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4248,"PHASE3":4250,"PHASE4":4256,"NA":4258},{"trials":4245,"activeCount":101},[],{"trials":4247,"activeCount":101},[],{"trials":4249,"activeCount":101},[],{"trials":4251,"activeCount":101},[4252],{"nctId":4226,"briefTitle":4227,"status":223,"phases":4253,"primaryCompletion":4229,"completion":4230,"start":4231,"enrollment":4232,"conditions":4254,"interventions":4255},[91],[4234,4235],[4215,4237],{"trials":4257,"activeCount":101},[],{"trials":4259,"activeCount":101},[],{"intervention":4261,"totalTrials":204,"cells":4262},"Pregabalin plus BBCET",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4280,"NA":4282},{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[],{"trials":4268,"activeCount":101},[],{"trials":4270,"activeCount":101},[4271],{"nctId":4272,"briefTitle":4273,"status":158,"phases":4274,"primaryCompletion":4275,"completion":4275,"start":4276,"enrollment":17,"conditions":4277,"interventions":4279},"NCT02884908","Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD",[91],"2022-01-19","2017-07-07",[4278,1937],"PTSD",[4261],{"trials":4281,"activeCount":101},[],{"trials":4283,"activeCount":101},[],{"intervention":4285,"totalTrials":204,"cells":4286},"Imatinib",{"EARLY_PHASE1":4287,"PHASE1":4289,"PHASE2":4291,"PHASE3":4293,"PHASE4":4305,"NA":4307},{"trials":4288,"activeCount":101},[],{"trials":4290,"activeCount":101},[],{"trials":4292,"activeCount":101},[],{"trials":4294,"activeCount":101},[4295],{"nctId":4296,"briefTitle":4297,"status":223,"phases":4298,"primaryCompletion":4299,"completion":4300,"start":4301,"enrollment":10,"conditions":4302,"interventions":4304},"NCT04394416","Trial of Imatinib for Hospitalized Adults With COVID-19",[91],"2024-06-30","2025-07-17","2020-06-02",[4303],"COVID-19",[4285],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"intervention":4310,"totalTrials":204,"cells":4311},"d-cycloserine",{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4318,"PHASE4":4328,"NA":4330},{"trials":4313,"activeCount":101},[],{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[],{"trials":4319,"activeCount":101},[4320],{"nctId":4321,"briefTitle":4322,"status":158,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":2509,"enrollment":128,"conditions":4325,"interventions":4326},"NCT00222235","Adjunctive Treatment for Decreasing Symptoms of Schizophrenia",[90,91],"2004-06",[16,19],[4310,4327],"glycine",{"trials":4329,"activeCount":101},[],{"trials":4331,"activeCount":101},[],{"intervention":4327,"totalTrials":204,"cells":4333},{"EARLY_PHASE1":4334,"PHASE1":4336,"PHASE2":4338,"PHASE3":4340,"PHASE4":4346,"NA":4348},{"trials":4335,"activeCount":101},[],{"trials":4337,"activeCount":101},[],{"trials":4339,"activeCount":101},[],{"trials":4341,"activeCount":101},[4342],{"nctId":4321,"briefTitle":4322,"status":158,"phases":4343,"primaryCompletion":4324,"completion":4324,"start":2509,"enrollment":128,"conditions":4344,"interventions":4345},[90,91],[16,19],[4310,4327],{"trials":4347,"activeCount":101},[],{"trials":4349,"activeCount":101},[],{"intervention":4351,"totalTrials":204,"cells":4352},"Switch to Maraviroc + Raltegravir or Dolutegravir",{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4359,"PHASE4":4369,"NA":4371},{"trials":4354,"activeCount":101},[],{"trials":4356,"activeCount":101},[],{"trials":4358,"activeCount":101},[],{"trials":4360,"activeCount":101},[4361],{"nctId":4362,"briefTitle":4363,"status":158,"phases":4364,"primaryCompletion":4365,"completion":4365,"start":4366,"enrollment":1107,"conditions":4367,"interventions":4368},"NCT01896921","Switch to Maraviroc + Integrase Inhibitor",[91],"2018-12","2013-09",[28],[4351],{"trials":4370,"activeCount":101},[],{"trials":4372,"activeCount":101},[],{"intervention":4374,"totalTrials":204,"cells":4375},"Bupropion",{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4382,"PHASE4":4392,"NA":4394},{"trials":4377,"activeCount":101},[],{"trials":4379,"activeCount":101},[],{"trials":4381,"activeCount":101},[],{"trials":4383,"activeCount":101},[4384],{"nctId":4385,"briefTitle":4386,"status":158,"phases":4387,"primaryCompletion":198,"completion":198,"start":4388,"enrollment":4389,"conditions":4390,"interventions":4391},"NCT03342027","Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya",[91],"2020-08-01",300,[28,201],[4374],{"trials":4393,"activeCount":101},[],{"trials":4395,"activeCount":101},[],{"intervention":4397,"totalTrials":204,"cells":4398},"VTE prophylaxis with Enoxaparin 30mg BID",{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4405,"PHASE4":4419,"NA":4421},{"trials":4400,"activeCount":101},[],{"trials":4402,"activeCount":101},[],{"trials":4404,"activeCount":101},[],{"trials":4406,"activeCount":101},[4407],{"nctId":4408,"briefTitle":4409,"status":158,"phases":4410,"primaryCompletion":4411,"completion":4412,"start":4413,"enrollment":4414,"conditions":4415,"interventions":4417},"NCT02774265","A Different Approach to Preventing Thrombosis",[91],"2017-05","2017-09","2016-01",329,[4416,4190],"Venous Thromboembolism",[4397,4418],"VTE prophylaxis with Aspirin 81mg BID",{"trials":4420,"activeCount":101},[],{"trials":4422,"activeCount":101},[],{"intervention":4418,"totalTrials":204,"cells":4424},{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4437,"NA":4439},{"trials":4426,"activeCount":101},[],{"trials":4428,"activeCount":101},[],{"trials":4430,"activeCount":101},[],{"trials":4432,"activeCount":101},[4433],{"nctId":4408,"briefTitle":4409,"status":158,"phases":4434,"primaryCompletion":4411,"completion":4412,"start":4413,"enrollment":4414,"conditions":4435,"interventions":4436},[91],[4416,4190],[4397,4418],{"trials":4438,"activeCount":101},[],{"trials":4440,"activeCount":101},[],{"intervention":4442,"totalTrials":204,"cells":4443},"Quetiapine, Risperidone, Fluphenazine",{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4459,"NA":4461},{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":101},[],{"trials":4451,"activeCount":101},[4452],{"nctId":4453,"briefTitle":4454,"status":158,"phases":4455,"primaryCompletion":2251,"completion":2251,"start":4456,"enrollment":139,"conditions":4457,"interventions":4458},"NCT00161018","New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia",[91],"2003-11",[16],[4442],{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[],{"intervention":1494,"totalTrials":1444,"cells":4464},{"EARLY_PHASE1":4465,"PHASE1":4467,"PHASE2":4469,"PHASE3":4507,"PHASE4":4509,"NA":4511},{"trials":4466,"activeCount":101},[],{"trials":4468,"activeCount":101},[],{"trials":4470,"activeCount":101},[4471,4475,4479,4483,4487,4491,4495,4499,4503],{"nctId":1482,"briefTitle":1483,"status":158,"phases":4472,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":4473,"interventions":4474},[90],[1488],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1497,"briefTitle":1483,"status":158,"phases":4476,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":4477,"interventions":4478},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":1504,"briefTitle":1505,"status":158,"phases":4480,"primaryCompletion":1507,"completion":1507,"start":1486,"enrollment":1508,"conditions":4481,"interventions":4482},[90],[22],[1511,1490,1443,1494,1512],{"nctId":1514,"briefTitle":1515,"status":158,"phases":4484,"primaryCompletion":1517,"completion":1517,"start":1486,"enrollment":1518,"conditions":4485,"interventions":4486},[90],[1520],[1511,1490,1443,1494,1495],{"nctId":2223,"briefTitle":2224,"status":158,"phases":4488,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":2226,"conditions":4489,"interventions":4490},[90],[1529,1530,1488,2209],[2229,2230,1491,1494],{"nctId":1523,"briefTitle":1524,"status":158,"phases":4492,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":4493,"interventions":4494},[90],[1529,1530],[1490,1443,1491,1492,1493,1494,1495],{"nctId":2236,"briefTitle":2237,"status":158,"phases":4496,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":4497,"interventions":4498},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":2248,"briefTitle":2249,"status":158,"phases":4500,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":4501,"interventions":4502},[89,90],[2254,1488],[1511,2256,2246,2257,1490,1491,1494],{"nctId":1533,"briefTitle":1534,"status":158,"phases":4504,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4505,"interventions":4506},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4508,"activeCount":101},[],{"trials":4510,"activeCount":101},[],{"trials":4512,"activeCount":101},[],{"intervention":1490,"totalTrials":4514,"cells":4515},8,{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4517,"activeCount":101},[],{"trials":4519,"activeCount":101},[],{"trials":4521,"activeCount":101},[4522,4526,4530,4534,4538,4542,4546,4550],{"nctId":1482,"briefTitle":1483,"status":158,"phases":4523,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":4524,"interventions":4525},[90],[1488],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1497,"briefTitle":1483,"status":158,"phases":4527,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":4528,"interventions":4529},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":1504,"briefTitle":1505,"status":158,"phases":4531,"primaryCompletion":1507,"completion":1507,"start":1486,"enrollment":1508,"conditions":4532,"interventions":4533},[90],[22],[1511,1490,1443,1494,1512],{"nctId":1514,"briefTitle":1515,"status":158,"phases":4535,"primaryCompletion":1517,"completion":1517,"start":1486,"enrollment":1518,"conditions":4536,"interventions":4537},[90],[1520],[1511,1490,1443,1494,1495],{"nctId":1523,"briefTitle":1524,"status":158,"phases":4539,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":4540,"interventions":4541},[90],[1529,1530],[1490,1443,1491,1492,1493,1494,1495],{"nctId":2236,"briefTitle":2237,"status":158,"phases":4543,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":4544,"interventions":4545},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":2248,"briefTitle":2249,"status":158,"phases":4547,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":4548,"interventions":4549},[89,90],[2254,1488],[1511,2256,2246,2257,1490,1491,1494],{"nctId":1533,"briefTitle":1534,"status":158,"phases":4551,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4552,"interventions":4553},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4555,"activeCount":101},[],{"trials":4557,"activeCount":101},[],{"trials":4559,"activeCount":101},[],{"intervention":1493,"totalTrials":1107,"cells":4561},{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4574,"PHASE3":4596,"PHASE4":4598,"NA":4600},{"trials":4563,"activeCount":101},[],{"trials":4565,"activeCount":101},[4566,4570],{"nctId":2203,"briefTitle":2204,"status":158,"phases":4567,"primaryCompletion":2206,"completion":2206,"start":2207,"conditions":4568,"interventions":4569},[89],[1529,1530,1488,2209],[1511,2211,1491,1493],{"nctId":1468,"briefTitle":1469,"status":1470,"phases":4571,"primaryCompletion":1254,"completion":1472,"start":1253,"enrollment":1176,"conditions":4572,"interventions":4573},[89],[1474],[1476,1477,717,1478],{"trials":4575,"activeCount":101},[4576,4580,4584,4588,4592],{"nctId":1482,"briefTitle":1483,"status":158,"phases":4577,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":4578,"interventions":4579},[90],[1488],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1497,"briefTitle":1483,"status":158,"phases":4581,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":4582,"interventions":4583},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":1523,"briefTitle":1524,"status":158,"phases":4585,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":4586,"interventions":4587},[90],[1529,1530],[1490,1443,1491,1492,1493,1494,1495],{"nctId":2236,"briefTitle":2237,"status":158,"phases":4589,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":4590,"interventions":4591},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":1533,"briefTitle":1534,"status":158,"phases":4593,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4594,"interventions":4595},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4597,"activeCount":101},[],{"trials":4599,"activeCount":101},[],{"trials":4601,"activeCount":101},[],{"intervention":1495,"totalTrials":2400,"cells":4603},{"EARLY_PHASE1":4604,"PHASE1":4606,"PHASE2":4608,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":101},[],{"trials":4609,"activeCount":101},[4610,4614,4618,4626,4630,4634],{"nctId":1482,"briefTitle":1483,"status":158,"phases":4611,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":4612,"interventions":4613},[90],[1488],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1497,"briefTitle":1483,"status":158,"phases":4615,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":4616,"interventions":4617},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":4619,"briefTitle":4620,"status":158,"phases":4621,"primaryCompletion":2387,"completion":2387,"start":2270,"enrollment":4622,"conditions":4623,"interventions":4624},"NCT00005028","Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer",[90],46,[22],[4625,1495],"bryostatin 1",{"nctId":1514,"briefTitle":1515,"status":158,"phases":4627,"primaryCompletion":1517,"completion":1517,"start":1486,"enrollment":1518,"conditions":4628,"interventions":4629},[90],[1520],[1511,1490,1443,1494,1495],{"nctId":1523,"briefTitle":1524,"status":158,"phases":4631,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":4632,"interventions":4633},[90],[1529,1530],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1533,"briefTitle":1534,"status":158,"phases":4635,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4636,"interventions":4637},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":101},[],{"intervention":1492,"totalTrials":659,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4650,"PHASE3":4677,"PHASE4":4679,"NA":4681},{"trials":4647,"activeCount":101},[],{"trials":4649,"activeCount":101},[],{"trials":4651,"activeCount":101},[4652,4656,4660,4664,4673],{"nctId":1482,"briefTitle":1483,"status":158,"phases":4653,"primaryCompletion":1485,"completion":1485,"start":1486,"conditions":4654,"interventions":4655},[90],[1488],[1490,1443,1491,1492,1493,1494,1495],{"nctId":1497,"briefTitle":1483,"status":158,"phases":4657,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":4658,"interventions":4659},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":1523,"briefTitle":1524,"status":158,"phases":4661,"primaryCompletion":1526,"completion":1526,"start":1499,"enrollment":1527,"conditions":4662,"interventions":4663},[90],[1529,1530],[1490,1443,1491,1492,1493,1494,1495],{"nctId":4665,"briefTitle":4666,"status":158,"phases":4667,"primaryCompletion":4668,"completion":4668,"start":1485,"conditions":4669,"interventions":4670},"NCT00049374","Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90],"2006-01",[1488],[4671,1492,4672],"oblimersen sodium","thalidomide",{"nctId":1533,"briefTitle":1534,"status":158,"phases":4674,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4675,"interventions":4676},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4678,"activeCount":101},[],{"trials":4680,"activeCount":101},[],{"trials":4682,"activeCount":101},[],{"intervention":1502,"totalTrials":97,"cells":4684},{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4689,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4686,"activeCount":101},[],{"trials":4688,"activeCount":101},[],{"trials":4690,"activeCount":101},[4691,4695,4699],{"nctId":1497,"briefTitle":1483,"status":158,"phases":4692,"primaryCompletion":1485,"completion":1485,"start":1499,"conditions":4693,"interventions":4694},[90],[1488],[1490,1443,1491,1492,1493,1502,1494,1495],{"nctId":2236,"briefTitle":2237,"status":158,"phases":4696,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":4697,"interventions":4698},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":1533,"briefTitle":1534,"status":158,"phases":4700,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4701,"interventions":4702},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4704,"activeCount":101},[],{"trials":4706,"activeCount":101},[],{"trials":4708,"activeCount":101},[],{"intervention":2211,"totalTrials":208,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4719,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4712,"activeCount":101},[],{"trials":4714,"activeCount":101},[4715],{"nctId":2203,"briefTitle":2204,"status":158,"phases":4716,"primaryCompletion":2206,"completion":2206,"start":2207,"conditions":4717,"interventions":4718},[89],[1529,1530,1488,2209],[1511,2211,1491,1493],{"trials":4720,"activeCount":101},[4721],{"nctId":2505,"briefTitle":2506,"status":158,"phases":4722,"primaryCompletion":2508,"completion":2508,"start":2509,"conditions":4723,"interventions":4724},[90],[1529,1530,1488,2209],[2512,2211,2513,2514],{"trials":4726,"activeCount":101},[],{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[],{"intervention":4732,"totalTrials":208,"cells":4733},"CVD 1208S, a Shigella flexneri 2a live, oral vaccine",{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4747,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4735,"activeCount":101},[],{"trials":4737,"activeCount":101},[4738],{"nctId":4739,"briefTitle":4740,"status":158,"phases":4741,"primaryCompletion":4742,"completion":4742,"start":4743,"enrollment":3234,"conditions":4744,"interventions":4746},"NCT01531530","Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP",[89],"2012-09","2011-07",[4745],"Shigella",[4732],{"trials":4748,"activeCount":101},[4749],{"nctId":4750,"briefTitle":4751,"status":223,"phases":4752,"primaryCompletion":4753,"completion":4753,"start":3916,"enrollment":679,"conditions":4754,"interventions":4755},"NCT00866476","Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa",[90],"2010-02",[4745],[4732],{"trials":4757,"activeCount":101},[],{"trials":4759,"activeCount":101},[],{"trials":4761,"activeCount":101},[],{"intervention":4763,"totalTrials":208,"cells":4764},"Suvorexant",{"EARLY_PHASE1":4765,"PHASE1":4781,"PHASE2":4783,"PHASE3":4795,"PHASE4":4797,"NA":4799},{"trials":4766,"activeCount":101},[4767],{"nctId":4768,"briefTitle":4769,"status":1470,"phases":4770,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":4773,"conditions":4774,"interventions":4776},"NCT05829655","Measuring Acute Drug Demand in Humans",[88],"2027-10-31","2023-08-08",75,[30,4775],"Opioid Dependence",[4777,4778,4779,4780,4763],"Drug A","Drug B","Drug C","Drug D",{"trials":4782,"activeCount":101},[],{"trials":4784,"activeCount":101},[4785],{"nctId":4786,"briefTitle":4787,"status":158,"phases":4788,"primaryCompletion":4789,"completion":4789,"start":4790,"enrollment":392,"conditions":4791,"interventions":4793},"NCT05908526","Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes",[90],"2024-08-08","2023-10-09",[4792],"Insomnia",[4794],"suvorexant",{"trials":4796,"activeCount":101},[],{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":101},[],{"intervention":4802,"totalTrials":208,"cells":4803},"lapatinib",{"EARLY_PHASE1":4804,"PHASE1":4806,"PHASE2":4808,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4805,"activeCount":101},[],{"trials":4807,"activeCount":101},[],{"trials":4809,"activeCount":101},[4810,4823],{"nctId":4811,"briefTitle":4812,"status":223,"phases":4813,"primaryCompletion":4814,"completion":4815,"start":3623,"enrollment":1107,"conditions":4816,"interventions":4820},"NCT01499160","Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer",[90],"2014-11","2016-12",[4817,4818,4819],"Breast Neoplasms","Endocrine Breast Diseases","Neoplasm Metastasis",[4821,4802,4822],"letrozole","everolimus",{"nctId":4824,"briefTitle":4825,"status":223,"phases":4826,"primaryCompletion":1858,"completion":1858,"start":4827,"enrollment":26,"conditions":4828,"interventions":4829},"NCT01118975","GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers",[89,90],"2010-03",[25,4819],[4830,4831],"Vorinostat","Lapatinib",{"trials":4833,"activeCount":101},[],{"trials":4835,"activeCount":101},[],{"trials":4837,"activeCount":101},[],{"intervention":1539,"totalTrials":208,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4854,"PHASE4":4856,"NA":4858},{"trials":4841,"activeCount":101},[],{"trials":4843,"activeCount":101},[],{"trials":4845,"activeCount":101},[4846,4850],{"nctId":2236,"briefTitle":2237,"status":158,"phases":4847,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":4848,"interventions":4849},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":1533,"briefTitle":1534,"status":158,"phases":4851,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":4852,"interventions":4853},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":4855,"activeCount":101},[],{"trials":4857,"activeCount":101},[],{"trials":4859,"activeCount":101},[],{"intervention":2246,"totalTrials":208,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4876,"PHASE4":4878,"NA":4880},{"trials":4863,"activeCount":101},[],{"trials":4865,"activeCount":101},[],{"trials":4867,"activeCount":101},[4868,4872],{"nctId":2236,"briefTitle":2237,"status":158,"phases":4869,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":4870,"interventions":4871},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"nctId":2248,"briefTitle":2249,"status":158,"phases":4873,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":4874,"interventions":4875},[89,90],[2254,1488],[1511,2256,2246,2257,1490,1491,1494],{"trials":4877,"activeCount":101},[],{"trials":4879,"activeCount":101},[],{"trials":4881,"activeCount":101},[],{"intervention":4883,"totalTrials":208,"cells":4884},"Ondansetron",{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4911,"PHASE4":4913,"NA":4915},{"trials":4886,"activeCount":101},[],{"trials":4888,"activeCount":101},[],{"trials":4890,"activeCount":101},[4891,4902],{"nctId":4892,"briefTitle":4893,"status":223,"phases":4894,"primaryCompletion":1418,"completion":4895,"start":4896,"enrollment":4897,"conditions":4898,"interventions":4901},"NCT00890149","Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults",[90],"2017-03","2015-09",74,[4899,4900],"Alcohol Abuse","Alcoholism",[4883],{"nctId":4903,"briefTitle":4904,"status":158,"phases":4905,"primaryCompletion":4906,"completion":4906,"start":4907,"enrollment":4908,"conditions":4909,"interventions":4910},"NCT02354703","Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder",[90],"2020-03-31","2015-08",293,[1937],[4883],{"trials":4912,"activeCount":101},[],{"trials":4914,"activeCount":101},[],{"trials":4916,"activeCount":101},[],{"intervention":741,"totalTrials":204,"cells":4918},{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4929,"PHASE4":4931,"NA":4933},{"trials":4920,"activeCount":101},[],{"trials":4922,"activeCount":101},[],{"trials":4924,"activeCount":101},[4925],{"nctId":731,"briefTitle":732,"status":733,"phases":4926,"primaryCompletion":735,"completion":736,"start":737,"enrollment":101,"conditions":4927,"interventions":4928},[90],[22,739,25],[741,700],{"trials":4930,"activeCount":101},[],{"trials":4932,"activeCount":101},[],{"trials":4934,"activeCount":101},[],{"intervention":4936,"totalTrials":204,"cells":4937},"Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe",{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4953,"PHASE4":4955,"NA":4957},{"trials":4939,"activeCount":101},[],{"trials":4941,"activeCount":101},[],{"trials":4943,"activeCount":101},[4944],{"nctId":4945,"briefTitle":4946,"status":223,"phases":4947,"primaryCompletion":4948,"completion":4948,"start":4949,"enrollment":659,"conditions":4950,"interventions":4952},"NCT05162027","Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)",[90],"2023-01-03","2022-05-26",[4951],"Temporomandibular Disorders",[4936],{"trials":4954,"activeCount":101},[],{"trials":4956,"activeCount":101},[],{"trials":4958,"activeCount":101},[],{"intervention":4960,"totalTrials":204,"cells":4961},"Hesperidin",{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4966,"PHASE3":4976,"PHASE4":4978,"NA":4980},{"trials":4963,"activeCount":101},[],{"trials":4965,"activeCount":101},[],{"trials":4967,"activeCount":101},[4968],{"nctId":4969,"briefTitle":4970,"status":733,"phases":4971,"primaryCompletion":4972,"completion":4972,"start":4023,"enrollment":101,"conditions":4973,"interventions":4975},"NCT01773486","Effects of Hesperidin on Insulin Sensitivity",[90],"2015-12",[1624,4974],"Insulin Resistance",[4960],{"trials":4977,"activeCount":101},[],{"trials":4979,"activeCount":101},[],{"trials":4981,"activeCount":101},[],{"intervention":4983,"totalTrials":204,"cells":4984},"Ledipasvir 90 MG \u002F Sofosbuvir 400 MG Oral Tablet [Harvoni]",{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4989,"PHASE3":5002,"PHASE4":5004,"NA":5006},{"trials":4986,"activeCount":101},[],{"trials":4988,"activeCount":101},[],{"trials":4990,"activeCount":101},[4991],{"nctId":4992,"briefTitle":4993,"status":158,"phases":4994,"primaryCompletion":4995,"completion":4996,"start":4997,"enrollment":10,"conditions":4998,"interventions":4999},"NCT03312023","Ledipasvir\u002FSofosbuvir for Hepatitis B Virus Infection",[90],"2020-08-10","2021-06-30","2018-02-01",[1749],[4983,5000,5001],"Sofosbuvir 400 MG [Sovaldi]","Ledipasvir 90 MG",{"trials":5003,"activeCount":101},[],{"trials":5005,"activeCount":101},[],{"trials":5007,"activeCount":101},[],{"intervention":5000,"totalTrials":204,"cells":5009},{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5020,"PHASE4":5022,"NA":5024},{"trials":5011,"activeCount":101},[],{"trials":5013,"activeCount":101},[],{"trials":5015,"activeCount":101},[5016],{"nctId":4992,"briefTitle":4993,"status":158,"phases":5017,"primaryCompletion":4995,"completion":4996,"start":4997,"enrollment":10,"conditions":5018,"interventions":5019},[90],[1749],[4983,5000,5001],{"trials":5021,"activeCount":101},[],{"trials":5023,"activeCount":101},[],{"trials":5025,"activeCount":101},[],{"intervention":5001,"totalTrials":204,"cells":5027},{"EARLY_PHASE1":5028,"PHASE1":5030,"PHASE2":5032,"PHASE3":5038,"PHASE4":5040,"NA":5042},{"trials":5029,"activeCount":101},[],{"trials":5031,"activeCount":101},[],{"trials":5033,"activeCount":101},[5034],{"nctId":4992,"briefTitle":4993,"status":158,"phases":5035,"primaryCompletion":4995,"completion":4996,"start":4997,"enrollment":10,"conditions":5036,"interventions":5037},[90],[1749],[4983,5000,5001],{"trials":5039,"activeCount":101},[],{"trials":5041,"activeCount":101},[],{"trials":5043,"activeCount":101},[],{"intervention":5045,"totalTrials":204,"cells":5046},"ANS-6637",{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5062,"PHASE4":5064,"NA":5066},{"trials":5048,"activeCount":101},[],{"trials":5050,"activeCount":101},[],{"trials":5052,"activeCount":101},[5053],{"nctId":5054,"briefTitle":5055,"status":733,"phases":5056,"primaryCompletion":5057,"completion":5057,"start":5058,"enrollment":101,"conditions":5059,"interventions":5061},"NCT04169360","Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder",[90],"2021-01-12","2021-01",[5060],"Opioid-use Disorder",[5045],{"trials":5063,"activeCount":101},[],{"trials":5065,"activeCount":101},[],{"trials":5067,"activeCount":101},[],{"intervention":4625,"totalTrials":204,"cells":5069},{"EARLY_PHASE1":5070,"PHASE1":5072,"PHASE2":5074,"PHASE3":5080,"PHASE4":5082,"NA":5084},{"trials":5071,"activeCount":101},[],{"trials":5073,"activeCount":101},[],{"trials":5075,"activeCount":101},[5076],{"nctId":4619,"briefTitle":4620,"status":158,"phases":5077,"primaryCompletion":2387,"completion":2387,"start":2270,"enrollment":4622,"conditions":5078,"interventions":5079},[90],[22],[4625,1495],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[],{"trials":5085,"activeCount":101},[],{"intervention":5087,"totalTrials":204,"cells":5088},"Rhenium Re 188-P2045",{"EARLY_PHASE1":5089,"PHASE1":5091,"PHASE2":5093,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5090,"activeCount":101},[],{"trials":5092,"activeCount":101},[],{"trials":5094,"activeCount":101},[5095],{"nctId":5096,"briefTitle":5097,"status":733,"phases":5098,"primaryCompletion":5099,"completion":5100,"start":737,"enrollment":101,"conditions":5101,"interventions":5105},"NCT02030184","Phase I\u002FII Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas",[89,90],"2019-06","2021-06",[5102,5103,5104],"Small Cell Lung Cancer (SCLC)","Neuroendocrine (NE) Tumors","Large Cell Neuroendocrine (NE) Tumors",[5087],{"trials":5107,"activeCount":101},[],{"trials":5109,"activeCount":101},[],{"trials":5111,"activeCount":101},[],{"intervention":5113,"totalTrials":204,"cells":5114},"BLINCYTO",{"EARLY_PHASE1":5115,"PHASE1":5117,"PHASE2":5119,"PHASE3":5130,"PHASE4":5132,"NA":5134},{"trials":5116,"activeCount":101},[],{"trials":5118,"activeCount":101},[],{"trials":5120,"activeCount":101},[5121],{"nctId":5122,"briefTitle":5123,"status":158,"phases":5124,"primaryCompletion":3303,"completion":3303,"start":5125,"enrollment":208,"conditions":5126,"interventions":5129},"NCT04827745","Blinatumomab for Treatment of R\u002FR or MRD-positive CD19-Positive MPAL",[90],"2021-06-11",[5127,5128],"Mixed Phenotype Acute Leukemia (MPAL)","Measurable Residual Disease (MRD)",[5113],{"trials":5131,"activeCount":101},[],{"trials":5133,"activeCount":101},[],{"trials":5135,"activeCount":101},[],{"intervention":5137,"totalTrials":204,"cells":5138},"PSA prostate cancer vaccine",{"EARLY_PHASE1":5139,"PHASE1":5141,"PHASE2":5143,"PHASE3":5152,"PHASE4":5154,"NA":5156},{"trials":5140,"activeCount":101},[],{"trials":5142,"activeCount":101},[],{"trials":5144,"activeCount":101},[5145],{"nctId":5146,"briefTitle":5147,"status":158,"phases":5148,"primaryCompletion":2252,"completion":2252,"start":2509,"conditions":5149,"interventions":5150},"NCT00030602","Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer",[90],[22],[5137,5151],"incomplete Freund's adjuvant",{"trials":5153,"activeCount":101},[],{"trials":5155,"activeCount":101},[],{"trials":5157,"activeCount":101},[],{"intervention":5151,"totalTrials":204,"cells":5159},{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5164,"PHASE3":5170,"PHASE4":5172,"NA":5174},{"trials":5161,"activeCount":101},[],{"trials":5163,"activeCount":101},[],{"trials":5165,"activeCount":101},[5166],{"nctId":5146,"briefTitle":5147,"status":158,"phases":5167,"primaryCompletion":2252,"completion":2252,"start":2509,"conditions":5168,"interventions":5169},[90],[22],[5137,5151],{"trials":5171,"activeCount":101},[],{"trials":5173,"activeCount":101},[],{"trials":5175,"activeCount":101},[],{"intervention":5177,"totalTrials":204,"cells":5178},"Erenumab-Aooe",{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5183,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5180,"activeCount":101},[],{"trials":5182,"activeCount":101},[],{"trials":5184,"activeCount":101},[5185],{"nctId":5186,"briefTitle":5187,"status":223,"phases":5188,"primaryCompletion":5189,"completion":5189,"start":5190,"enrollment":659,"conditions":5191,"interventions":5193},"NCT05142228","Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.",[90],"2022-10-27","2022-05-31",[5192],"Trigeminal Neuropathy",[5177],{"trials":5195,"activeCount":101},[],{"trials":5197,"activeCount":101},[],{"trials":5199,"activeCount":101},[],{"intervention":5201,"totalTrials":204,"cells":5202},"Combination Radiation, Immunotherapy, Surgery",{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5204,"activeCount":101},[],{"trials":5206,"activeCount":101},[],{"trials":5208,"activeCount":101},[5209],{"nctId":5210,"briefTitle":5211,"status":223,"phases":5212,"primaryCompletion":5213,"completion":5213,"start":5214,"enrollment":2242,"conditions":5215,"interventions":5217},"NCT03116529","Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma",[89,90],"2024-06-21","2017-06-21",[5216],"Soft Tissue Sarcoma",[5201],{"trials":5219,"activeCount":101},[],{"trials":5221,"activeCount":101},[],{"trials":5223,"activeCount":101},[],{"intervention":5225,"totalTrials":204,"cells":5226},"Donepezil 5-10 Mg Oral",{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5228,"activeCount":101},[],{"trials":5230,"activeCount":101},[],{"trials":5232,"activeCount":101},[5233],{"nctId":5234,"briefTitle":5235,"status":223,"phases":5236,"primaryCompletion":5237,"completion":5237,"start":5238,"enrollment":1107,"conditions":5239,"interventions":5240},"NCT04507438","The Effect of Donepezil on Glycemic Control in Type II Diabetics",[90],"2023-09-12","2019-07-12",[1421],[5225],{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[],{"trials":5246,"activeCount":101},[],{"intervention":5248,"totalTrials":204,"cells":5249},"HLXL",{"EARLY_PHASE1":5250,"PHASE1":5252,"PHASE2":5254,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5251,"activeCount":101},[],{"trials":5253,"activeCount":101},[],{"trials":5255,"activeCount":101},[5256],{"nctId":5257,"briefTitle":5258,"status":158,"phases":5259,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":5264,"interventions":5266},"NCT00755326","Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee",[90],"2010-04","2010-07","2007-04",92,[5265],"Osteoarthritis of the Knee",[5248],{"trials":5268,"activeCount":101},[],{"trials":5270,"activeCount":101},[],{"trials":5272,"activeCount":101},[],{"intervention":5274,"totalTrials":204,"cells":5275},"PXVX0200 10E8",{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5292,"PHASE4":5294,"NA":5296},{"trials":5277,"activeCount":101},[],{"trials":5279,"activeCount":101},[],{"trials":5281,"activeCount":101},[5282],{"nctId":5283,"briefTitle":5284,"status":158,"phases":5285,"primaryCompletion":5286,"completion":5286,"start":2524,"enrollment":139,"conditions":5287,"interventions":5289},"NCT02145377","PXVX0200 (CVD103-HgR) vs Shanchol in Mali",[90],"2015-03",[5288],"Cholera",[5274,5290,5291],"PXVX0200 10E9","Shanchol",{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[],{"trials":5297,"activeCount":101},[],{"intervention":5290,"totalTrials":204,"cells":5299},{"EARLY_PHASE1":5300,"PHASE1":5302,"PHASE2":5304,"PHASE3":5310,"PHASE4":5312,"NA":5314},{"trials":5301,"activeCount":101},[],{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[5306],{"nctId":5283,"briefTitle":5284,"status":158,"phases":5307,"primaryCompletion":5286,"completion":5286,"start":2524,"enrollment":139,"conditions":5308,"interventions":5309},[90],[5288],[5274,5290,5291],{"trials":5311,"activeCount":101},[],{"trials":5313,"activeCount":101},[],{"trials":5315,"activeCount":101},[],{"intervention":5291,"totalTrials":204,"cells":5317},{"EARLY_PHASE1":5318,"PHASE1":5320,"PHASE2":5322,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5319,"activeCount":101},[],{"trials":5321,"activeCount":101},[],{"trials":5323,"activeCount":101},[5324],{"nctId":5283,"briefTitle":5284,"status":158,"phases":5325,"primaryCompletion":5286,"completion":5286,"start":2524,"enrollment":139,"conditions":5326,"interventions":5327},[90],[5288],[5274,5290,5291],{"trials":5329,"activeCount":101},[],{"trials":5331,"activeCount":101},[],{"trials":5333,"activeCount":101},[],{"intervention":1512,"totalTrials":204,"cells":5335},{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5340,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5337,"activeCount":101},[],{"trials":5339,"activeCount":101},[],{"trials":5341,"activeCount":101},[5342],{"nctId":1504,"briefTitle":1505,"status":158,"phases":5343,"primaryCompletion":1507,"completion":1507,"start":1486,"enrollment":1508,"conditions":5344,"interventions":5345},[90],[22],[1511,1490,1443,1494,1512],{"trials":5347,"activeCount":101},[],{"trials":5349,"activeCount":101},[],{"trials":5351,"activeCount":101},[],{"intervention":5353,"totalTrials":204,"cells":5354},"Assigned Interventions",{"EARLY_PHASE1":5355,"PHASE1":5357,"PHASE2":5359,"PHASE3":5372,"PHASE4":5374,"NA":5376},{"trials":5356,"activeCount":101},[],{"trials":5358,"activeCount":101},[],{"trials":5360,"activeCount":101},[5361],{"nctId":5362,"briefTitle":5363,"status":733,"phases":5364,"primaryCompletion":4299,"completion":5365,"start":5366,"enrollment":101,"conditions":5367,"interventions":5371},"NCT04415476","Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)",[90],"2028-06-30","2020-06-30",[5368,5369,5370],"Disorder Related to Lung Transplantation","Chronic Rejection of Lung Transplant","Decreased Immunologic Activity",[5353],{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[],{"intervention":5379,"totalTrials":204,"cells":5380},"Decitabine",{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5385,"PHASE3":5397,"PHASE4":5399,"NA":5401},{"trials":5382,"activeCount":101},[],{"trials":5384,"activeCount":101},[],{"trials":5386,"activeCount":101},[5387],{"nctId":5388,"briefTitle":5389,"status":158,"phases":5390,"primaryCompletion":5391,"completion":5392,"start":2749,"enrollment":253,"conditions":5393,"interventions":5395},"NCT02878785","Decitabine and Talazoparib in Untreated AML and R\u002FR AML",[89,90],"2020-01-05","2020-11-19",[5394],"Acute Myeloid Leukemia",[5379,5396],"talazoparib",{"trials":5398,"activeCount":101},[],{"trials":5400,"activeCount":101},[],{"trials":5402,"activeCount":101},[],{"intervention":5396,"totalTrials":204,"cells":5404},{"EARLY_PHASE1":5405,"PHASE1":5407,"PHASE2":5409,"PHASE3":5415,"PHASE4":5417,"NA":5419},{"trials":5406,"activeCount":101},[],{"trials":5408,"activeCount":101},[],{"trials":5410,"activeCount":101},[5411],{"nctId":5388,"briefTitle":5389,"status":158,"phases":5412,"primaryCompletion":5391,"completion":5392,"start":2749,"enrollment":253,"conditions":5413,"interventions":5414},[89,90],[5394],[5379,5396],{"trials":5416,"activeCount":101},[],{"trials":5418,"activeCount":101},[],{"trials":5420,"activeCount":101},[],{"intervention":5422,"totalTrials":204,"cells":5423},"FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}",{"EARLY_PHASE1":5424,"PHASE1":5426,"PHASE2":5428,"PHASE3":5438,"PHASE4":5440,"NA":5442},{"trials":5425,"activeCount":101},[],{"trials":5427,"activeCount":101},[],{"trials":5429,"activeCount":101},[5430],{"nctId":5431,"briefTitle":5432,"status":223,"phases":5433,"primaryCompletion":5434,"completion":5434,"start":5286,"enrollment":97,"conditions":5435,"interventions":5437},"NCT02319304","Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma",[90],"2018-10-05",[5436],"Rectal Adenocarcinoma",[5422],{"trials":5439,"activeCount":101},[],{"trials":5441,"activeCount":101},[],{"trials":5443,"activeCount":101},[],{"intervention":5445,"totalTrials":204,"cells":5446},"Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir",{"EARLY_PHASE1":5447,"PHASE1":5449,"PHASE2":5451,"PHASE3":5462,"PHASE4":5464,"NA":5466},{"trials":5448,"activeCount":101},[],{"trials":5450,"activeCount":101},[],{"trials":5452,"activeCount":101},[5453],{"nctId":5454,"briefTitle":5455,"status":158,"phases":5456,"primaryCompletion":5457,"completion":5457,"start":2820,"enrollment":5458,"conditions":5459,"interventions":5461},"NCT02745535","Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience",[90],"2018-10-24",77,[5460],"Chronic Hepatitis C",[5445],{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[],{"intervention":5469,"totalTrials":204,"cells":5470},"gefitinib",{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5487,"PHASE4":5489,"NA":5491},{"trials":5472,"activeCount":101},[],{"trials":5474,"activeCount":101},[],{"trials":5476,"activeCount":101},[5477],{"nctId":5478,"briefTitle":5479,"status":158,"phases":5480,"primaryCompletion":5481,"completion":5482,"start":5483,"conditions":5484,"interventions":5486},"NCT00014183","ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer",[90],"2002-05","2005-08","2001-01",[5485],"Kidney Cancer",[5469],{"trials":5488,"activeCount":101},[],{"trials":5490,"activeCount":101},[],{"trials":5492,"activeCount":101},[],{"intervention":5494,"totalTrials":204,"cells":5495},"Azithromycin",{"EARLY_PHASE1":5496,"PHASE1":5498,"PHASE2":5500,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5497,"activeCount":101},[],{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":101},[5502],{"nctId":5503,"briefTitle":5504,"status":158,"phases":5505,"primaryCompletion":4815,"completion":5506,"start":1885,"enrollment":5507,"conditions":5508,"interventions":5510},"NCT01778634","Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants",[90],"2020-11-03",121,[5509],"Ureaplasma Infections",[5494],{"trials":5512,"activeCount":101},[],{"trials":5514,"activeCount":101},[],{"trials":5516,"activeCount":101},[],{"intervention":5518,"totalTrials":204,"cells":5519},"VSL#3",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5536,"PHASE4":5538,"NA":5540},{"trials":5521,"activeCount":101},[],{"trials":5523,"activeCount":101},[],{"trials":5525,"activeCount":101},[5526],{"nctId":5527,"briefTitle":5528,"status":223,"phases":5529,"primaryCompletion":5530,"completion":5530,"start":5531,"enrollment":97,"conditions":5532,"interventions":5534},"NCT00852124","Safety of VSL#3 in Adult Asthmatics",[89,90],"2013-01","2007-02",[5533],"Asthma",[5518,5535],"VSL#3 or placebo",{"trials":5537,"activeCount":101},[],{"trials":5539,"activeCount":101},[],{"trials":5541,"activeCount":101},[],{"intervention":5535,"totalTrials":204,"cells":5543},{"EARLY_PHASE1":5544,"PHASE1":5546,"PHASE2":5548,"PHASE3":5554,"PHASE4":5556,"NA":5558},{"trials":5545,"activeCount":101},[],{"trials":5547,"activeCount":101},[],{"trials":5549,"activeCount":101},[5550],{"nctId":5527,"briefTitle":5528,"status":223,"phases":5551,"primaryCompletion":5530,"completion":5530,"start":5531,"enrollment":97,"conditions":5552,"interventions":5553},[89,90],[5533],[5518,5535],{"trials":5555,"activeCount":101},[],{"trials":5557,"activeCount":101},[],{"trials":5559,"activeCount":101},[],{"intervention":5561,"totalTrials":204,"cells":5562},"Liposomal aerosol cyclosporine",{"EARLY_PHASE1":5563,"PHASE1":5565,"PHASE2":5567,"PHASE3":5577,"PHASE4":5579,"NA":5581},{"trials":5564,"activeCount":101},[],{"trials":5566,"activeCount":101},[],{"trials":5568,"activeCount":101},[5569],{"nctId":5570,"briefTitle":5571,"status":158,"phases":5572,"primaryCompletion":4907,"completion":3445,"start":5573,"enrollment":10,"conditions":5574,"interventions":5576},"NCT01650545","Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients",[89,90],"2012-07",[5368,5575,5370,5369],"Bronchiolitis Obliterans",[5561],{"trials":5578,"activeCount":101},[],{"trials":5580,"activeCount":101},[],{"trials":5582,"activeCount":101},[],{"intervention":5584,"totalTrials":204,"cells":5585},"Trastuzumab plus Pertuzumab",{"EARLY_PHASE1":5586,"PHASE1":5588,"PHASE2":5590,"PHASE3":5602,"PHASE4":5604,"NA":5606},{"trials":5587,"activeCount":101},[],{"trials":5589,"activeCount":101},[],{"trials":5591,"activeCount":101},[5592],{"nctId":5593,"briefTitle":5594,"status":223,"phases":5595,"primaryCompletion":5596,"completion":4413,"start":3100,"enrollment":208,"conditions":5597,"interventions":5599},"NCT02000596","1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.",[90],"2015-11",[5598],"Metastatic Breast Cancer",[5584,5600,5601],"Hormonal Therapy with Anastrozole and Fulvestrant","Chemotherapy with Eribulin",{"trials":5603,"activeCount":101},[],{"trials":5605,"activeCount":101},[],{"trials":5607,"activeCount":101},[],{"intervention":5600,"totalTrials":204,"cells":5609},{"EARLY_PHASE1":5610,"PHASE1":5612,"PHASE2":5614,"PHASE3":5620,"PHASE4":5622,"NA":5624},{"trials":5611,"activeCount":101},[],{"trials":5613,"activeCount":101},[],{"trials":5615,"activeCount":101},[5616],{"nctId":5593,"briefTitle":5594,"status":223,"phases":5617,"primaryCompletion":5596,"completion":4413,"start":3100,"enrollment":208,"conditions":5618,"interventions":5619},[90],[5598],[5584,5600,5601],{"trials":5621,"activeCount":101},[],{"trials":5623,"activeCount":101},[],{"trials":5625,"activeCount":101},[],{"intervention":5601,"totalTrials":204,"cells":5627},{"EARLY_PHASE1":5628,"PHASE1":5630,"PHASE2":5632,"PHASE3":5638,"PHASE4":5640,"NA":5642},{"trials":5629,"activeCount":101},[],{"trials":5631,"activeCount":101},[],{"trials":5633,"activeCount":101},[5634],{"nctId":5593,"briefTitle":5594,"status":223,"phases":5635,"primaryCompletion":5596,"completion":4413,"start":3100,"enrollment":208,"conditions":5636,"interventions":5637},[90],[5598],[5584,5600,5601],{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":101},[],{"intervention":5645,"totalTrials":204,"cells":5646},"carboplatin and paclitaxel",{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5651,"PHASE3":5662,"PHASE4":5664,"NA":5666},{"trials":5648,"activeCount":101},[],{"trials":5650,"activeCount":101},[],{"trials":5652,"activeCount":101},[5653],{"nctId":5654,"briefTitle":5655,"status":223,"phases":5656,"primaryCompletion":5657,"completion":5657,"start":5658,"enrollment":208,"conditions":5659,"interventions":5661},"NCT04527900","The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach",[90],"2024-07-02","2021-02-23",[5660],"Endometrial Cancer",[5645],{"trials":5663,"activeCount":101},[],{"trials":5665,"activeCount":101},[],{"trials":5667,"activeCount":101},[],{"intervention":4822,"totalTrials":204,"cells":5669},{"EARLY_PHASE1":5670,"PHASE1":5672,"PHASE2":5674,"PHASE3":5680,"PHASE4":5682,"NA":5684},{"trials":5671,"activeCount":101},[],{"trials":5673,"activeCount":101},[],{"trials":5675,"activeCount":101},[5676],{"nctId":4811,"briefTitle":4812,"status":223,"phases":5677,"primaryCompletion":4814,"completion":4815,"start":3623,"enrollment":1107,"conditions":5678,"interventions":5679},[90],[4817,4818,4819],[4821,4802,4822],{"trials":5681,"activeCount":101},[],{"trials":5683,"activeCount":101},[],{"trials":5685,"activeCount":101},[],{"intervention":5687,"totalTrials":204,"cells":5688},"20-herb formulation",{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5705,"PHASE4":5707,"NA":5709},{"trials":5690,"activeCount":101},[],{"trials":5692,"activeCount":101},[],{"trials":5694,"activeCount":101},[5695],{"nctId":5696,"briefTitle":5697,"status":158,"phases":5698,"primaryCompletion":2700,"completion":5699,"start":5700,"enrollment":5701,"conditions":5702,"interventions":5704},"NCT03300804","Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS)",[90],"2011-06","2008-05",104,[5703],"Irritable Bowel Syndrome",[5687],{"trials":5706,"activeCount":101},[],{"trials":5708,"activeCount":101},[],{"trials":5710,"activeCount":101},[],{"intervention":5712,"totalTrials":204,"cells":5713},"Combination Oral Budesonide and Rectal Hydrocortisone",{"EARLY_PHASE1":5714,"PHASE1":5716,"PHASE2":5718,"PHASE3":5729,"PHASE4":5731,"NA":5733},{"trials":5715,"activeCount":101},[],{"trials":5717,"activeCount":101},[],{"trials":5719,"activeCount":101},[5720],{"nctId":5721,"briefTitle":5722,"status":223,"phases":5723,"primaryCompletion":4066,"completion":4827,"start":5724,"enrollment":204,"conditions":5725,"interventions":5728},"NCT00805285","The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis",[90],"2008-10",[5726,5727],"Inflammatory Bowel Disease","Ulcerative Colitis",[5712],{"trials":5730,"activeCount":101},[],{"trials":5732,"activeCount":101},[],{"trials":5734,"activeCount":101},[],{"intervention":5736,"totalTrials":204,"cells":5737},"Cannabidiol",{"EARLY_PHASE1":5738,"PHASE1":5740,"PHASE2":5742,"PHASE3":5755,"PHASE4":5757,"NA":5759},{"trials":5739,"activeCount":101},[],{"trials":5741,"activeCount":101},[],{"trials":5743,"activeCount":101},[5744],{"nctId":5745,"briefTitle":5746,"status":733,"phases":5747,"primaryCompletion":5748,"completion":5749,"start":5750,"enrollment":101,"conditions":5751,"interventions":5754},"NCT03883360","Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis",[90],"2050-02","2050-03","2050-01",[5752,5753],"Schizophrenia Spectrum Disorders","Cannabis Use",[5736],{"trials":5756,"activeCount":101},[],{"trials":5758,"activeCount":101},[],{"trials":5760,"activeCount":101},[],{"intervention":5762,"totalTrials":204,"cells":5763},"Emergency preservation and resuscitation",{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5768,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5765,"activeCount":101},[],{"trials":5767,"activeCount":101},[],{"trials":5769,"activeCount":101},[5770],{"nctId":5771,"briefTitle":5772,"status":223,"phases":5773,"primaryCompletion":5774,"completion":5774,"start":5775,"enrollment":679,"conditions":5776,"interventions":5778},"NCT01042015","Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma",[90],"2025-11-21","2016-10",[5777],"Cardiac Arrest From Trauma",[5762],{"trials":5780,"activeCount":101},[],{"trials":5782,"activeCount":101},[],{"trials":5784,"activeCount":101},[],{"intervention":5786,"totalTrials":204,"cells":5787},"apricoxib",{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5789,"activeCount":101},[],{"trials":5791,"activeCount":101},[],{"trials":5793,"activeCount":101},[5794],{"nctId":5795,"briefTitle":5796,"status":158,"phases":5797,"primaryCompletion":3623,"completion":2190,"start":5798,"enrollment":5799,"conditions":5800,"interventions":5803},"NCT00771953","0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib\u002FPlacebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer",[90],"2008-11",109,[5801,5802],"Lung Cancer","Non Small Cell Lung Cancer",[5786,5804],"Docetaxel or Pemetrexed",{"trials":5806,"activeCount":101},[],{"trials":5808,"activeCount":101},[],{"trials":5810,"activeCount":101},[],{"intervention":5804,"totalTrials":204,"cells":5812},{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5817,"PHASE3":5823,"PHASE4":5825,"NA":5827},{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[],{"trials":5818,"activeCount":101},[5819],{"nctId":5795,"briefTitle":5796,"status":158,"phases":5820,"primaryCompletion":3623,"completion":2190,"start":5798,"enrollment":5799,"conditions":5821,"interventions":5822},[90],[5801,5802],[5786,5804],{"trials":5824,"activeCount":101},[],{"trials":5826,"activeCount":101},[],{"trials":5828,"activeCount":101},[],{"intervention":2230,"totalTrials":204,"cells":5830},{"EARLY_PHASE1":5831,"PHASE1":5833,"PHASE2":5835,"PHASE3":5841,"PHASE4":5843,"NA":5845},{"trials":5832,"activeCount":101},[],{"trials":5834,"activeCount":101},[],{"trials":5836,"activeCount":101},[5837],{"nctId":2223,"briefTitle":2224,"status":158,"phases":5838,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":2226,"conditions":5839,"interventions":5840},[90],[1529,1530,1488,2209],[2229,2230,1491,1494],{"trials":5842,"activeCount":101},[],{"trials":5844,"activeCount":101},[],{"trials":5846,"activeCount":101},[],{"intervention":2245,"totalTrials":204,"cells":5848},{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5859,"PHASE4":5861,"NA":5863},{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"trials":5854,"activeCount":101},[5855],{"nctId":2236,"briefTitle":2237,"status":158,"phases":5856,"primaryCompletion":2239,"completion":2240,"start":2241,"enrollment":2242,"conditions":5857,"interventions":5858},[90],[1529],[1511,2245,1539,2246,1490,1491,1493,1502,1494],{"trials":5860,"activeCount":101},[],{"trials":5862,"activeCount":101},[],{"trials":5864,"activeCount":101},[],{"intervention":5866,"totalTrials":204,"cells":5867},"Oxycodone",{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5886,"PHASE4":5888,"NA":5890},{"trials":5869,"activeCount":101},[],{"trials":5871,"activeCount":101},[],{"trials":5873,"activeCount":101},[5874],{"nctId":5875,"briefTitle":5876,"status":223,"phases":5877,"primaryCompletion":5878,"completion":5879,"start":1399,"enrollment":97,"conditions":5880,"interventions":5884},"NCT03426137","Relieving Acute Pain (RAP) Study: A Pilot Study",[90],"2019-03-30","2020-01-21",[5881,5882,5883],"Trauma","Opioid Use","Spine Fusion",[5866,5885],"Ketorolac",{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[],{"trials":5891,"activeCount":101},[],{"intervention":5885,"totalTrials":204,"cells":5893},{"EARLY_PHASE1":5894,"PHASE1":5896,"PHASE2":5898,"PHASE3":5904,"PHASE4":5906,"NA":5908},{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[],{"trials":5899,"activeCount":101},[5900],{"nctId":5875,"briefTitle":5876,"status":223,"phases":5901,"primaryCompletion":5878,"completion":5879,"start":1399,"enrollment":97,"conditions":5902,"interventions":5903},[90],[5881,5882,5883],[5866,5885],{"trials":5905,"activeCount":101},[],{"trials":5907,"activeCount":101},[],{"trials":5909,"activeCount":101},[],{"intervention":5911,"totalTrials":204,"cells":5912},"Chemotherapy with Temodar.",{"EARLY_PHASE1":5913,"PHASE1":5915,"PHASE2":5917,"PHASE3":5928,"PHASE4":5930,"NA":5932},{"trials":5914,"activeCount":101},[],{"trials":5916,"activeCount":101},[],{"trials":5918,"activeCount":101},[5919],{"nctId":5920,"briefTitle":5921,"status":223,"phases":5922,"primaryCompletion":5923,"completion":5923,"start":5924,"enrollment":726,"conditions":5925,"interventions":5927},"NCT01822275","Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme",[90],"2019-09","2013-05",[5926],"Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)",[5911],{"trials":5929,"activeCount":101},[],{"trials":5931,"activeCount":101},[],{"trials":5933,"activeCount":101},[],{"intervention":5935,"totalTrials":204,"cells":5936},"Metformin",{"EARLY_PHASE1":5937,"PHASE1":5939,"PHASE2":5941,"PHASE3":5953,"PHASE4":5955,"NA":5957},{"trials":5938,"activeCount":101},[],{"trials":5940,"activeCount":101},[],{"trials":5942,"activeCount":101},[5943],{"nctId":5944,"briefTitle":5945,"status":733,"phases":5946,"primaryCompletion":594,"completion":5947,"start":5948,"enrollment":101,"conditions":5949,"interventions":5951},"NCT05910554","Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis",[90],"2027-09-01","2025-12-10",[5950],"Sarcoidosis, Pulmonary",[5935,5952],"Cellulose",{"trials":5954,"activeCount":101},[],{"trials":5956,"activeCount":101},[],{"trials":5958,"activeCount":101},[],{"intervention":5952,"totalTrials":204,"cells":5960},{"EARLY_PHASE1":5961,"PHASE1":5963,"PHASE2":5965,"PHASE3":5971,"PHASE4":5973,"NA":5975},{"trials":5962,"activeCount":101},[],{"trials":5964,"activeCount":101},[],{"trials":5966,"activeCount":101},[5967],{"nctId":5944,"briefTitle":5945,"status":733,"phases":5968,"primaryCompletion":594,"completion":5947,"start":5948,"enrollment":101,"conditions":5969,"interventions":5970},[90],[5950],[5935,5952],{"trials":5972,"activeCount":101},[],{"trials":5974,"activeCount":101},[],{"trials":5976,"activeCount":101},[],{"intervention":5978,"totalTrials":204,"cells":5979},"Rimonabant",{"EARLY_PHASE1":5980,"PHASE1":5982,"PHASE2":5984,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5981,"activeCount":101},[],{"trials":5983,"activeCount":101},[],{"trials":5985,"activeCount":101},[5986],{"nctId":5987,"briefTitle":5988,"status":223,"phases":5989,"primaryCompletion":5990,"completion":5990,"start":162,"enrollment":2575,"conditions":5991,"interventions":5992},"NCT00547118","The Effects of Rimonabant, on Weight and Metabolic Risk Factors",[90],"2009-03",[16,19,1624,3449,177],[5978],{"trials":5994,"activeCount":101},[],{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":101},[],{"intervention":2256,"totalTrials":204,"cells":6000},{"EARLY_PHASE1":6001,"PHASE1":6003,"PHASE2":6005,"PHASE3":6011,"PHASE4":6013,"NA":6015},{"trials":6002,"activeCount":101},[],{"trials":6004,"activeCount":101},[],{"trials":6006,"activeCount":101},[6007],{"nctId":2248,"briefTitle":2249,"status":158,"phases":6008,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":6009,"interventions":6010},[89,90],[2254,1488],[1511,2256,2246,2257,1490,1491,1494],{"trials":6012,"activeCount":101},[],{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"intervention":2257,"totalTrials":204,"cells":6018},{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6023,"PHASE3":6029,"PHASE4":6031,"NA":6033},{"trials":6020,"activeCount":101},[],{"trials":6022,"activeCount":101},[],{"trials":6024,"activeCount":101},[6025],{"nctId":2248,"briefTitle":2249,"status":158,"phases":6026,"primaryCompletion":2251,"completion":2240,"start":2252,"conditions":6027,"interventions":6028},[89,90],[2254,1488],[1511,2256,2246,2257,1490,1491,1494],{"trials":6030,"activeCount":101},[],{"trials":6032,"activeCount":101},[],{"trials":6034,"activeCount":101},[],{"intervention":6036,"totalTrials":204,"cells":6037},"Zydelig",{"EARLY_PHASE1":6038,"PHASE1":6040,"PHASE2":6042,"PHASE3":6059,"PHASE4":6061,"NA":6063},{"trials":6039,"activeCount":101},[],{"trials":6041,"activeCount":101},[],{"trials":6043,"activeCount":101},[6044],{"nctId":6045,"briefTitle":6046,"status":158,"phases":6047,"primaryCompletion":6048,"completion":6049,"start":6050,"enrollment":2575,"conditions":6051,"interventions":6058},"NCT03133221","1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",[90],"2023-06-15","2024-09-29","2017-10-23",[6052,1652,6053,6054,6055,1658,6056,1656,6057],"Non Hodgkin Lymphoma","Indolent Lymphoma","B-cell Lymphoma","Transformed Lymphoma","Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma",[6036],{"trials":6060,"activeCount":101},[],{"trials":6062,"activeCount":101},[],{"trials":6064,"activeCount":101},[],{"intervention":4830,"totalTrials":204,"cells":6066},{"EARLY_PHASE1":6067,"PHASE1":6069,"PHASE2":6071,"PHASE3":6077,"PHASE4":6079,"NA":6081},{"trials":6068,"activeCount":101},[],{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[6073],{"nctId":4824,"briefTitle":4825,"status":223,"phases":6074,"primaryCompletion":1858,"completion":1858,"start":4827,"enrollment":26,"conditions":6075,"interventions":6076},[89,90],[25,4819],[4830,4831],{"trials":6078,"activeCount":101},[],{"trials":6080,"activeCount":101},[],{"trials":6082,"activeCount":101},[],{"intervention":6084,"totalTrials":204,"cells":6085},"Neupogen",{"EARLY_PHASE1":6086,"PHASE1":6088,"PHASE2":6090,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6087,"activeCount":101},[],{"trials":6089,"activeCount":101},[],{"trials":6091,"activeCount":101},[6092],{"nctId":6093,"briefTitle":6094,"status":733,"phases":6095,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":101,"conditions":6099,"interventions":6103},"NCT02682953","Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers",[90],"2017-02","2017-08","2015-10",[6100,6101,6102,1530],"Bone Marrow Transplantation","Hematopoietic Stem Cells","Multiple Myeloma",[6084,6104],"Plerixafor",{"trials":6106,"activeCount":101},[],{"trials":6108,"activeCount":101},[],{"trials":6110,"activeCount":101},[],{"intervention":6104,"totalTrials":204,"cells":6112},{"EARLY_PHASE1":6113,"PHASE1":6115,"PHASE2":6117,"PHASE3":6123,"PHASE4":6125,"NA":6127},{"trials":6114,"activeCount":101},[],{"trials":6116,"activeCount":101},[],{"trials":6118,"activeCount":101},[6119],{"nctId":6093,"briefTitle":6094,"status":733,"phases":6120,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":101,"conditions":6121,"interventions":6122},[90],[6100,6101,6102,1530],[6084,6104],{"trials":6124,"activeCount":101},[],{"trials":6126,"activeCount":101},[],{"trials":6128,"activeCount":101},[],{"intervention":6130,"totalTrials":204,"cells":6131},"SF2a-TT15 Shigella Vaccine",{"EARLY_PHASE1":6132,"PHASE1":6134,"PHASE2":6136,"PHASE3":6149,"PHASE4":6151,"NA":6153},{"trials":6133,"activeCount":101},[],{"trials":6135,"activeCount":101},[],{"trials":6137,"activeCount":101},[6138],{"nctId":6139,"briefTitle":6140,"status":158,"phases":6141,"primaryCompletion":6142,"completion":6143,"start":6144,"enrollment":6145,"conditions":6146,"interventions":6147},"NCT04078022","Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine",[90],"2023-01-24","2024-01-25","2020-03-02",58,[4745],[6130,6148],"S. flexneri 2a strain 2457T Challenge Agent",{"trials":6150,"activeCount":101},[],{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[],{"intervention":6148,"totalTrials":204,"cells":6156},{"EARLY_PHASE1":6157,"PHASE1":6159,"PHASE2":6161,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6158,"activeCount":101},[],{"trials":6160,"activeCount":101},[],{"trials":6162,"activeCount":101},[6163],{"nctId":6139,"briefTitle":6140,"status":158,"phases":6164,"primaryCompletion":6142,"completion":6143,"start":6144,"enrollment":6145,"conditions":6165,"interventions":6166},[90],[4745],[6130,6148],{"trials":6168,"activeCount":101},[],{"trials":6170,"activeCount":101},[],{"trials":6172,"activeCount":101},[],{"intervention":6174,"totalTrials":204,"cells":6175},"entinostat",{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6197,"PHASE4":6199,"NA":6201},{"trials":6177,"activeCount":101},[],{"trials":6179,"activeCount":101},[],{"trials":6181,"activeCount":101},[6182],{"nctId":6183,"briefTitle":6184,"status":223,"phases":6185,"primaryCompletion":4411,"completion":4411,"start":6186,"enrollment":659,"conditions":6187,"interventions":6195},"NCT01234532","Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery",[90],"2010-10",[6188,6189,6190,6191,6192,6193,6194],"Estrogen Receptor-negative Breast Cancer","HER2-negative Breast Cancer","Progesterone Receptor-negative Breast Cancer","Stage I Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Triple-negative Breast Cancer",[6174,6196],"anastrozole",{"trials":6198,"activeCount":101},[],{"trials":6200,"activeCount":101},[],{"trials":6202,"activeCount":101},[],{"intervention":6204,"totalTrials":204,"cells":6205},"Belantamab Mafodotin, Cyclophosphamide and Dexamethasone",{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6210,"PHASE3":6221,"PHASE4":6223,"NA":6225},{"trials":6207,"activeCount":101},[],{"trials":6209,"activeCount":101},[],{"trials":6211,"activeCount":101},[6212],{"nctId":6213,"briefTitle":6214,"status":223,"phases":6215,"primaryCompletion":6216,"completion":1767,"start":6217,"enrollment":31,"conditions":6218,"interventions":6220},"NCT04896658","Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed\u002FRefractory Multiple Myeloma",[89,90],"2023-06-30","2021-12-03",[6219],"Relapsed\u002FRefractory Multiple Myeloma",[6204],{"trials":6222,"activeCount":101},[],{"trials":6224,"activeCount":101},[],{"trials":6226,"activeCount":101},[],{"intervention":6228,"totalTrials":204,"cells":6229},"Vitamin D3",{"EARLY_PHASE1":6230,"PHASE1":6232,"PHASE2":6234,"PHASE3":6246,"PHASE4":6248,"NA":6250},{"trials":6231,"activeCount":101},[],{"trials":6233,"activeCount":101},[],{"trials":6235,"activeCount":101},[6236],{"nctId":6237,"briefTitle":6238,"status":158,"phases":6239,"primaryCompletion":6240,"completion":784,"start":6241,"enrollment":6242,"conditions":6243,"interventions":6245},"NCT02786498","Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing",[90],"2019-08","2016-11-21",102,[6244],"Fracture",[6228],{"trials":6247,"activeCount":101},[],{"trials":6249,"activeCount":101},[],{"trials":6251,"activeCount":101},[],{"intervention":4671,"totalTrials":204,"cells":6253},{"EARLY_PHASE1":6254,"PHASE1":6256,"PHASE2":6258,"PHASE3":6264,"PHASE4":6266,"NA":6268},{"trials":6255,"activeCount":101},[],{"trials":6257,"activeCount":101},[],{"trials":6259,"activeCount":101},[6260],{"nctId":4665,"briefTitle":4666,"status":158,"phases":6261,"primaryCompletion":4668,"completion":4668,"start":1485,"conditions":6262,"interventions":6263},[90],[1488],[4671,1492,4672],{"trials":6265,"activeCount":101},[],{"trials":6267,"activeCount":101},[],{"trials":6269,"activeCount":101},[],{"intervention":4672,"totalTrials":204,"cells":6271},{"EARLY_PHASE1":6272,"PHASE1":6274,"PHASE2":6276,"PHASE3":6282,"PHASE4":6284,"NA":6286},{"trials":6273,"activeCount":101},[],{"trials":6275,"activeCount":101},[],{"trials":6277,"activeCount":101},[6278],{"nctId":4665,"briefTitle":4666,"status":158,"phases":6279,"primaryCompletion":4668,"completion":4668,"start":1485,"conditions":6280,"interventions":6281},[90],[1488],[4671,1492,4672],{"trials":6283,"activeCount":101},[],{"trials":6285,"activeCount":101},[],{"trials":6287,"activeCount":101},[],{"intervention":6289,"totalTrials":204,"cells":6290},"Pioglitazone 15mg",{"EARLY_PHASE1":6291,"PHASE1":6293,"PHASE2":6295,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6292,"activeCount":101},[],{"trials":6294,"activeCount":101},[],{"trials":6296,"activeCount":101},[6297],{"nctId":6298,"briefTitle":6299,"status":223,"phases":6300,"primaryCompletion":6301,"completion":6302,"start":6303,"enrollment":204,"conditions":6304,"interventions":6306},"NCT05582707","Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone",[90],"2024-09-19","2025-12-25","2023-05-08",[6305],"Intracerebral Haemorrhage, Intraventricular",[6289],{"trials":6308,"activeCount":101},[],{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[],{"intervention":6314,"totalTrials":204,"cells":6315},"Precedex",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6332,"PHASE4":6334,"NA":6336},{"trials":6317,"activeCount":101},[],{"trials":6319,"activeCount":101},[],{"trials":6321,"activeCount":101},[6322],{"nctId":6323,"briefTitle":6324,"status":733,"phases":6325,"primaryCompletion":6326,"completion":6327,"start":3916,"enrollment":101,"conditions":6328,"interventions":6329},"NCT01007773","Safety of Dexmedetomidine in Severe Traumatic Brain Injury",[90],"2011-01","2012-01",[35],[6314,6330,6331,6330],"Propofol","Fentanyl",{"trials":6333,"activeCount":101},[],{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"intervention":6330,"totalTrials":204,"cells":6339},{"EARLY_PHASE1":6340,"PHASE1":6342,"PHASE2":6344,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6341,"activeCount":101},[],{"trials":6343,"activeCount":101},[],{"trials":6345,"activeCount":101},[6346],{"nctId":6323,"briefTitle":6324,"status":733,"phases":6347,"primaryCompletion":6326,"completion":6327,"start":3916,"enrollment":101,"conditions":6348,"interventions":6349},[90],[35],[6314,6330,6331,6330],{"trials":6351,"activeCount":101},[],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[],{"intervention":6331,"totalTrials":204,"cells":6357},{"EARLY_PHASE1":6358,"PHASE1":6360,"PHASE2":6362,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6359,"activeCount":101},[],{"trials":6361,"activeCount":101},[],{"trials":6363,"activeCount":101},[6364],{"nctId":6323,"briefTitle":6324,"status":733,"phases":6365,"primaryCompletion":6326,"completion":6327,"start":3916,"enrollment":101,"conditions":6366,"interventions":6367},[90],[35],[6314,6330,6331,6330],{"trials":6369,"activeCount":101},[],{"trials":6371,"activeCount":101},[],{"trials":6373,"activeCount":101},[],{"intervention":6375,"totalTrials":204,"cells":6376},"Niagen",{"EARLY_PHASE1":6377,"PHASE1":6379,"PHASE2":6381,"PHASE3":6392,"PHASE4":6394,"NA":6396},{"trials":6378,"activeCount":101},[],{"trials":6380,"activeCount":101},[],{"trials":6382,"activeCount":101},[6383],{"nctId":6384,"briefTitle":6385,"status":223,"phases":6386,"primaryCompletion":6387,"completion":6387,"start":6388,"enrollment":31,"conditions":6389,"interventions":6391},"NCT03685253","Nicotinamide Riboside for Diabetic Neuropathy",[89,90],"2022-05-01","2019-01-24",[6390],"Diabetic Neuropathy Peripheral",[6375],{"trials":6393,"activeCount":101},[],{"trials":6395,"activeCount":101},[],{"trials":6397,"activeCount":101},[],{"intervention":4156,"totalTrials":204,"cells":6399},{"EARLY_PHASE1":6400,"PHASE1":6402,"PHASE2":6404,"PHASE3":6410,"PHASE4":6412,"NA":6414},{"trials":6401,"activeCount":101},[],{"trials":6403,"activeCount":101},[],{"trials":6405,"activeCount":101},[6406],{"nctId":4149,"briefTitle":4150,"status":158,"phases":6407,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":996,"conditions":6408,"interventions":6409},[89,90],[16,19,189],[4156,4140],{"trials":6411,"activeCount":101},[],{"trials":6413,"activeCount":101},[],{"trials":6415,"activeCount":101},[],{"intervention":2512,"totalTrials":204,"cells":6417},{"EARLY_PHASE1":6418,"PHASE1":6420,"PHASE2":6422,"PHASE3":6428,"PHASE4":6430,"NA":6432},{"trials":6419,"activeCount":101},[],{"trials":6421,"activeCount":101},[],{"trials":6423,"activeCount":101},[6424],{"nctId":2505,"briefTitle":2506,"status":158,"phases":6425,"primaryCompletion":2508,"completion":2508,"start":2509,"conditions":6426,"interventions":6427},[90],[1529,1530,1488,2209],[2512,2211,2513,2514],{"trials":6429,"activeCount":101},[],{"trials":6431,"activeCount":101},[],{"trials":6433,"activeCount":101},[],{"intervention":2513,"totalTrials":204,"cells":6435},{"EARLY_PHASE1":6436,"PHASE1":6438,"PHASE2":6440,"PHASE3":6446,"PHASE4":6448,"NA":6450},{"trials":6437,"activeCount":101},[],{"trials":6439,"activeCount":101},[],{"trials":6441,"activeCount":101},[6442],{"nctId":2505,"briefTitle":2506,"status":158,"phases":6443,"primaryCompletion":2508,"completion":2508,"start":2509,"conditions":6444,"interventions":6445},[90],[1529,1530,1488,2209],[2512,2211,2513,2514],{"trials":6447,"activeCount":101},[],{"trials":6449,"activeCount":101},[],{"trials":6451,"activeCount":101},[],{"intervention":1538,"totalTrials":204,"cells":6453},{"EARLY_PHASE1":6454,"PHASE1":6456,"PHASE2":6458,"PHASE3":6464,"PHASE4":6466,"NA":6468},{"trials":6455,"activeCount":101},[],{"trials":6457,"activeCount":101},[],{"trials":6459,"activeCount":101},[6460],{"nctId":1533,"briefTitle":1534,"status":158,"phases":6461,"primaryCompletion":1526,"completion":1526,"start":1486,"enrollment":253,"conditions":6462,"interventions":6463},[90],[1530],[1511,1538,1539,1490,1443,1491,1492,1493,1502,1494,1495],{"trials":6465,"activeCount":101},[],{"trials":6467,"activeCount":101},[],{"trials":6469,"activeCount":101},[],{"intervention":6471,"totalTrials":204,"cells":6472},"Erbitux, Paclitaxel & Carboplatin",{"EARLY_PHASE1":6473,"PHASE1":6475,"PHASE2":6477,"PHASE3":6488,"PHASE4":6490,"NA":6492},{"trials":6474,"activeCount":101},[],{"trials":6476,"activeCount":101},[],{"trials":6478,"activeCount":101},[6479],{"nctId":6480,"briefTitle":6481,"status":158,"phases":6482,"primaryCompletion":5699,"completion":3623,"start":6483,"enrollment":6484,"conditions":6485,"interventions":6487},"NCT00343083","Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)",[90],"2004-12",43,[6486],"Cancer of Head and Neck",[6471],{"trials":6489,"activeCount":101},[],{"trials":6491,"activeCount":101},[],{"trials":6493,"activeCount":101},[],{"intervention":6495,"totalTrials":204,"cells":6496},"Donepezil",{"EARLY_PHASE1":6497,"PHASE1":6499,"PHASE2":6501,"PHASE3":6514,"PHASE4":6516,"NA":6518},{"trials":6498,"activeCount":101},[],{"trials":6500,"activeCount":101},[],{"trials":6502,"activeCount":101},[6503],{"nctId":6504,"briefTitle":6505,"status":6506,"phases":6507,"primaryCompletion":6508,"completion":6508,"start":6509,"enrollment":679,"conditions":6510,"interventions":6512},"NCT04505670","The Effect of Donepezil on Wound Healing","UNKNOWN",[90],"2023-07-30","2020-08-30",[6511],"Wound Heal",[6495,6513],"Topical Zinc Oxide",{"trials":6515,"activeCount":101},[],{"trials":6517,"activeCount":101},[],{"trials":6519,"activeCount":101},[],{"intervention":6513,"totalTrials":204,"cells":6521},{"EARLY_PHASE1":6522,"PHASE1":6524,"PHASE2":6526,"PHASE3":6532,"PHASE4":6534,"NA":6536},{"trials":6523,"activeCount":101},[],{"trials":6525,"activeCount":101},[],{"trials":6527,"activeCount":101},[6528],{"nctId":6504,"briefTitle":6505,"status":6506,"phases":6529,"primaryCompletion":6508,"completion":6508,"start":6509,"enrollment":679,"conditions":6530,"interventions":6531},[90],[6511],[6495,6513],{"trials":6533,"activeCount":101},[],{"trials":6535,"activeCount":101},[],{"trials":6537,"activeCount":101},[],{"intervention":6539,"totalTrials":204,"cells":6540},"EGCG",{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6545,"PHASE3":6554,"PHASE4":6556,"NA":6558},{"trials":6542,"activeCount":101},[],{"trials":6544,"activeCount":101},[],{"trials":6546,"activeCount":101},[6547],{"nctId":6548,"briefTitle":6549,"status":733,"phases":6550,"primaryCompletion":4972,"completion":4972,"start":5531,"enrollment":101,"conditions":6551,"interventions":6553},"NCT00434499","Effect of EGCG on the Body's Response to Insulin",[90],[3449,1624,6552,4974],"Type 2 Diabetes",[6539],{"trials":6555,"activeCount":101},[],{"trials":6557,"activeCount":101},[],{"trials":6559,"activeCount":101},[],{"intervention":538,"totalTrials":204,"cells":6561},{"EARLY_PHASE1":6562,"PHASE1":6564,"PHASE2":6566,"PHASE3":6572,"PHASE4":6574,"NA":6576},{"trials":6563,"activeCount":101},[],{"trials":6565,"activeCount":101},[],{"trials":6567,"activeCount":101},[6568],{"nctId":528,"briefTitle":529,"status":158,"phases":6569,"primaryCompletion":531,"completion":532,"start":533,"enrollment":534,"conditions":6570,"interventions":6571},[90],[536],[51,538],{"trials":6573,"activeCount":101},[],{"trials":6575,"activeCount":101},[],{"trials":6577,"activeCount":101},[],{"intervention":6579,"totalTrials":204,"cells":6580},"CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a",{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6593,"PHASE4":6595,"NA":6597},{"trials":6582,"activeCount":101},[],{"trials":6584,"activeCount":101},[],{"trials":6586,"activeCount":101},[6587],{"nctId":6588,"briefTitle":6589,"status":223,"phases":6590,"primaryCompletion":4753,"completion":4753,"start":3916,"enrollment":679,"conditions":6591,"interventions":6592},"NCT00866242","Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb",[90],[4745],[6579],{"trials":6594,"activeCount":101},[],{"trials":6596,"activeCount":101},[],{"trials":6598,"activeCount":101},[],{"intervention":6600,"totalTrials":204,"cells":6601},"Doxycycline",{"EARLY_PHASE1":6602,"PHASE1":6604,"PHASE2":6606,"PHASE3":6617,"PHASE4":6619,"NA":6621},{"trials":6603,"activeCount":101},[],{"trials":6605,"activeCount":101},[],{"trials":6607,"activeCount":101},[6608],{"nctId":6609,"briefTitle":6610,"status":158,"phases":6611,"primaryCompletion":6612,"completion":6612,"start":5924,"enrollment":6613,"conditions":6614,"interventions":6616},"NCT01756833","Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial",[90],"2019-07-23",261,[6615],"Aneurysm",[6600],{"trials":6618,"activeCount":101},[],{"trials":6620,"activeCount":101},[],{"trials":6622,"activeCount":101},[],{"intervention":6624,"totalTrials":204,"cells":6625},"pentamidine",{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6630,"PHASE3":6641,"PHASE4":6643,"NA":6645},{"trials":6627,"activeCount":101},[],{"trials":6629,"activeCount":101},[],{"trials":6631,"activeCount":101},[6632],{"nctId":6633,"briefTitle":6634,"status":223,"phases":6635,"primaryCompletion":6636,"completion":6637,"start":3256,"enrollment":2400,"conditions":6638,"interventions":6640},"NCT00729807","0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma",[90],"2012-08","2012-11",[6639],"Melanoma (Skin)",[6624],{"trials":6642,"activeCount":101},[],{"trials":6644,"activeCount":101},[],{"trials":6646,"activeCount":101},[],{"intervention":6648,"totalTrials":204,"cells":6649},"bevacizumab",{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6665,"PHASE4":6667,"NA":6669},{"trials":6651,"activeCount":101},[],{"trials":6653,"activeCount":101},[],{"trials":6655,"activeCount":101},[6656],{"nctId":6657,"briefTitle":6658,"status":158,"phases":6659,"primaryCompletion":6660,"completion":3257,"start":3029,"conditions":6661,"interventions":6662},"NCT00015951","Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers",[90],"2003-04",[1529,2209],[6648,6663,6664],"cytarabine","mitoxantrone hydrochloride",{"trials":6666,"activeCount":101},[],{"trials":6668,"activeCount":101},[],{"trials":6670,"activeCount":101},[],{"intervention":6663,"totalTrials":204,"cells":6672},{"EARLY_PHASE1":6673,"PHASE1":6675,"PHASE2":6677,"PHASE3":6683,"PHASE4":6685,"NA":6687},{"trials":6674,"activeCount":101},[],{"trials":6676,"activeCount":101},[],{"trials":6678,"activeCount":101},[6679],{"nctId":6657,"briefTitle":6658,"status":158,"phases":6680,"primaryCompletion":6660,"completion":3257,"start":3029,"conditions":6681,"interventions":6682},[90],[1529,2209],[6648,6663,6664],{"trials":6684,"activeCount":101},[],{"trials":6686,"activeCount":101},[],{"trials":6688,"activeCount":101},[],{"intervention":6664,"totalTrials":204,"cells":6690},{"EARLY_PHASE1":6691,"PHASE1":6693,"PHASE2":6695,"PHASE3":6701,"PHASE4":6703,"NA":6705},{"trials":6692,"activeCount":101},[],{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[6697],{"nctId":6657,"briefTitle":6658,"status":158,"phases":6698,"primaryCompletion":6660,"completion":3257,"start":3029,"conditions":6699,"interventions":6700},[90],[1529,2209],[6648,6663,6664],{"trials":6702,"activeCount":101},[],{"trials":6704,"activeCount":101},[],{"trials":6706,"activeCount":101},[],{"intervention":6708,"totalTrials":204,"cells":6709},"Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail",{"EARLY_PHASE1":6710,"PHASE1":6712,"PHASE2":6714,"PHASE3":6727,"PHASE4":6729,"NA":6731},{"trials":6711,"activeCount":101},[],{"trials":6713,"activeCount":101},[],{"trials":6715,"activeCount":101},[6716],{"nctId":6717,"briefTitle":6718,"status":733,"phases":6719,"primaryCompletion":1105,"completion":1746,"start":6720,"enrollment":101,"conditions":6721,"interventions":6726},"NCT06447194","Effect of RECK in Posterior Spinal Fusion",[89,90],"2025-10-01",[6722,6723,6724,6725],"Degenerative Lumbar Spinal Stenosis","Degenerative Disc Disease","Degenerative Spondylolisthesis","Degenerative Disease",[6708],{"trials":6728,"activeCount":101},[],{"trials":6730,"activeCount":101},[],{"trials":6732,"activeCount":101},[],{"intervention":6734,"totalTrials":204,"cells":6735},"Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose",{"EARLY_PHASE1":6736,"PHASE1":6738,"PHASE2":6750,"PHASE3":6752,"PHASE4":6754,"NA":6756},{"trials":6737,"activeCount":101},[],{"trials":6739,"activeCount":101},[6740],{"nctId":6741,"briefTitle":6742,"status":158,"phases":6743,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":679,"conditions":6746,"interventions":6748},"NCT05268302","Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)",[89],"2024-01-04","2022-02-28",[6747],"Dengue",[6734,6749],"Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge",{"trials":6751,"activeCount":101},[],{"trials":6753,"activeCount":101},[],{"trials":6755,"activeCount":101},[],{"trials":6757,"activeCount":101},[],{"intervention":6749,"totalTrials":204,"cells":6759},{"EARLY_PHASE1":6760,"PHASE1":6762,"PHASE2":6768,"PHASE3":6770,"PHASE4":6772,"NA":6774},{"trials":6761,"activeCount":101},[],{"trials":6763,"activeCount":101},[6764],{"nctId":6741,"briefTitle":6742,"status":158,"phases":6765,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":679,"conditions":6766,"interventions":6767},[89],[6747],[6734,6749],{"trials":6769,"activeCount":101},[],{"trials":6771,"activeCount":101},[],{"trials":6773,"activeCount":101},[],{"trials":6775,"activeCount":101},[],{"intervention":6777,"totalTrials":204,"cells":6778},"ciprofloxacin",{"EARLY_PHASE1":6779,"PHASE1":6781,"PHASE2":6790,"PHASE3":6792,"PHASE4":6794,"NA":6796},{"trials":6780,"activeCount":101},[],{"trials":6782,"activeCount":101},[6783],{"nctId":6784,"briefTitle":6785,"status":158,"phases":6786,"primaryCompletion":6787,"completion":6787,"start":5530,"enrollment":20,"conditions":6788,"interventions":6789},"NCT00992329","Impact of Formulation on Ciprofloxacin Oral Absorption",[89],"2013-11",[395],[6777],{"trials":6791,"activeCount":101},[],{"trials":6793,"activeCount":101},[],{"trials":6795,"activeCount":101},[],{"trials":6797,"activeCount":101},[],{"intervention":6799,"totalTrials":204,"cells":6800},"3TC, TDF, NLV",{"EARLY_PHASE1":6801,"PHASE1":6803,"PHASE2":6813,"PHASE3":6815,"PHASE4":6817,"NA":6819},{"trials":6802,"activeCount":101},[],{"trials":6804,"activeCount":101},[6805],{"nctId":6806,"briefTitle":6807,"status":158,"phases":6808,"primaryCompletion":6809,"completion":6809,"start":6810,"enrollment":2400,"conditions":6811,"interventions":6812},"NCT00336778","Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression",[89],"2008-04","2004-01",[3515],[6799],{"trials":6814,"activeCount":101},[],{"trials":6816,"activeCount":101},[],{"trials":6818,"activeCount":101},[],{"trials":6820,"activeCount":101},[],{"intervention":6822,"totalTrials":204,"cells":6823},"CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine",{"EARLY_PHASE1":6824,"PHASE1":6826,"PHASE2":6837,"PHASE3":6839,"PHASE4":6841,"NA":6843},{"trials":6825,"activeCount":101},[],{"trials":6827,"activeCount":101},[6828],{"nctId":6829,"briefTitle":6830,"status":158,"phases":6831,"primaryCompletion":4064,"completion":6832,"start":185,"enrollment":6833,"conditions":6834,"interventions":6836},"NCT01129453","Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection",[89],"2013-04",51,[6835],"Salmonella",[6822],{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"trials":6844,"activeCount":101},[],{"intervention":6846,"totalTrials":204,"cells":6847},"MAGE-A3",{"EARLY_PHASE1":6848,"PHASE1":6850,"PHASE2":6861,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6849,"activeCount":101},[],{"trials":6851,"activeCount":101},[6852],{"nctId":6853,"briefTitle":6854,"status":158,"phases":6855,"primaryCompletion":1858,"completion":1858,"start":6856,"enrollment":2575,"conditions":6857,"interventions":6859},"NCT00257738","0804 GCC: MAGE-A3\u002FHPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck",[89],"2005-11",[6858],"Squamous Cell Carcinoma of the Head and Neck",[6846,6860],"HPV-16 vaccine",{"trials":6862,"activeCount":101},[],{"trials":6864,"activeCount":101},[],{"trials":6866,"activeCount":101},[],{"trials":6868,"activeCount":101},[],{"intervention":6860,"totalTrials":204,"cells":6870},{"EARLY_PHASE1":6871,"PHASE1":6873,"PHASE2":6879,"PHASE3":6881,"PHASE4":6883,"NA":6885},{"trials":6872,"activeCount":101},[],{"trials":6874,"activeCount":101},[6875],{"nctId":6853,"briefTitle":6854,"status":158,"phases":6876,"primaryCompletion":1858,"completion":1858,"start":6856,"enrollment":2575,"conditions":6877,"interventions":6878},[89],[6858],[6846,6860],{"trials":6880,"activeCount":101},[],{"trials":6882,"activeCount":101},[],{"trials":6884,"activeCount":101},[],{"trials":6886,"activeCount":101},[],{"intervention":6888,"totalTrials":204,"cells":6889},"LMB-9 immunotoxin",{"EARLY_PHASE1":6890,"PHASE1":6892,"PHASE2":6905,"PHASE3":6907,"PHASE4":6909,"NA":6911},{"trials":6891,"activeCount":101},[],{"trials":6893,"activeCount":101},[6894],{"nctId":6895,"briefTitle":6896,"status":158,"phases":6897,"primaryCompletion":6898,"completion":6898,"start":6899,"enrollment":253,"conditions":6900,"interventions":6904},"NCT00005858","LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer",[89],"2003-12","2000-04",[6901,25,6902,5801,1520,6903],"Bladder Cancer","Colorectal Cancer","Pancreatic Cancer",[6888],{"trials":6906,"activeCount":101},[],{"trials":6908,"activeCount":101},[],{"trials":6910,"activeCount":101},[],{"trials":6912,"activeCount":101},[],{"intervention":6914,"totalTrials":204,"cells":6915},"Lactulose -rhamnose solution",{"EARLY_PHASE1":6916,"PHASE1":6918,"PHASE2":6929,"PHASE3":6931,"PHASE4":6933,"NA":6935},{"trials":6917,"activeCount":101},[],{"trials":6919,"activeCount":101},[6920],{"nctId":6921,"briefTitle":6922,"status":158,"phases":6923,"primaryCompletion":2361,"completion":2361,"start":6924,"enrollment":832,"conditions":6925,"interventions":6928},"NCT01756040","Intestinal Permeability in Preterm Infants",[89],"2013-02-01",[6926,6927],"Prematurity","Intestinal Permeability",[6914],{"trials":6930,"activeCount":101},[],{"trials":6932,"activeCount":101},[],{"trials":6934,"activeCount":101},[],{"trials":6936,"activeCount":101},[],{"intervention":1462,"totalTrials":204,"cells":6938},{"EARLY_PHASE1":6939,"PHASE1":6941,"PHASE2":6947,"PHASE3":6949,"PHASE4":6951,"NA":6953},{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[6943],{"nctId":1451,"briefTitle":1452,"status":223,"phases":6944,"primaryCompletion":1454,"completion":1455,"start":1456,"enrollment":1457,"conditions":6945,"interventions":6946},[89],[1459,1460],[1462,717],{"trials":6948,"activeCount":101},[],{"trials":6950,"activeCount":101},[],{"trials":6952,"activeCount":101},[],{"trials":6954,"activeCount":101},[],{"intervention":6956,"totalTrials":204,"cells":6957},"LPS",{"EARLY_PHASE1":6958,"PHASE1":6960,"PHASE2":6970,"PHASE3":6972,"PHASE4":6974,"NA":6976},{"trials":6959,"activeCount":101},[],{"trials":6961,"activeCount":101},[6962],{"nctId":6963,"briefTitle":6964,"status":733,"phases":6965,"primaryCompletion":6966,"completion":6966,"start":6967,"enrollment":101,"conditions":6968,"interventions":6969},"NCT03271814","Brain Biomarker on Inflammation Response",[89],"2025-12-15","2025-01-01",[16],[6956],{"trials":6971,"activeCount":101},[],{"trials":6973,"activeCount":101},[],{"trials":6975,"activeCount":101},[],{"trials":6977,"activeCount":101},[],{"intervention":6979,"totalTrials":204,"cells":6980},"Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation",{"EARLY_PHASE1":6981,"PHASE1":6983,"PHASE2":6996,"PHASE3":6998,"PHASE4":7000,"NA":7002},{"trials":6982,"activeCount":101},[],{"trials":6984,"activeCount":101},[6985],{"nctId":6986,"briefTitle":6987,"status":158,"phases":6988,"primaryCompletion":6989,"completion":6989,"start":6990,"enrollment":6991,"conditions":6992,"interventions":6993},"NCT05525546","Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease",[89],"2023-06-12","2022-08-15",82,[141],[6979,6994,6995],"Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation","Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation",{"trials":6997,"activeCount":101},[],{"trials":6999,"activeCount":101},[],{"trials":7001,"activeCount":101},[],{"trials":7003,"activeCount":101},[],{"intervention":6994,"totalTrials":204,"cells":7005},{"EARLY_PHASE1":7006,"PHASE1":7008,"PHASE2":7014,"PHASE3":7016,"PHASE4":7018,"NA":7020},{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[7010],{"nctId":6986,"briefTitle":6987,"status":158,"phases":7011,"primaryCompletion":6989,"completion":6989,"start":6990,"enrollment":6991,"conditions":7012,"interventions":7013},[89],[141],[6979,6994,6995],{"trials":7015,"activeCount":101},[],{"trials":7017,"activeCount":101},[],{"trials":7019,"activeCount":101},[],{"trials":7021,"activeCount":101},[],{"intervention":6995,"totalTrials":204,"cells":7023},{"EARLY_PHASE1":7024,"PHASE1":7026,"PHASE2":7032,"PHASE3":7034,"PHASE4":7036,"NA":7038},{"trials":7025,"activeCount":101},[],{"trials":7027,"activeCount":101},[7028],{"nctId":6986,"briefTitle":6987,"status":158,"phases":7029,"primaryCompletion":6989,"completion":6989,"start":6990,"enrollment":6991,"conditions":7030,"interventions":7031},[89],[141],[6979,6994,6995],{"trials":7033,"activeCount":101},[],{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[],{"trials":7039,"activeCount":101},[],{"intervention":1476,"totalTrials":204,"cells":7041},{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7050,"PHASE3":7052,"PHASE4":7054,"NA":7056},{"trials":7043,"activeCount":101},[],{"trials":7045,"activeCount":101},[7046],{"nctId":1468,"briefTitle":1469,"status":1470,"phases":7047,"primaryCompletion":1254,"completion":1472,"start":1253,"enrollment":1176,"conditions":7048,"interventions":7049},[89],[1474],[1476,1477,717,1478],{"trials":7051,"activeCount":101},[],{"trials":7053,"activeCount":101},[],{"trials":7055,"activeCount":101},[],{"trials":7057,"activeCount":101},[],{"intervention":1478,"totalTrials":204,"cells":7059},{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7068,"PHASE3":7070,"PHASE4":7072,"NA":7074},{"trials":7061,"activeCount":101},[],{"trials":7063,"activeCount":101},[7064],{"nctId":1468,"briefTitle":1469,"status":1470,"phases":7065,"primaryCompletion":1254,"completion":1472,"start":1253,"enrollment":1176,"conditions":7066,"interventions":7067},[89],[1474],[1476,1477,717,1478],{"trials":7069,"activeCount":101},[],{"trials":7071,"activeCount":101},[],{"trials":7073,"activeCount":101},[],{"trials":7075,"activeCount":101},[],{"intervention":1590,"totalTrials":204,"cells":7077},{"EARLY_PHASE1":7078,"PHASE1":7080,"PHASE2":7086,"PHASE3":7088,"PHASE4":7090,"NA":7092},{"trials":7079,"activeCount":101},[],{"trials":7081,"activeCount":101},[7082],{"nctId":1582,"briefTitle":1583,"status":158,"phases":7083,"primaryCompletion":1585,"completion":1585,"start":1586,"enrollment":726,"conditions":7084,"interventions":7085},[89],[22,1588],[1575,1590],{"trials":7087,"activeCount":101},[],{"trials":7089,"activeCount":101},[],{"trials":7091,"activeCount":101},[],{"trials":7093,"activeCount":101},[],{"intervention":7095,"totalTrials":204,"cells":7096},"Venetoclax and pegcrisantaspase",{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7110,"PHASE3":7112,"PHASE4":7114,"NA":7116},{"trials":7098,"activeCount":101},[],{"trials":7100,"activeCount":101},[7101],{"nctId":7102,"briefTitle":7103,"status":158,"phases":7104,"primaryCompletion":45,"completion":3304,"start":7105,"enrollment":7106,"conditions":7107,"interventions":7109},"NCT04666649","Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R\u002FR AML)",[89],"2021-03-10",27,[7108],"Relapsed or Refractory Acute Myeloid Leukemia",[7095],{"trials":7111,"activeCount":101},[],{"trials":7113,"activeCount":101},[],{"trials":7115,"activeCount":101},[],{"trials":7117,"activeCount":101},[],{"intervention":7119,"totalTrials":204,"cells":7120},"dendritic cell vaccine",{"EARLY_PHASE1":7121,"PHASE1":7123,"PHASE2":7134,"PHASE3":7136,"PHASE4":7138,"NA":7140},{"trials":7122,"activeCount":101},[],{"trials":7124,"activeCount":101},[7125],{"nctId":7126,"briefTitle":7127,"status":733,"phases":7128,"primaryCompletion":7129,"completion":3489,"start":7130,"enrollment":101,"conditions":7131,"interventions":7133},"NCT00492947","Dendritic Cell Vaccine for Head and Neck Cancer",[89],"2010-06","2007-06",[7132],"Squamous Cell Carcinoma of Head and Neck",[7119],{"trials":7135,"activeCount":101},[],{"trials":7137,"activeCount":101},[],{"trials":7139,"activeCount":101},[],{"trials":7141,"activeCount":101},[],{"intervention":7143,"totalTrials":204,"cells":7144},"l-THP",{"EARLY_PHASE1":7145,"PHASE1":7147,"PHASE2":7156,"PHASE3":7158,"PHASE4":7160,"NA":7162},{"trials":7146,"activeCount":101},[],{"trials":7148,"activeCount":101},[7149],{"nctId":7150,"briefTitle":7151,"status":158,"phases":7152,"primaryCompletion":737,"completion":737,"start":1858,"enrollment":679,"conditions":7153,"interventions":7155},"NCT01631383","Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use",[89],[7154],"Cocaine Use",[7143],{"trials":7157,"activeCount":101},[],{"trials":7159,"activeCount":101},[],{"trials":7161,"activeCount":101},[],{"trials":7163,"activeCount":101},[],{"intervention":7165,"totalTrials":204,"cells":7166},"AVL-3288",{"EARLY_PHASE1":7167,"PHASE1":7169,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7168,"activeCount":101},[],{"trials":7170,"activeCount":101},[7171],{"nctId":7172,"briefTitle":7173,"status":733,"phases":7174,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":101,"conditions":7177,"interventions":7179},"NCT03281694","The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine",[89],"2019-02","2018-05",[7178],"Cognitive Change",[7180,7165,7181],"Nicotine","Nicotine + AVL-3288",{"trials":7183,"activeCount":101},[],{"trials":7185,"activeCount":101},[],{"trials":7187,"activeCount":101},[],{"trials":7189,"activeCount":101},[],{"intervention":7181,"totalTrials":204,"cells":7191},{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7200,"PHASE3":7202,"PHASE4":7204,"NA":7206},{"trials":7193,"activeCount":101},[],{"trials":7195,"activeCount":101},[7196],{"nctId":7172,"briefTitle":7173,"status":733,"phases":7197,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":101,"conditions":7198,"interventions":7199},[89],[7178],[7180,7165,7181],{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"trials":7205,"activeCount":101},[],{"trials":7207,"activeCount":101},[],{"intervention":7209,"totalTrials":204,"cells":7210},"strain CVD 1208S-122",{"EARLY_PHASE1":7211,"PHASE1":7213,"PHASE2":7225,"PHASE3":7227,"PHASE4":7229,"NA":7231},{"trials":7212,"activeCount":101},[],{"trials":7214,"activeCount":101},[7215],{"nctId":7216,"briefTitle":7217,"status":158,"phases":7218,"primaryCompletion":3847,"completion":3847,"start":7219,"enrollment":7220,"conditions":7221,"interventions":7224},"NCT04634513","Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122",[89],"2022-09-29",53,[7222,7223],"Shigella Infection","Enterotoxigenic Escherichia Coli Infection",[7209],{"trials":7226,"activeCount":101},[],{"trials":7228,"activeCount":101},[],{"trials":7230,"activeCount":101},[],{"trials":7232,"activeCount":101},[],{"intervention":7234,"totalTrials":204,"cells":7235},"Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z",{"EARLY_PHASE1":7236,"PHASE1":7238,"PHASE2":7250,"PHASE3":7252,"PHASE4":7254,"NA":7256},{"trials":7237,"activeCount":101},[],{"trials":7239,"activeCount":101},[7240],{"nctId":7241,"briefTitle":7242,"status":158,"phases":7243,"primaryCompletion":7244,"completion":7244,"start":4024,"enrollment":187,"conditions":7245,"interventions":7248},"NCT02267109","Phase 1 Trial of Ebola Vaccine in Mali",[89],"2016-04-20",[7246,7247],"Ebola Virus Disease","Hemorrhagic Fever",[7234,7249],"Booster-MVA-BN® Filo or saline placebo",{"trials":7251,"activeCount":101},[],{"trials":7253,"activeCount":101},[],{"trials":7255,"activeCount":101},[],{"trials":7257,"activeCount":101},[],{"intervention":7249,"totalTrials":204,"cells":7259},{"EARLY_PHASE1":7260,"PHASE1":7262,"PHASE2":7268,"PHASE3":7270,"PHASE4":7272,"NA":7274},{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[7264],{"nctId":7241,"briefTitle":7242,"status":158,"phases":7265,"primaryCompletion":7244,"completion":7244,"start":4024,"enrollment":187,"conditions":7266,"interventions":7267},[89],[7246,7247],[7234,7249],{"trials":7269,"activeCount":101},[],{"trials":7271,"activeCount":101},[],{"trials":7273,"activeCount":101},[],{"trials":7275,"activeCount":101},[],{"intervention":7277,"totalTrials":204,"cells":7278},"Trivalent Invasive Salmonella Disease Vaccine",{"EARLY_PHASE1":7279,"PHASE1":7281,"PHASE2":7292,"PHASE3":7294,"PHASE4":7296,"NA":7298},{"trials":7280,"activeCount":101},[],{"trials":7282,"activeCount":101},[7283],{"nctId":7284,"briefTitle":7285,"status":158,"phases":7286,"primaryCompletion":7287,"completion":7287,"start":7288,"enrollment":7289,"conditions":7290,"interventions":7291},"NCT03981952","Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine",[89],"2021-05-07","2019-10-28",96,[141],[7277,7277,7277,7277],{"trials":7293,"activeCount":101},[],{"trials":7295,"activeCount":101},[],{"trials":7297,"activeCount":101},[],{"trials":7299,"activeCount":101},[],{"intervention":7301,"totalTrials":204,"cells":7302},"Exenatide",{"EARLY_PHASE1":7303,"PHASE1":7305,"PHASE2":7318,"PHASE3":7320,"PHASE4":7322,"NA":7324},{"trials":7304,"activeCount":101},[],{"trials":7306,"activeCount":101},[7307],{"nctId":7308,"briefTitle":7309,"status":223,"phases":7310,"primaryCompletion":7311,"completion":7312,"start":7313,"enrollment":7314,"conditions":7315,"interventions":7316},"NCT05762744","Pharmacogenomics of GLP1 Receptor Agonists",[89],"2018-11-30","2022-10-31","2016-06-01",63,[6552],[7301,7317],"Exenatide injection before the second FSIGT)",{"trials":7319,"activeCount":101},[],{"trials":7321,"activeCount":101},[],{"trials":7323,"activeCount":101},[],{"trials":7325,"activeCount":101},[],{"intervention":7317,"totalTrials":204,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7336,"PHASE3":7338,"PHASE4":7340,"NA":7342},{"trials":7329,"activeCount":101},[],{"trials":7331,"activeCount":101},[7332],{"nctId":7308,"briefTitle":7309,"status":223,"phases":7333,"primaryCompletion":7311,"completion":7312,"start":7313,"enrollment":7314,"conditions":7334,"interventions":7335},[89],[6552],[7301,7317],{"trials":7337,"activeCount":101},[],{"trials":7339,"activeCount":101},[],{"trials":7341,"activeCount":101},[],{"trials":7343,"activeCount":101},[],{"intervention":7345,"totalTrials":204,"cells":7346},"cimetidine",{"EARLY_PHASE1":7347,"PHASE1":7349,"PHASE2":7359,"PHASE3":7361,"PHASE4":7363,"NA":7365},{"trials":7348,"activeCount":101},[],{"trials":7350,"activeCount":101},[7351],{"nctId":7352,"briefTitle":7353,"status":158,"phases":7354,"primaryCompletion":4064,"completion":4064,"start":7355,"enrollment":7356,"conditions":7357,"interventions":7358},"NCT01010698","Class 3 Biowaivers",[89],"2009-06",48,[395],[7345],{"trials":7360,"activeCount":101},[],{"trials":7362,"activeCount":101},[],{"trials":7364,"activeCount":101},[],{"trials":7366,"activeCount":101},[],{"intervention":7368,"totalTrials":204,"cells":7369},"VRC-EBOADC069-00-vp",{"EARLY_PHASE1":7370,"PHASE1":7372,"PHASE2":7382,"PHASE3":7384,"PHASE4":7386,"NA":7388},{"trials":7371,"activeCount":101},[],{"trials":7373,"activeCount":101},[7374],{"nctId":7375,"briefTitle":7376,"status":158,"phases":7377,"primaryCompletion":7378,"completion":7378,"start":5286,"enrollment":785,"conditions":7379,"interventions":7380},"NCT02368119","Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)",[89],"2016-09-27",[7246,7247],[7368,7368,7381],"MVA-EbolaZ",{"trials":7383,"activeCount":101},[],{"trials":7385,"activeCount":101},[],{"trials":7387,"activeCount":101},[],{"trials":7389,"activeCount":101},[],{"intervention":7381,"totalTrials":204,"cells":7391},{"EARLY_PHASE1":7392,"PHASE1":7394,"PHASE2":7400,"PHASE3":7402,"PHASE4":7404,"NA":7406},{"trials":7393,"activeCount":101},[],{"trials":7395,"activeCount":101},[7396],{"nctId":7375,"briefTitle":7376,"status":158,"phases":7397,"primaryCompletion":7378,"completion":7378,"start":5286,"enrollment":785,"conditions":7398,"interventions":7399},[89],[7246,7247],[7368,7368,7381],{"trials":7401,"activeCount":101},[],{"trials":7403,"activeCount":101},[],{"trials":7405,"activeCount":101},[],{"trials":7407,"activeCount":101},[],{"intervention":7409,"totalTrials":204,"cells":7410},"tipifarnib",{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7422,"PHASE3":7424,"PHASE4":7426,"NA":7428},{"trials":7412,"activeCount":101},[],{"trials":7414,"activeCount":101},[7415],{"nctId":7416,"briefTitle":7417,"status":158,"phases":7418,"primaryCompletion":3029,"completion":3029,"start":7419,"conditions":7420,"interventions":7421},"NCT00004009","R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia",[89],"1999-06",[1529],[7409],{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"intervention":7431,"totalTrials":204,"cells":7432},"IV bolus injection of Sildenafil",{"EARLY_PHASE1":7433,"PHASE1":7435,"PHASE2":7444,"PHASE3":7446,"PHASE4":7448,"NA":7450},{"trials":7434,"activeCount":101},[],{"trials":7436,"activeCount":101},[7437],{"nctId":7438,"briefTitle":7439,"status":223,"phases":7440,"primaryCompletion":6098,"completion":6098,"start":2699,"enrollment":208,"conditions":7441,"interventions":7443},"NCT01954524","A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis",[89],[7442],"Cirrhosis",[7431],{"trials":7445,"activeCount":101},[],{"trials":7447,"activeCount":101},[],{"trials":7449,"activeCount":101},[],{"trials":7451,"activeCount":101},[],{"intervention":7453,"totalTrials":204,"cells":7454},"300 ug FLSC vaccine",{"EARLY_PHASE1":7455,"PHASE1":7457,"PHASE2":7469,"PHASE3":7471,"PHASE4":7473,"NA":7475},{"trials":7456,"activeCount":101},[],{"trials":7458,"activeCount":101},[7459],{"nctId":7460,"briefTitle":7461,"status":158,"phases":7462,"primaryCompletion":7463,"completion":7463,"start":5596,"enrollment":4134,"conditions":7464,"interventions":7466},"NCT02756208","A Safety and Immunogenicity Trial of IHV01",[89],"2018-07",[7465],"HIV Infection",[7453,7467,7468],"150 ug FLSC vaccine","75 ug FLSC vaccine",{"trials":7470,"activeCount":101},[],{"trials":7472,"activeCount":101},[],{"trials":7474,"activeCount":101},[],{"trials":7476,"activeCount":101},[],{"intervention":7467,"totalTrials":204,"cells":7478},{"EARLY_PHASE1":7479,"PHASE1":7481,"PHASE2":7487,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7480,"activeCount":101},[],{"trials":7482,"activeCount":101},[7483],{"nctId":7460,"briefTitle":7461,"status":158,"phases":7484,"primaryCompletion":7463,"completion":7463,"start":5596,"enrollment":4134,"conditions":7485,"interventions":7486},[89],[7465],[7453,7467,7468],{"trials":7488,"activeCount":101},[],{"trials":7490,"activeCount":101},[],{"trials":7492,"activeCount":101},[],{"trials":7494,"activeCount":101},[],{"intervention":7468,"totalTrials":204,"cells":7496},{"EARLY_PHASE1":7497,"PHASE1":7499,"PHASE2":7505,"PHASE3":7507,"PHASE4":7509,"NA":7511},{"trials":7498,"activeCount":101},[],{"trials":7500,"activeCount":101},[7501],{"nctId":7460,"briefTitle":7461,"status":158,"phases":7502,"primaryCompletion":7463,"completion":7463,"start":5596,"enrollment":4134,"conditions":7503,"interventions":7504},[89],[7465],[7453,7467,7468],{"trials":7506,"activeCount":101},[],{"trials":7508,"activeCount":101},[],{"trials":7510,"activeCount":101},[],{"trials":7512,"activeCount":101},[],{"intervention":7514,"totalTrials":204,"cells":7515},"Ketamine Hydrochloride",{"EARLY_PHASE1":7516,"PHASE1":7518,"PHASE2":7530,"PHASE3":7532,"PHASE4":7534,"NA":7536},{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[7520],{"nctId":7521,"briefTitle":7522,"status":223,"phases":7523,"primaryCompletion":7524,"completion":7525,"start":7526,"enrollment":659,"conditions":7527,"interventions":7529},"NCT05051449","Ketamine for OUD and Comorbid Depression (OUDCD)",[89],"2023-11-17","2023-11-30","2022-04-04",[30,7528],"Depressive Disorder",[7514],{"trials":7531,"activeCount":101},[],{"trials":7533,"activeCount":101},[],{"trials":7535,"activeCount":101},[],{"trials":7537,"activeCount":101},[],{"intervention":7539,"totalTrials":204,"cells":7540},"Dengue 1 Live Virus Human Challenge",{"EARLY_PHASE1":7541,"PHASE1":7543,"PHASE2":7553,"PHASE3":7555,"PHASE4":7557,"NA":7559},{"trials":7542,"activeCount":101},[],{"trials":7544,"activeCount":101},[7545],{"nctId":7546,"briefTitle":7547,"status":158,"phases":7548,"primaryCompletion":7549,"completion":7549,"start":7550,"enrollment":31,"conditions":7551,"interventions":7552},"NCT04786457","ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)",[89],"2021-07-09","2020-11-30",[6747],[7539],{"trials":7554,"activeCount":101},[],{"trials":7556,"activeCount":101},[],{"trials":7558,"activeCount":101},[],{"trials":7560,"activeCount":101},[],{"intervention":7562,"totalTrials":204,"cells":7563},"CRD3874",{"EARLY_PHASE1":7564,"PHASE1":7566,"PHASE2":7577,"PHASE3":7579,"PHASE4":7581,"NA":7583},{"trials":7565,"activeCount":101},[],{"trials":7567,"activeCount":101},[7568],{"nctId":7569,"briefTitle":7570,"status":1470,"phases":7571,"primaryCompletion":7572,"completion":7573,"start":7574,"enrollment":2400,"conditions":7575,"interventions":7576},"NCT06626633","2321GCCC: CRD3874-SI in Patients With Relapsed\u002FRefractory AML",[89],"2025-08-25","2028-01-31","2024-08-26",[5394],[7562],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"trials":7582,"activeCount":101},[],{"trials":7584,"activeCount":101},[],{"intervention":7586,"totalTrials":204,"cells":7587},"Diclofenac Epolamine Patch",{"EARLY_PHASE1":7588,"PHASE1":7601,"PHASE2":7603,"PHASE3":7605,"PHASE4":7607,"NA":7609},{"trials":7589,"activeCount":101},[7590],{"nctId":7591,"briefTitle":7592,"status":158,"phases":7593,"primaryCompletion":7594,"completion":7595,"start":7596,"enrollment":26,"conditions":7597,"interventions":7599},"NCT03145259","Evaluation of Bioavailability of Diclofenac Dermal Products",[88],"2019-08-29","2020-05-15","2017-04-19",[7598],"Bioavailability",[7586,7600],"diclofenac sodium solution",{"trials":7602,"activeCount":101},[],{"trials":7604,"activeCount":101},[],{"trials":7606,"activeCount":101},[],{"trials":7608,"activeCount":101},[],{"trials":7610,"activeCount":101},[],{"intervention":7600,"totalTrials":204,"cells":7612},{"EARLY_PHASE1":7613,"PHASE1":7619,"PHASE2":7621,"PHASE3":7623,"PHASE4":7625,"NA":7627},{"trials":7614,"activeCount":101},[7615],{"nctId":7591,"briefTitle":7592,"status":158,"phases":7616,"primaryCompletion":7594,"completion":7595,"start":7596,"enrollment":26,"conditions":7617,"interventions":7618},[88],[7598],[7586,7600],{"trials":7620,"activeCount":101},[],{"trials":7622,"activeCount":101},[],{"trials":7624,"activeCount":101},[],{"trials":7626,"activeCount":101},[],{"trials":7628,"activeCount":101},[],{"intervention":7630,"totalTrials":204,"cells":7631},"Divigel 0.1% Topical Gel",{"EARLY_PHASE1":7632,"PHASE1":7645,"PHASE2":7647,"PHASE3":7649,"PHASE4":7651,"NA":7653},{"trials":7633,"activeCount":101},[7634],{"nctId":7635,"briefTitle":7636,"status":158,"phases":7637,"primaryCompletion":7638,"completion":7639,"start":7640,"enrollment":4514,"conditions":7641,"interventions":7643},"NCT05645406","Estrogen Hormone Products",[88],"2025-06-12","2025-06-15","2024-05-14",[7642],"Menopause",[7630,7644],"Compounded estradiol product",{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[],{"trials":7652,"activeCount":101},[],{"trials":7654,"activeCount":101},[],{"intervention":7644,"totalTrials":204,"cells":7656},{"EARLY_PHASE1":7657,"PHASE1":7663,"PHASE2":7665,"PHASE3":7667,"PHASE4":7669,"NA":7671},{"trials":7658,"activeCount":101},[7659],{"nctId":7635,"briefTitle":7636,"status":158,"phases":7660,"primaryCompletion":7638,"completion":7639,"start":7640,"enrollment":4514,"conditions":7661,"interventions":7662},[88],[7642],[7630,7644],{"trials":7664,"activeCount":101},[],{"trials":7666,"activeCount":101},[],{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"intervention":7674,"totalTrials":204,"cells":7675},"Metronidazole gel 1",{"EARLY_PHASE1":7676,"PHASE1":7690,"PHASE2":7692,"PHASE3":7694,"PHASE4":7696,"NA":7698},{"trials":7677,"activeCount":101},[7678],{"nctId":7679,"briefTitle":7680,"status":158,"phases":7681,"primaryCompletion":7682,"completion":7683,"start":7684,"enrollment":1107,"conditions":7685,"interventions":7687},"NCT03271983","Pharmacokinetics of Metronidazole Dermal Products",[88],"2019-10-31","2019-11-03","2019-04-09",[7686],"Bioequivalence",[7674,7688,7689],"Metronidazole gel 2","Metronidazole cream",{"trials":7691,"activeCount":101},[],{"trials":7693,"activeCount":101},[],{"trials":7695,"activeCount":101},[],{"trials":7697,"activeCount":101},[],{"trials":7699,"activeCount":101},[],{"intervention":7688,"totalTrials":204,"cells":7701},{"EARLY_PHASE1":7702,"PHASE1":7708,"PHASE2":7710,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7703,"activeCount":101},[7704],{"nctId":7679,"briefTitle":7680,"status":158,"phases":7705,"primaryCompletion":7682,"completion":7683,"start":7684,"enrollment":1107,"conditions":7706,"interventions":7707},[88],[7686],[7674,7688,7689],{"trials":7709,"activeCount":101},[],{"trials":7711,"activeCount":101},[],{"trials":7713,"activeCount":101},[],{"trials":7715,"activeCount":101},[],{"trials":7717,"activeCount":101},[],{"intervention":7689,"totalTrials":204,"cells":7719},{"EARLY_PHASE1":7720,"PHASE1":7726,"PHASE2":7728,"PHASE3":7730,"PHASE4":7732,"NA":7734},{"trials":7721,"activeCount":101},[7722],{"nctId":7679,"briefTitle":7680,"status":158,"phases":7723,"primaryCompletion":7682,"completion":7683,"start":7684,"enrollment":1107,"conditions":7724,"interventions":7725},[88],[7686],[7674,7688,7689],{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[],{"trials":7731,"activeCount":101},[],{"trials":7733,"activeCount":101},[],{"trials":7735,"activeCount":101},[],{"intervention":7737,"totalTrials":204,"cells":7738},"Subcutaneous fat injection of Recombivax-HB",{"EARLY_PHASE1":7739,"PHASE1":7751,"PHASE2":7753,"PHASE3":7755,"PHASE4":7757,"NA":7759},{"trials":7740,"activeCount":101},[7741],{"nctId":7742,"briefTitle":7743,"status":158,"phases":7744,"primaryCompletion":7745,"completion":7745,"start":7746,"enrollment":3030,"conditions":7747,"interventions":7749},"NCT04162223","Hepatitis B Vaccine in Seniors",[88],"2003-05-20","2000-03-29",[7748],"Hepatitis B Vaccination",[7737,7750],"Intramuscular injection of Recombivax-HB",{"trials":7752,"activeCount":101},[],{"trials":7754,"activeCount":101},[],{"trials":7756,"activeCount":101},[],{"trials":7758,"activeCount":101},[],{"trials":7760,"activeCount":101},[],{"intervention":7750,"totalTrials":204,"cells":7762},{"EARLY_PHASE1":7763,"PHASE1":7769,"PHASE2":7771,"PHASE3":7773,"PHASE4":7775,"NA":7777},{"trials":7764,"activeCount":101},[7765],{"nctId":7742,"briefTitle":7743,"status":158,"phases":7766,"primaryCompletion":7745,"completion":7745,"start":7746,"enrollment":3030,"conditions":7767,"interventions":7768},[88],[7748],[7737,7750],{"trials":7770,"activeCount":101},[],{"trials":7772,"activeCount":101},[],{"trials":7774,"activeCount":101},[],{"trials":7776,"activeCount":101},[],{"trials":7778,"activeCount":101},[],{"intervention":7780,"totalTrials":204,"cells":7781},"Rivastigmine (RLD) transdermal patch",{"EARLY_PHASE1":7782,"PHASE1":7793,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7783,"activeCount":101},[7784],{"nctId":7785,"briefTitle":7786,"status":158,"phases":7787,"primaryCompletion":7788,"completion":7788,"start":7789,"enrollment":1107,"conditions":7790,"interventions":7791},"NCT03915626","Effect of Heat on Rivastigmine TDS Products",[88],"2021-05-04","2019-10-04",[7598],[7780,7792],"Rivastigmine (generic) transdermal patch",{"trials":7794,"activeCount":101},[],{"trials":7796,"activeCount":101},[],{"trials":7798,"activeCount":101},[],{"trials":7800,"activeCount":101},[],{"trials":7802,"activeCount":101},[],{"intervention":7792,"totalTrials":204,"cells":7804},{"EARLY_PHASE1":7805,"PHASE1":7811,"PHASE2":7813,"PHASE3":7815,"PHASE4":7817,"NA":7819},{"trials":7806,"activeCount":101},[7807],{"nctId":7785,"briefTitle":7786,"status":158,"phases":7808,"primaryCompletion":7788,"completion":7788,"start":7789,"enrollment":1107,"conditions":7809,"interventions":7810},[88],[7598],[7780,7792],{"trials":7812,"activeCount":101},[],{"trials":7814,"activeCount":101},[],{"trials":7816,"activeCount":101},[],{"trials":7818,"activeCount":101},[],{"trials":7820,"activeCount":101},[],{"intervention":2334,"totalTrials":204,"cells":7822},{"EARLY_PHASE1":7823,"PHASE1":7829,"PHASE2":7831,"PHASE3":7833,"PHASE4":7835,"NA":7837},{"trials":7824,"activeCount":101},[7825],{"nctId":2326,"briefTitle":2327,"status":733,"phases":7826,"primaryCompletion":2329,"completion":2329,"start":2330,"enrollment":101,"conditions":7827,"interventions":7828},[88],[2332],[2334,2321],{"trials":7830,"activeCount":101},[],{"trials":7832,"activeCount":101},[],{"trials":7834,"activeCount":101},[],{"trials":7836,"activeCount":101},[],{"trials":7838,"activeCount":101},[],{"intervention":7840,"totalTrials":204,"cells":7841},"Direct Acting Antivirals",{"EARLY_PHASE1":7842,"PHASE1":7851,"PHASE2":7853,"PHASE3":7855,"PHASE4":7857,"NA":7859},{"trials":7843,"activeCount":101},[7844],{"nctId":7845,"briefTitle":7846,"status":733,"phases":7847,"primaryCompletion":7848,"completion":7848,"start":7848,"enrollment":101,"conditions":7849,"interventions":7850},"NCT03702218","Hepatitis C Positive Donor Into Hepatitis C Negative Recipients",[88],"2019-07-01",[2194],[7840],{"trials":7852,"activeCount":101},[],{"trials":7854,"activeCount":101},[],{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[],{"intervention":7862,"totalTrials":204,"cells":7863},"-Oxaliplatin 85 mg\u002Fm2 IV on Day 1",{"EARLY_PHASE1":7864,"PHASE1":7877,"PHASE2":7879,"PHASE3":7881,"PHASE4":7883,"NA":7885},{"trials":7865,"activeCount":101},[7866],{"nctId":7867,"briefTitle":7868,"status":158,"phases":7869,"primaryCompletion":7870,"completion":7870,"start":7871,"enrollment":4514,"conditions":7872,"interventions":7874},"NCT01992705","Borderline Pancreas Study: FOLFIRINOX +SBRT",[88],"2018-09-27","2014-03",[7873],"Resectable Pancreatic Cancer",[7862,7875,7876],"-Irinotecan 180 mg\u002Fm2 IV on Day 1","-5-FU (Fluorouracil) 2,400 mg\u002Fm2 IV over 46-48 hours",{"trials":7878,"activeCount":101},[],{"trials":7880,"activeCount":101},[],{"trials":7882,"activeCount":101},[],{"trials":7884,"activeCount":101},[],{"trials":7886,"activeCount":101},[],{"intervention":7875,"totalTrials":204,"cells":7888},{"EARLY_PHASE1":7889,"PHASE1":7895,"PHASE2":7897,"PHASE3":7899,"PHASE4":7901,"NA":7903},{"trials":7890,"activeCount":101},[7891],{"nctId":7867,"briefTitle":7868,"status":158,"phases":7892,"primaryCompletion":7870,"completion":7870,"start":7871,"enrollment":4514,"conditions":7893,"interventions":7894},[88],[7873],[7862,7875,7876],{"trials":7896,"activeCount":101},[],{"trials":7898,"activeCount":101},[],{"trials":7900,"activeCount":101},[],{"trials":7902,"activeCount":101},[],{"trials":7904,"activeCount":101},[],{"intervention":7876,"totalTrials":204,"cells":7906},{"EARLY_PHASE1":7907,"PHASE1":7913,"PHASE2":7915,"PHASE3":7917,"PHASE4":7919,"NA":7921},{"trials":7908,"activeCount":101},[7909],{"nctId":7867,"briefTitle":7868,"status":158,"phases":7910,"primaryCompletion":7870,"completion":7870,"start":7871,"enrollment":4514,"conditions":7911,"interventions":7912},[88],[7873],[7862,7875,7876],{"trials":7914,"activeCount":101},[],{"trials":7916,"activeCount":101},[],{"trials":7918,"activeCount":101},[],{"trials":7920,"activeCount":101},[],{"trials":7922,"activeCount":101},[],{"intervention":7924,"totalTrials":204,"cells":7925},"N-acetyl cysteine",{"EARLY_PHASE1":7926,"PHASE1":7937,"PHASE2":7939,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7927,"activeCount":101},[7928],{"nctId":7929,"briefTitle":7930,"status":223,"phases":7931,"primaryCompletion":7932,"completion":7932,"start":7933,"enrollment":4514,"conditions":7934,"interventions":7936},"NCT03056014","Antioxidant Use in Diabetes to Reduce Oxidative Stress",[88],"2020-03-12","2018-11-01",[7935],"Ameliorating Oxidative Stress in Type 1 Diabetes",[7924],{"trials":7938,"activeCount":101},[],{"trials":7940,"activeCount":101},[],{"trials":7942,"activeCount":101},[],{"trials":7944,"activeCount":101},[],{"trials":7946,"activeCount":101},[],{"intervention":7948,"totalTrials":204,"cells":7949},"oxybutynin",{"EARLY_PHASE1":7950,"PHASE1":7961,"PHASE2":7963,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7951,"activeCount":101},[7952],{"nctId":7953,"briefTitle":7954,"status":158,"phases":7955,"primaryCompletion":7956,"completion":7956,"start":7957,"enrollment":23,"conditions":7958,"interventions":7960},"NCT03205605","Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products",[88],"2019-11-13","2018-01-02",[7959],"Heat Effect",[7948,7948],{"trials":7962,"activeCount":101},[],{"trials":7964,"activeCount":101},[],{"trials":7966,"activeCount":101},[],{"trials":7968,"activeCount":101},[],{"trials":7970,"activeCount":101},[],{"intervention":4777,"totalTrials":204,"cells":7972},{"EARLY_PHASE1":7973,"PHASE1":7979,"PHASE2":7981,"PHASE3":7983,"PHASE4":7985,"NA":7987},{"trials":7974,"activeCount":101},[7975],{"nctId":4768,"briefTitle":4769,"status":1470,"phases":7976,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":4773,"conditions":7977,"interventions":7978},[88],[30,4775],[4777,4778,4779,4780,4763],{"trials":7980,"activeCount":101},[],{"trials":7982,"activeCount":101},[],{"trials":7984,"activeCount":101},[],{"trials":7986,"activeCount":101},[],{"trials":7988,"activeCount":101},[],{"intervention":4778,"totalTrials":204,"cells":7990},{"EARLY_PHASE1":7991,"PHASE1":7997,"PHASE2":7999,"PHASE3":8001,"PHASE4":8003,"NA":8005},{"trials":7992,"activeCount":101},[7993],{"nctId":4768,"briefTitle":4769,"status":1470,"phases":7994,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":4773,"conditions":7995,"interventions":7996},[88],[30,4775],[4777,4778,4779,4780,4763],{"trials":7998,"activeCount":101},[],{"trials":8000,"activeCount":101},[],{"trials":8002,"activeCount":101},[],{"trials":8004,"activeCount":101},[],{"trials":8006,"activeCount":101},[],{"intervention":4779,"totalTrials":204,"cells":8008},{"EARLY_PHASE1":8009,"PHASE1":8015,"PHASE2":8017,"PHASE3":8019,"PHASE4":8021,"NA":8023},{"trials":8010,"activeCount":101},[8011],{"nctId":4768,"briefTitle":4769,"status":1470,"phases":8012,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":4773,"conditions":8013,"interventions":8014},[88],[30,4775],[4777,4778,4779,4780,4763],{"trials":8016,"activeCount":101},[],{"trials":8018,"activeCount":101},[],{"trials":8020,"activeCount":101},[],{"trials":8022,"activeCount":101},[],{"trials":8024,"activeCount":101},[],{"intervention":4780,"totalTrials":204,"cells":8026},{"EARLY_PHASE1":8027,"PHASE1":8033,"PHASE2":8035,"PHASE3":8037,"PHASE4":8039,"NA":8041},{"trials":8028,"activeCount":101},[8029],{"nctId":4768,"briefTitle":4769,"status":1470,"phases":8030,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":4773,"conditions":8031,"interventions":8032},[88],[30,4775],[4777,4778,4779,4780,4763],{"trials":8034,"activeCount":101},[],{"trials":8036,"activeCount":101},[],{"trials":8038,"activeCount":101},[],{"trials":8040,"activeCount":101},[],{"trials":8042,"activeCount":101},[],{"intervention":8044,"totalTrials":204,"cells":8045},"Dehydroepiandrosterone",{"EARLY_PHASE1":8046,"PHASE1":8055,"PHASE2":8057,"PHASE3":8059,"PHASE4":8061,"NA":8063},{"trials":8047,"activeCount":101},[8048],{"nctId":8049,"briefTitle":8050,"status":158,"phases":8051,"primaryCompletion":8052,"completion":8052,"start":6186,"enrollment":1176,"conditions":8053,"interventions":8054},"NCT00607646","Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus",[88],"2018-10-09",[1861],[8044],{"trials":8056,"activeCount":101},[],{"trials":8058,"activeCount":101},[],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[],{"trials":8064,"activeCount":101},[],{"intervention":8066,"totalTrials":204,"cells":8067},"Alprazolam",{"EARLY_PHASE1":8068,"PHASE1":8077,"PHASE2":8079,"PHASE3":8081,"PHASE4":8083,"NA":8085},{"trials":8069,"activeCount":101},[8070],{"nctId":8071,"briefTitle":8072,"status":158,"phases":8073,"primaryCompletion":3555,"completion":3555,"start":8074,"enrollment":4232,"conditions":8075,"interventions":8076},"NCT00574639","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2",[88],"2007-07",[1861],[8066],{"trials":8078,"activeCount":101},[],{"trials":8080,"activeCount":101},[],{"trials":8082,"activeCount":101},[],{"trials":8084,"activeCount":101},[],{"trials":8086,"activeCount":101},[],{"intervention":8088,"totalTrials":204,"cells":8089},"Lidocaine patch",{"EARLY_PHASE1":8090,"PHASE1":8100,"PHASE2":8102,"PHASE3":8104,"PHASE4":8106,"NA":8108},{"trials":8091,"activeCount":101},[8092],{"nctId":8093,"briefTitle":8094,"status":158,"phases":8095,"primaryCompletion":8096,"completion":7595,"start":8097,"enrollment":4232,"conditions":8098,"interventions":8099},"NCT03145207","PK and DPK of Lidocaine Dermal Products",[88],"2019-01-10","2016-12-14",[7959],[8088],{"trials":8101,"activeCount":101},[],{"trials":8103,"activeCount":101},[],{"trials":8105,"activeCount":101},[],{"trials":8107,"activeCount":101},[],{"trials":8109,"activeCount":101},[],{"intervention":8111,"totalTrials":204,"cells":8112},"Ramipril",{"EARLY_PHASE1":8113,"PHASE1":8124,"PHASE2":8126,"PHASE3":8128,"PHASE4":8130,"NA":8132},{"trials":8114,"activeCount":101},[8115],{"nctId":8116,"briefTitle":8117,"status":223,"phases":8118,"primaryCompletion":8119,"completion":8119,"start":3512,"enrollment":2575,"conditions":8120,"interventions":8121},"NCT00574834","Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes",[88],"2014-08",[3667],[8111,8122,8123],"HCTZ-hydrochlorothiazide","Ramipril+HCTZ",{"trials":8125,"activeCount":101},[],{"trials":8127,"activeCount":101},[],{"trials":8129,"activeCount":101},[],{"trials":8131,"activeCount":101},[],{"trials":8133,"activeCount":101},[],{"intervention":8122,"totalTrials":204,"cells":8135},{"EARLY_PHASE1":8136,"PHASE1":8142,"PHASE2":8144,"PHASE3":8146,"PHASE4":8148,"NA":8150},{"trials":8137,"activeCount":101},[8138],{"nctId":8116,"briefTitle":8117,"status":223,"phases":8139,"primaryCompletion":8119,"completion":8119,"start":3512,"enrollment":2575,"conditions":8140,"interventions":8141},[88],[3667],[8111,8122,8123],{"trials":8143,"activeCount":101},[],{"trials":8145,"activeCount":101},[],{"trials":8147,"activeCount":101},[],{"trials":8149,"activeCount":101},[],{"trials":8151,"activeCount":101},[],{"intervention":8123,"totalTrials":204,"cells":8153},{"EARLY_PHASE1":8154,"PHASE1":8160,"PHASE2":8162,"PHASE3":8164,"PHASE4":8166,"NA":8168},{"trials":8155,"activeCount":101},[8156],{"nctId":8116,"briefTitle":8117,"status":223,"phases":8157,"primaryCompletion":8119,"completion":8119,"start":3512,"enrollment":2575,"conditions":8158,"interventions":8159},[88],[3667],[8111,8122,8123],{"trials":8161,"activeCount":101},[],{"trials":8163,"activeCount":101},[],{"trials":8165,"activeCount":101},[],{"trials":8167,"activeCount":101},[],{"trials":8169,"activeCount":101},[],{"intervention":8171,"totalTrials":204,"cells":8172},"Epinephrine",{"EARLY_PHASE1":8173,"PHASE1":8183,"PHASE2":8185,"PHASE3":8187,"PHASE4":8189,"NA":8191},{"trials":8174,"activeCount":101},[8175],{"nctId":8176,"briefTitle":8177,"status":158,"phases":8178,"primaryCompletion":8179,"completion":8179,"start":3555,"enrollment":1518,"conditions":8180,"interventions":8182},"NCT02692313","Dose Response of Epinephrine",[88],"2025-09",[8181],"Diabetes Complications",[8171],{"trials":8184,"activeCount":101},[],{"trials":8186,"activeCount":101},[],{"trials":8188,"activeCount":101},[],{"trials":8190,"activeCount":101},[],{"trials":8192,"activeCount":101},[],{"intervention":8194,"totalTrials":204,"cells":8195},"topical estrogen product",{"EARLY_PHASE1":8196,"PHASE1":8206,"PHASE2":8208,"PHASE3":8210,"PHASE4":8212,"NA":8214},{"trials":8197,"activeCount":101},[8198],{"nctId":8199,"briefTitle":8200,"status":158,"phases":8201,"primaryCompletion":8202,"completion":8202,"start":8203,"enrollment":147,"conditions":8204,"interventions":8205},"NCT05645393","Effect of Estradiol Topical Products",[88],"2025-03-30","2024-06-05",[7642],[8194],{"trials":8207,"activeCount":101},[],{"trials":8209,"activeCount":101},[],{"trials":8211,"activeCount":101},[],{"trials":8213,"activeCount":101},[],{"trials":8215,"activeCount":101},[],{"intervention":8217,"totalTrials":2400,"cells":8218},"Oxytocin",{"EARLY_PHASE1":8219,"PHASE1":8230,"PHASE2":8232,"PHASE3":8257,"PHASE4":8259,"NA":8267},{"trials":8220,"activeCount":101},[8221],{"nctId":8222,"briefTitle":8223,"status":158,"phases":8224,"primaryCompletion":2749,"completion":2749,"start":4024,"enrollment":8225,"conditions":8226,"interventions":8229},"NCT02228031","Oxytocin, Emotions and Mirror Neurons",[88],44,[8227,8228],"Social Cognition","Expressed Emotion",[8217],{"trials":8231,"activeCount":101},[],{"trials":8233,"activeCount":101},[8234,8241,8249],{"nctId":8235,"briefTitle":8236,"status":158,"phases":8237,"primaryCompletion":8238,"completion":8238,"start":4066,"enrollment":7106,"conditions":8239,"interventions":8240},"NCT00663039","Effects of Oxytocin Nasal Spray on Social Affiliation",[90],"2015-07",[16],[8217],{"nctId":8242,"briefTitle":8243,"status":158,"phases":8244,"primaryCompletion":2524,"completion":2524,"start":4753,"enrollment":8245,"conditions":8246,"interventions":8247},"NCT01012167","Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia",[90],86,[16],[8217,8248],"Galantamine",{"nctId":8250,"briefTitle":8251,"status":158,"phases":8252,"primaryCompletion":6327,"completion":6327,"start":3916,"enrollment":1886,"conditions":8253,"interventions":8256},"NCT00884897","Oxytocin and Social Cognition in Schizophrenia",[90],[8227,8254,8255],"Social Anxiety","Emotional Intelligence",[8217],{"trials":8258,"activeCount":101},[],{"trials":8260,"activeCount":101},[8261],{"nctId":8262,"briefTitle":8263,"status":158,"phases":8264,"primaryCompletion":3100,"completion":3100,"start":3489,"enrollment":726,"conditions":8265,"interventions":8266},"NCT01614093","Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia",[92],[16],[8217],{"trials":8268,"activeCount":101},[8269],{"nctId":8270,"briefTitle":8271,"status":733,"phases":8272,"primaryCompletion":6326,"completion":5530,"start":5261,"enrollment":101,"conditions":8273,"interventions":8274},"NCT01123317","Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia",[93],[16],[8217],{"intervention":2393,"totalTrials":659,"cells":8276},{"EARLY_PHASE1":8277,"PHASE1":8279,"PHASE2":8281,"PHASE3":8283,"PHASE4":8285,"NA":8303},{"trials":8278,"activeCount":101},[],{"trials":8280,"activeCount":101},[],{"trials":8282,"activeCount":101},[],{"trials":8284,"activeCount":101},[],{"trials":8286,"activeCount":101},[8287,8291,8295,8299],{"nctId":2383,"briefTitle":2384,"status":158,"phases":8288,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":2388,"conditions":8289,"interventions":8290},[92],[2390,2391],[2393,2370],{"nctId":2769,"briefTitle":2770,"status":223,"phases":8292,"primaryCompletion":1885,"completion":1885,"start":2386,"enrollment":1444,"conditions":8293,"interventions":8294},[92],[33,2773],[2775,2756],{"nctId":3415,"briefTitle":3416,"status":158,"phases":8296,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":3420,"conditions":8297,"interventions":8298},[92],[3422,3423,2409],[2393,3402],{"nctId":2395,"briefTitle":2396,"status":158,"phases":8300,"primaryCompletion":2398,"completion":2398,"start":2399,"enrollment":2400,"conditions":8301,"interventions":8302},[92],[2402,2403,2404,33,2405,2406,2407,2408,2409,2410],[2393,2370],{"trials":8304,"activeCount":101},[8305],{"nctId":8306,"briefTitle":8307,"status":158,"phases":8308,"primaryCompletion":746,"completion":746,"start":5261,"enrollment":1597,"conditions":8309,"interventions":8311},"NCT01341600","Clopidogrel Pharmacogenetics (PGX) Bench to Bedside",[93],[8310],"Metabolism of Clopidogrel",[2393,8312],"Omeprazole\u002FClopidogrel",{"intervention":8248,"totalTrials":147,"cells":8314},{"EARLY_PHASE1":8315,"PHASE1":8317,"PHASE2":8319,"PHASE3":8332,"PHASE4":8334,"NA":8345},{"trials":8316,"activeCount":101},[],{"trials":8318,"activeCount":101},[],{"trials":8320,"activeCount":101},[8321,8325],{"nctId":8242,"briefTitle":8243,"status":158,"phases":8322,"primaryCompletion":2524,"completion":2524,"start":4753,"enrollment":8245,"conditions":8323,"interventions":8324},[90],[16],[8217,8248],{"nctId":8326,"briefTitle":8327,"status":158,"phases":8328,"primaryCompletion":8329,"completion":8329,"start":185,"enrollment":26,"conditions":8330,"interventions":8331},"NCT01100775","Effects of Galantamine on Cognition",[90],"2014-08-21",[16],[8248],{"trials":8333,"activeCount":101},[],{"trials":8335,"activeCount":101},[8336],{"nctId":8337,"briefTitle":8338,"status":158,"phases":8339,"primaryCompletion":8340,"completion":8340,"start":5481,"enrollment":8341,"conditions":8342,"interventions":8343},"NCT00176423","Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia",[92],"2006-12",117,[16,19],[8344],"galantamine",{"trials":8346,"activeCount":101},[8347],{"nctId":8348,"briefTitle":8349,"status":158,"phases":8350,"completion":8351,"start":8352,"enrollment":679,"conditions":8353,"interventions":8355},"NCT00161044","An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms",[93],"2005-09","2004-09",[8354],"Chronic Schizophrenia",[8248],{"intervention":8357,"totalTrials":97,"cells":8358},"Regadenoson",{"EARLY_PHASE1":8359,"PHASE1":8371,"PHASE2":8373,"PHASE3":8384,"PHASE4":8386,"NA":8388},{"trials":8360,"activeCount":101},[8361],{"nctId":8362,"briefTitle":8363,"status":158,"phases":8364,"primaryCompletion":8365,"completion":1935,"start":8366,"enrollment":8367,"conditions":8368,"interventions":8370},"NCT04521569","Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System",[88],"2024-06-23","2020-06-22",47,[8369],"Lung Transplant",[8357],{"trials":8372,"activeCount":101},[],{"trials":8374,"activeCount":101},[8375],{"nctId":8376,"briefTitle":8377,"status":158,"phases":8378,"primaryCompletion":8379,"completion":8379,"start":8380,"enrollment":659,"conditions":8381,"interventions":8383},"NCT04606069","Treat COVID-19 Patients With Regadenoson",[89,90],"2023-04-24","2021-05-06",[4303,8382],"Lung Inflammation",[8357],{"trials":8385,"activeCount":101},[],{"trials":8387,"activeCount":101},[],{"trials":8389,"activeCount":101},[8390],{"nctId":8391,"briefTitle":8392,"status":158,"phases":8393,"primaryCompletion":8394,"completion":8394,"start":3281,"enrollment":392,"conditions":8395,"interventions":8397},"NCT01026012","Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing",[93],"2010-09",[8396],"Cardiac Function",[8398],"regadenoson",{"intervention":8400,"totalTrials":97,"cells":8401},"Duloxetine",{"EARLY_PHASE1":8402,"PHASE1":8404,"PHASE2":8406,"PHASE3":8418,"PHASE4":8420,"NA":8431},{"trials":8403,"activeCount":101},[],{"trials":8405,"activeCount":101},[],{"trials":8407,"activeCount":101},[8408],{"nctId":8409,"briefTitle":8410,"status":158,"phases":8411,"primaryCompletion":8412,"completion":8412,"start":8413,"enrollment":6484,"conditions":8414,"interventions":8417},"NCT04111627","Exercise Plus Duloxetine for Knee Osteoarthritis",[90],"2025-08-11","2021-10-07",[8415,8416],"Knee Osteoarthritis","Depression",[8400],{"trials":8419,"activeCount":101},[],{"trials":8421,"activeCount":101},[8422],{"nctId":8423,"briefTitle":8424,"status":223,"phases":8425,"primaryCompletion":8426,"completion":8426,"start":8427,"enrollment":443,"conditions":8428,"interventions":8430},"NCT01451606","Duloxetine for the Treatment of Chronic Pelvic Pain",[92],"2015-11-04","2011-07-11",[8429],"Pelvis Pain Chronic",[8400],{"trials":8432,"activeCount":101},[8433],{"nctId":8434,"briefTitle":8435,"status":158,"phases":8436,"primaryCompletion":3664,"completion":8437,"start":8438,"enrollment":726,"conditions":8439,"interventions":8441},"NCT00981149","Duloxetine for Treatment of Painful Temporomandibular Joint Disorder",[93],"2011-12","2009-05",[8440],"Temporomandibular Joint Disorders",[8442],"duloxetine",{"intervention":7180,"totalTrials":97,"cells":8444},{"EARLY_PHASE1":8445,"PHASE1":8447,"PHASE2":8453,"PHASE3":8455,"PHASE4":8457,"NA":8459},{"trials":8446,"activeCount":101},[],{"trials":8448,"activeCount":101},[8449],{"nctId":7172,"briefTitle":7173,"status":733,"phases":8450,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":101,"conditions":8451,"interventions":8452},[89],[7178],[7180,7165,7181],{"trials":8454,"activeCount":101},[],{"trials":8456,"activeCount":101},[],{"trials":8458,"activeCount":101},[],{"trials":8460,"activeCount":101},[8461,8470],{"nctId":8462,"briefTitle":8463,"status":158,"phases":8464,"primaryCompletion":4366,"completion":4366,"start":6186,"enrollment":10,"conditions":8465,"interventions":8469},"NCT01223404","Nicotinic Modulation of the Default Network",[93],[8466,8467,7180,8468],"Magnetic Resonance Imaging","Cognition","Mecamylamine",[7180,8468],{"nctId":8471,"briefTitle":8472,"status":733,"phases":8473,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":101,"conditions":8476,"interventions":8478},"NCT03416569","Effects of Prazosin on the Attention-Enhancing Effects of Nicotine",[93],"2019-01","2018-03",[8477],"no Condition, Basic Science",[7180,8479,8480],"Prazosin","Nicotine + Prazosin",{"intervention":8482,"totalTrials":97,"cells":8483},"Minocycline",{"EARLY_PHASE1":8484,"PHASE1":8486,"PHASE2":8511,"PHASE3":8513,"PHASE4":8515,"NA":8525},{"trials":8485,"activeCount":101},[],{"trials":8487,"activeCount":101},[8488],{"nctId":8489,"briefTitle":8490,"status":158,"phases":8491,"primaryCompletion":8492,"completion":8492,"start":8493,"enrollment":8494,"conditions":8495,"interventions":8509},"NCT04210713","Neuroimmune Dysfunction in Alcohol Use Disorder",[89],"2023-09-20","2020-02-03",142,[8496,1770,8497,8498,4900,8499,8500,8501,8502,8503,8504,8505,8506,8482,8507,8508],"Alcohol Drinking","Disease","Inflammation","Cognitive Dysfunction","Pathologic Processes","Drinking Behavior","Substance-Related Disorders","Chemically-Induced Disorders","Mental Disorder","Cognition Disorder","Neurocognitive Disorders","Anti-Bacterial Agents","Anti-Infective Agents",[8482,8510],"Sugar pill",{"trials":8512,"activeCount":101},[],{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[8517],{"nctId":8518,"briefTitle":8519,"status":158,"phases":8520,"primaryCompletion":6612,"completion":6612,"start":8521,"enrollment":1518,"conditions":8522,"interventions":8524},"NCT02968602","Minocycline and Tobacco Craving in Smokers With Schizophrenia",[92],"2017-03-31",[16,8523],"Tobacco Use",[8482],{"trials":8526,"activeCount":101},[8527],{"nctId":8528,"briefTitle":8529,"status":158,"phases":8530,"primaryCompletion":3100,"completion":3100,"start":4743,"enrollment":3030,"conditions":8531,"interventions":8532},"NCT01433055","Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients",[93],[16],[8482],{"intervention":8534,"totalTrials":208,"cells":8535},"l-tetrahydropalmatine",{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8549,"PHASE4":8551,"NA":8553},{"trials":8537,"activeCount":101},[],{"trials":8539,"activeCount":101},[],{"trials":8541,"activeCount":101},[8542],{"nctId":8543,"briefTitle":8544,"status":733,"phases":8545,"primaryCompletion":3555,"completion":3555,"start":8546,"enrollment":101,"conditions":8547,"interventions":8548},"NCT02139761","L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder",[90],"2014-09",[7154],[8534],{"trials":8550,"activeCount":101},[],{"trials":8552,"activeCount":101},[],{"trials":8554,"activeCount":101},[8555],{"nctId":8556,"briefTitle":8557,"status":158,"phases":8558,"primaryCompletion":4365,"completion":5099,"start":8546,"enrollment":7314,"conditions":8559,"interventions":8560},"NCT02118610","Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity",[93],[16],[8561,8510],"L-tetrahydropalmatine",{"intervention":4821,"totalTrials":208,"cells":8563},{"EARLY_PHASE1":8564,"PHASE1":8566,"PHASE2":8568,"PHASE3":8574,"PHASE4":8576,"NA":8578},{"trials":8565,"activeCount":101},[],{"trials":8567,"activeCount":101},[],{"trials":8569,"activeCount":101},[8570],{"nctId":4811,"briefTitle":4812,"status":223,"phases":8571,"primaryCompletion":4814,"completion":4815,"start":3623,"enrollment":1107,"conditions":8572,"interventions":8573},[90],[4817,4818,4819],[4821,4802,4822],{"trials":8575,"activeCount":101},[],{"trials":8577,"activeCount":101},[],{"trials":8579,"activeCount":101},[8580],{"nctId":8581,"briefTitle":8582,"status":223,"phases":8583,"primaryCompletion":8584,"completion":8585,"start":8586,"enrollment":2226,"conditions":8587,"interventions":8588},"NCT02095184","GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients",[93],"2024-07-24","2024-08-02","2015-05-25",[25],[8589,8590],"Anastrozole","Letrozole",{"intervention":8510,"totalTrials":208,"cells":8592},{"EARLY_PHASE1":8593,"PHASE1":8595,"PHASE2":8601,"PHASE3":8603,"PHASE4":8605,"NA":8607},{"trials":8594,"activeCount":101},[],{"trials":8596,"activeCount":101},[8597],{"nctId":8489,"briefTitle":8490,"status":158,"phases":8598,"primaryCompletion":8492,"completion":8492,"start":8493,"enrollment":8494,"conditions":8599,"interventions":8600},[89],[8496,1770,8497,8498,4900,8499,8500,8501,8502,8503,8504,8505,8506,8482,8507,8508],[8482,8510],{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":101},[],{"trials":8608,"activeCount":101},[8609],{"nctId":8556,"briefTitle":8557,"status":158,"phases":8610,"primaryCompletion":4365,"completion":5099,"start":8546,"enrollment":7314,"conditions":8611,"interventions":8612},[93],[16],[8561,8510],{"intervention":6196,"totalTrials":208,"cells":8614},{"EARLY_PHASE1":8615,"PHASE1":8617,"PHASE2":8619,"PHASE3":8625,"PHASE4":8627,"NA":8629},{"trials":8616,"activeCount":101},[],{"trials":8618,"activeCount":101},[],{"trials":8620,"activeCount":101},[8621],{"nctId":6183,"briefTitle":6184,"status":223,"phases":8622,"primaryCompletion":4411,"completion":4411,"start":6186,"enrollment":659,"conditions":8623,"interventions":8624},[90],[6188,6189,6190,6191,6192,6193,6194],[6174,6196],{"trials":8626,"activeCount":101},[],{"trials":8628,"activeCount":101},[],{"trials":8630,"activeCount":101},[8631],{"nctId":8581,"briefTitle":8582,"status":223,"phases":8632,"primaryCompletion":8584,"completion":8585,"start":8586,"enrollment":2226,"conditions":8633,"interventions":8634},[93],[25],[8589,8590],{"intervention":8636,"totalTrials":208,"cells":8637},"Atomoxetine",{"EARLY_PHASE1":8638,"PHASE1":8647,"PHASE2":8649,"PHASE3":8651,"PHASE4":8653,"NA":8655},{"trials":8639,"activeCount":101},[8640],{"nctId":8641,"briefTitle":8642,"status":158,"phases":8643,"primaryCompletion":2914,"completion":2914,"start":8438,"enrollment":8644,"conditions":8645,"interventions":8646},"NCT00780650","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine",[88],56,[1861],[8636],{"trials":8648,"activeCount":101},[],{"trials":8650,"activeCount":101},[],{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[],{"trials":8656,"activeCount":101},[8657],{"nctId":8658,"briefTitle":8659,"status":158,"phases":8660,"primaryCompletion":8340,"completion":8340,"start":8661,"enrollment":1041,"conditions":8662,"interventions":8663},"NCT00161031","Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia",[93],"2004-04",[16],[8636],{"intervention":8665,"totalTrials":208,"cells":8666},"Aripiprazole",{"EARLY_PHASE1":8667,"PHASE1":8669,"PHASE2":8671,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8668,"activeCount":101},[],{"trials":8670,"activeCount":101},[],{"trials":8672,"activeCount":101},[],{"trials":8674,"activeCount":101},[],{"trials":8676,"activeCount":101},[],{"trials":8678,"activeCount":101},[8679,8686],{"nctId":8680,"briefTitle":8681,"status":158,"phases":8682,"primaryCompletion":4815,"completion":4815,"start":6326,"enrollment":785,"conditions":8683,"interventions":8685},"NCT01338298","Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia",[93],[8684],"Hyperprolactinemia",[8665],{"nctId":8687,"briefTitle":8688,"status":223,"phases":8689,"primaryCompletion":6186,"completion":6186,"start":3077,"enrollment":659,"conditions":8690,"interventions":8692},"NCT00746252","Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder",[93],[8691],"Bipolar Disorder",[8693,8694],"risperidone","aripiprazole",{"intervention":8696,"totalTrials":204,"cells":8697},"Simplified Cascade Screening",{"EARLY_PHASE1":8698,"PHASE1":8700,"PHASE2":8702,"PHASE3":8704,"PHASE4":8706,"NA":8708},{"trials":8699,"activeCount":101},[],{"trials":8701,"activeCount":101},[],{"trials":8703,"activeCount":101},[],{"trials":8705,"activeCount":101},[],{"trials":8707,"activeCount":101},[],{"trials":8709,"activeCount":101},[8710],{"nctId":8711,"briefTitle":8712,"status":223,"phases":8713,"primaryCompletion":864,"completion":8714,"start":8715,"enrollment":8716,"conditions":8717,"interventions":8719},"NCT03783975","KCNQ1 Cascade Screening",[93],"2022-12-29","2019-03-07",131,[8718],"Long QT Syndrome",[8696],{"intervention":8721,"totalTrials":204,"cells":8722},"Sampling Research Cigarettes",{"EARLY_PHASE1":8723,"PHASE1":8725,"PHASE2":8727,"PHASE3":8729,"PHASE4":8731,"NA":8733},{"trials":8724,"activeCount":101},[],{"trials":8726,"activeCount":101},[],{"trials":8728,"activeCount":101},[],{"trials":8730,"activeCount":101},[],{"trials":8732,"activeCount":101},[],{"trials":8734,"activeCount":101},[8735],{"nctId":8736,"briefTitle":8737,"status":158,"phases":8738,"primaryCompletion":8739,"completion":8739,"start":8740,"enrollment":3004,"conditions":8741,"interventions":8743},"NCT04001114","Cigarette Smoking in Smokers With and Without Schizophrenia",[93],"2022-12-23","2021-07-15",[8742,16],"Tobacco Dependence",[8721],{"intervention":8745,"totalTrials":204,"cells":8746},"Dipyridamole",{"EARLY_PHASE1":8747,"PHASE1":8749,"PHASE2":8751,"PHASE3":8753,"PHASE4":8755,"NA":8757},{"trials":8748,"activeCount":101},[],{"trials":8750,"activeCount":101},[],{"trials":8752,"activeCount":101},[],{"trials":8754,"activeCount":101},[],{"trials":8756,"activeCount":101},[],{"trials":8758,"activeCount":101},[8759],{"nctId":8760,"briefTitle":8761,"status":158,"phases":8762,"primaryCompletion":8763,"completion":8764,"start":8765,"enrollment":8766,"conditions":8767,"interventions":8768},"NCT00349973","Clinical Trial of Dipyridamole in Schizophrenia",[93],"2008-09","2011-09","2001-05",29,[16,19,189],[8745],{"intervention":8770,"totalTrials":204,"cells":8771},"Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks",{"EARLY_PHASE1":8772,"PHASE1":8774,"PHASE2":8776,"PHASE3":8778,"PHASE4":8780,"NA":8782},{"trials":8773,"activeCount":101},[],{"trials":8775,"activeCount":101},[],{"trials":8777,"activeCount":101},[],{"trials":8779,"activeCount":101},[],{"trials":8781,"activeCount":101},[],{"trials":8783,"activeCount":101},[8784],{"nctId":8785,"briefTitle":8786,"status":158,"phases":8787,"primaryCompletion":8788,"completion":8788,"start":8789,"enrollment":31,"conditions":8790,"interventions":8793},"NCT04401982","Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects",[],"2022-02-22","2021-03-15",[8791,8792],"Ocular Hypertension","Suspect Glaucoma",[8770],{"intervention":8795,"totalTrials":204,"cells":8796},"Levetiracetam",{"EARLY_PHASE1":8797,"PHASE1":8799,"PHASE2":8801,"PHASE3":8803,"PHASE4":8805,"NA":8807},{"trials":8798,"activeCount":101},[],{"trials":8800,"activeCount":101},[],{"trials":8802,"activeCount":101},[],{"trials":8804,"activeCount":101},[],{"trials":8806,"activeCount":101},[],{"trials":8808,"activeCount":101},[8809],{"nctId":8810,"briefTitle":8811,"status":158,"phases":8812,"primaryCompletion":4163,"completion":4163,"start":8813,"enrollment":1597,"conditions":8814,"interventions":8818},"NCT03632915","Pharmacokinetics of Antiepileptics in Patients on CRRT",[],"2017-11-20",[3148,8815,8816,8817],"Renal Insufficiency","Renal Failure","Pharmacokinetics",[8795,8819,8820,8821,8822,8823],"Lacosamide","Phenytoin","Phenobarbital","Ketamine","Valproic Acid",{"intervention":8819,"totalTrials":204,"cells":8825},{"EARLY_PHASE1":8826,"PHASE1":8828,"PHASE2":8830,"PHASE3":8832,"PHASE4":8834,"NA":8836},{"trials":8827,"activeCount":101},[],{"trials":8829,"activeCount":101},[],{"trials":8831,"activeCount":101},[],{"trials":8833,"activeCount":101},[],{"trials":8835,"activeCount":101},[],{"trials":8837,"activeCount":101},[8838],{"nctId":8810,"briefTitle":8811,"status":158,"phases":8839,"primaryCompletion":4163,"completion":4163,"start":8813,"enrollment":1597,"conditions":8840,"interventions":8841},[],[3148,8815,8816,8817],[8795,8819,8820,8821,8822,8823],{"intervention":8820,"totalTrials":204,"cells":8843},{"EARLY_PHASE1":8844,"PHASE1":8846,"PHASE2":8848,"PHASE3":8850,"PHASE4":8852,"NA":8854},{"trials":8845,"activeCount":101},[],{"trials":8847,"activeCount":101},[],{"trials":8849,"activeCount":101},[],{"trials":8851,"activeCount":101},[],{"trials":8853,"activeCount":101},[],{"trials":8855,"activeCount":101},[8856],{"nctId":8810,"briefTitle":8811,"status":158,"phases":8857,"primaryCompletion":4163,"completion":4163,"start":8813,"enrollment":1597,"conditions":8858,"interventions":8859},[],[3148,8815,8816,8817],[8795,8819,8820,8821,8822,8823],{"intervention":8821,"totalTrials":204,"cells":8861},{"EARLY_PHASE1":8862,"PHASE1":8864,"PHASE2":8866,"PHASE3":8868,"PHASE4":8870,"NA":8872},{"trials":8863,"activeCount":101},[],{"trials":8865,"activeCount":101},[],{"trials":8867,"activeCount":101},[],{"trials":8869,"activeCount":101},[],{"trials":8871,"activeCount":101},[],{"trials":8873,"activeCount":101},[8874],{"nctId":8810,"briefTitle":8811,"status":158,"phases":8875,"primaryCompletion":4163,"completion":4163,"start":8813,"enrollment":1597,"conditions":8876,"interventions":8877},[],[3148,8815,8816,8817],[8795,8819,8820,8821,8822,8823],{"intervention":8822,"totalTrials":204,"cells":8879},{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8884,"PHASE3":8886,"PHASE4":8888,"NA":8890},{"trials":8881,"activeCount":101},[],{"trials":8883,"activeCount":101},[],{"trials":8885,"activeCount":101},[],{"trials":8887,"activeCount":101},[],{"trials":8889,"activeCount":101},[],{"trials":8891,"activeCount":101},[8892],{"nctId":8810,"briefTitle":8811,"status":158,"phases":8893,"primaryCompletion":4163,"completion":4163,"start":8813,"enrollment":1597,"conditions":8894,"interventions":8895},[],[3148,8815,8816,8817],[8795,8819,8820,8821,8822,8823],{"intervention":8823,"totalTrials":204,"cells":8897},{"EARLY_PHASE1":8898,"PHASE1":8900,"PHASE2":8902,"PHASE3":8904,"PHASE4":8906,"NA":8908},{"trials":8899,"activeCount":101},[],{"trials":8901,"activeCount":101},[],{"trials":8903,"activeCount":101},[],{"trials":8905,"activeCount":101},[],{"trials":8907,"activeCount":101},[],{"trials":8909,"activeCount":101},[8910],{"nctId":8810,"briefTitle":8811,"status":158,"phases":8911,"primaryCompletion":4163,"completion":4163,"start":8813,"enrollment":1597,"conditions":8912,"interventions":8913},[],[3148,8815,8816,8817],[8795,8819,8820,8821,8822,8823],{"intervention":8915,"totalTrials":204,"cells":8916},"Nicotine polacrilex lozenge",{"EARLY_PHASE1":8917,"PHASE1":8919,"PHASE2":8921,"PHASE3":8923,"PHASE4":8925,"NA":8927},{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[],{"trials":8922,"activeCount":101},[],{"trials":8924,"activeCount":101},[],{"trials":8926,"activeCount":101},[],{"trials":8928,"activeCount":101},[8929],{"nctId":8930,"briefTitle":8931,"status":158,"phases":8932,"primaryCompletion":737,"completion":737,"start":8933,"enrollment":3004,"conditions":8934,"interventions":8935},"NCT02069392","Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia",[93],"2015-01",[16,19],[8915],{"intervention":8937,"totalTrials":204,"cells":8938},"Topiramate",{"EARLY_PHASE1":8939,"PHASE1":8941,"PHASE2":8943,"PHASE3":8945,"PHASE4":8947,"NA":8949},{"trials":8940,"activeCount":101},[],{"trials":8942,"activeCount":101},[],{"trials":8944,"activeCount":101},[],{"trials":8946,"activeCount":101},[],{"trials":8948,"activeCount":101},[],{"trials":8950,"activeCount":101},[8951],{"nctId":8952,"briefTitle":8953,"status":223,"phases":8954,"primaryCompletion":1885,"completion":8955,"start":4742,"enrollment":147,"conditions":8956,"interventions":8959},"NCT01408641","Topiramate for Alcohol Use in Posttraumatic Stress Disorder",[93],"2013-08",[8957,4900,4899,1937,4278,8958],"Alcohol Dependence","Posttraumatic Stress Disorder",[8937],{"intervention":8961,"totalTrials":204,"cells":8962},"Anti-inflammatory Combination Therapy",{"EARLY_PHASE1":8963,"PHASE1":8965,"PHASE2":8967,"PHASE3":8969,"PHASE4":8971,"NA":8973},{"trials":8964,"activeCount":101},[],{"trials":8966,"activeCount":101},[],{"trials":8968,"activeCount":101},[],{"trials":8970,"activeCount":101},[],{"trials":8972,"activeCount":101},[],{"trials":8974,"activeCount":101},[8975],{"nctId":8976,"briefTitle":8977,"status":158,"phases":8978,"primaryCompletion":8979,"completion":8979,"start":3489,"enrollment":1176,"conditions":8980,"interventions":8981},"NCT01514682","Anti-Inflammatory Treatment of Schizophrenia",[93],"2017-04-17",[16],[8961],{"intervention":8983,"totalTrials":204,"cells":8984},"Tenofovir",{"EARLY_PHASE1":8985,"PHASE1":8987,"PHASE2":8989,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8986,"activeCount":101},[],{"trials":8988,"activeCount":101},[],{"trials":8990,"activeCount":101},[],{"trials":8992,"activeCount":101},[],{"trials":8994,"activeCount":101},[],{"trials":8996,"activeCount":101},[8997],{"nctId":8998,"briefTitle":8999,"status":158,"phases":9000,"primaryCompletion":9001,"completion":9001,"start":9002,"enrollment":1444,"conditions":9003,"interventions":9005},"NCT00344981","Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression",[93],"2006-11","2003-06",[3515,9004],"AIDS",[8983,9006],"Hydroxyurea",{"intervention":9006,"totalTrials":204,"cells":9008},{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9013,"PHASE3":9015,"PHASE4":9017,"NA":9019},{"trials":9010,"activeCount":101},[],{"trials":9012,"activeCount":101},[],{"trials":9014,"activeCount":101},[],{"trials":9016,"activeCount":101},[],{"trials":9018,"activeCount":101},[],{"trials":9020,"activeCount":101},[9021],{"nctId":8998,"briefTitle":8999,"status":158,"phases":9022,"primaryCompletion":9001,"completion":9001,"start":9002,"enrollment":1444,"conditions":9023,"interventions":9024},[93],[3515,9004],[8983,9006],{"intervention":9026,"totalTrials":204,"cells":9027},"Gadoteridol",{"EARLY_PHASE1":9028,"PHASE1":9030,"PHASE2":9032,"PHASE3":9034,"PHASE4":9036,"NA":9038},{"trials":9029,"activeCount":101},[],{"trials":9031,"activeCount":101},[],{"trials":9033,"activeCount":101},[],{"trials":9035,"activeCount":101},[],{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[9040],{"nctId":9041,"briefTitle":9042,"status":158,"phases":9043,"primaryCompletion":9044,"completion":9044,"start":9045,"enrollment":726,"conditions":9046,"interventions":9047},"NCT03396822","Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis",[],"2023-05-25","2018-09-24",[1700],[9026],{"intervention":9049,"totalTrials":204,"cells":9050},"Hydrophor",{"EARLY_PHASE1":9051,"PHASE1":9053,"PHASE2":9055,"PHASE3":9057,"PHASE4":9059,"NA":9061},{"trials":9052,"activeCount":101},[],{"trials":9054,"activeCount":101},[],{"trials":9056,"activeCount":101},[],{"trials":9058,"activeCount":101},[],{"trials":9060,"activeCount":101},[],{"trials":9062,"activeCount":101},[9063],{"nctId":9064,"briefTitle":9065,"status":158,"phases":9066,"primaryCompletion":4814,"completion":2190,"start":2523,"enrollment":443,"conditions":9067,"interventions":9069},"NCT02234479","MediHoney for Radiation Dermatitis",[93],[25,9068],"Radiation Dermatitis",[9049,9070],"MediHoney",{"intervention":9070,"totalTrials":204,"cells":9072},{"EARLY_PHASE1":9073,"PHASE1":9075,"PHASE2":9077,"PHASE3":9079,"PHASE4":9081,"NA":9083},{"trials":9074,"activeCount":101},[],{"trials":9076,"activeCount":101},[],{"trials":9078,"activeCount":101},[],{"trials":9080,"activeCount":101},[],{"trials":9082,"activeCount":101},[],{"trials":9084,"activeCount":101},[9085],{"nctId":9064,"briefTitle":9065,"status":158,"phases":9086,"primaryCompletion":4814,"completion":2190,"start":2523,"enrollment":443,"conditions":9087,"interventions":9088},[93],[25,9068],[9049,9070],{"intervention":9090,"totalTrials":204,"cells":9091},"Teriparatide",{"EARLY_PHASE1":9092,"PHASE1":9094,"PHASE2":9096,"PHASE3":9098,"PHASE4":9100,"NA":9102},{"trials":9093,"activeCount":101},[],{"trials":9095,"activeCount":101},[],{"trials":9097,"activeCount":101},[],{"trials":9099,"activeCount":101},[],{"trials":9101,"activeCount":101},[],{"trials":9103,"activeCount":101},[9104],{"nctId":9105,"briefTitle":9106,"status":158,"phases":9107,"primaryCompletion":9108,"completion":9108,"start":5531,"enrollment":679,"conditions":9109,"interventions":9111},"NCT00754442","Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism",[93],"2008-08",[9110],"Secondary Hyperparathyroidism",[9090],{"intervention":8468,"totalTrials":204,"cells":9113},{"EARLY_PHASE1":9114,"PHASE1":9116,"PHASE2":9118,"PHASE3":9120,"PHASE4":9122,"NA":9124},{"trials":9115,"activeCount":101},[],{"trials":9117,"activeCount":101},[],{"trials":9119,"activeCount":101},[],{"trials":9121,"activeCount":101},[],{"trials":9123,"activeCount":101},[],{"trials":9125,"activeCount":101},[9126],{"nctId":8462,"briefTitle":8463,"status":158,"phases":9127,"primaryCompletion":4366,"completion":4366,"start":6186,"enrollment":10,"conditions":9128,"interventions":9129},[93],[8466,8467,7180,8468],[7180,8468],{"intervention":9131,"totalTrials":204,"cells":9132},"Standard of Care prophylaxis",{"EARLY_PHASE1":9133,"PHASE1":9135,"PHASE2":9137,"PHASE3":9139,"PHASE4":9141,"NA":9143},{"trials":9134,"activeCount":101},[],{"trials":9136,"activeCount":101},[],{"trials":9138,"activeCount":101},[],{"trials":9140,"activeCount":101},[],{"trials":9142,"activeCount":101},[],{"trials":9144,"activeCount":101},[9145],{"nctId":9146,"briefTitle":9147,"status":158,"phases":9148,"primaryCompletion":9149,"completion":9149,"start":6637,"enrollment":9150,"conditions":9151,"interventions":9152},"NCT01650558","Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi",[93],"2018-07-31",1499,[28],[9131,9153],"Chloroquine (CQ) prophylaxis",{"intervention":9153,"totalTrials":204,"cells":9155},{"EARLY_PHASE1":9156,"PHASE1":9158,"PHASE2":9160,"PHASE3":9162,"PHASE4":9164,"NA":9166},{"trials":9157,"activeCount":101},[],{"trials":9159,"activeCount":101},[],{"trials":9161,"activeCount":101},[],{"trials":9163,"activeCount":101},[],{"trials":9165,"activeCount":101},[],{"trials":9167,"activeCount":101},[9168],{"nctId":9146,"briefTitle":9147,"status":158,"phases":9169,"primaryCompletion":9149,"completion":9149,"start":6637,"enrollment":9150,"conditions":9170,"interventions":9171},[93],[28],[9131,9153],{"intervention":9173,"totalTrials":204,"cells":9174},"fluoride varnish",{"EARLY_PHASE1":9175,"PHASE1":9177,"PHASE2":9179,"PHASE3":9181,"PHASE4":9183,"NA":9185},{"trials":9176,"activeCount":101},[],{"trials":9178,"activeCount":101},[],{"trials":9180,"activeCount":101},[],{"trials":9182,"activeCount":101},[],{"trials":9184,"activeCount":101},[],{"trials":9186,"activeCount":101},[9187],{"nctId":9188,"briefTitle":9189,"status":158,"phases":9190,"completion":9191,"start":4324,"enrollment":9192,"conditions":9193,"interventions":9195},"NCT00497029","Early Childhood Caries Prevention at a Pediatric Clinic",[93],"2006-08",219,[9194],"Dental Caries",[9173],{"intervention":9197,"totalTrials":204,"cells":9198},"Nicotine patch & placebo",{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9203,"PHASE3":9205,"PHASE4":9207,"NA":9209},{"trials":9200,"activeCount":101},[],{"trials":9202,"activeCount":101},[],{"trials":9204,"activeCount":101},[],{"trials":9206,"activeCount":101},[],{"trials":9208,"activeCount":101},[],{"trials":9210,"activeCount":101},[9211],{"nctId":9212,"briefTitle":9213,"status":158,"phases":9214,"primaryCompletion":4895,"completion":4895,"start":8546,"enrollment":6484,"conditions":9215,"interventions":9217},"NCT02420327","Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine",[93],[9216],"Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor",[9197,9218],"Nicotine patch and galantamine",{"intervention":9218,"totalTrials":204,"cells":9220},{"EARLY_PHASE1":9221,"PHASE1":9223,"PHASE2":9225,"PHASE3":9227,"PHASE4":9229,"NA":9231},{"trials":9222,"activeCount":101},[],{"trials":9224,"activeCount":101},[],{"trials":9226,"activeCount":101},[],{"trials":9228,"activeCount":101},[],{"trials":9230,"activeCount":101},[],{"trials":9232,"activeCount":101},[9233],{"nctId":9212,"briefTitle":9213,"status":158,"phases":9234,"primaryCompletion":4895,"completion":4895,"start":8546,"enrollment":6484,"conditions":9235,"interventions":9236},[93],[9216],[9197,9218],{"intervention":9238,"totalTrials":204,"cells":9239},"Raltegravir and Maraviroc in combination",{"EARLY_PHASE1":9240,"PHASE1":9242,"PHASE2":9244,"PHASE3":9246,"PHASE4":9248,"NA":9250},{"trials":9241,"activeCount":101},[],{"trials":9243,"activeCount":101},[],{"trials":9245,"activeCount":101},[],{"trials":9247,"activeCount":101},[],{"trials":9249,"activeCount":101},[],{"trials":9251,"activeCount":101},[9252],{"nctId":9253,"briefTitle":9254,"status":158,"phases":9255,"primaryCompletion":9256,"completion":9256,"start":8394,"enrollment":1107,"conditions":9257,"interventions":9258},"NCT01204905","R5 Integrase Study in HIV-1 Naive Patients",[93],"2014-05-16",[3515],[9238],{"intervention":9260,"totalTrials":204,"cells":9261},"REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group",{"EARLY_PHASE1":9262,"PHASE1":9264,"PHASE2":9266,"PHASE3":9268,"PHASE4":9270,"NA":9272},{"trials":9263,"activeCount":101},[],{"trials":9265,"activeCount":101},[],{"trials":9267,"activeCount":101},[],{"trials":9269,"activeCount":101},[],{"trials":9271,"activeCount":101},[],{"trials":9273,"activeCount":101},[9274],{"nctId":9275,"briefTitle":9276,"status":158,"phases":9277,"primaryCompletion":9278,"completion":9279,"start":9280,"enrollment":726,"conditions":9281,"interventions":9282},"NCT05854485","Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke",[93],"2025-05-30","2025-06-30","2023-09-06",[1333],[9260,9283],"Robot only group",{"intervention":9283,"totalTrials":204,"cells":9285},{"EARLY_PHASE1":9286,"PHASE1":9288,"PHASE2":9290,"PHASE3":9292,"PHASE4":9294,"NA":9296},{"trials":9287,"activeCount":101},[],{"trials":9289,"activeCount":101},[],{"trials":9291,"activeCount":101},[],{"trials":9293,"activeCount":101},[],{"trials":9295,"activeCount":101},[],{"trials":9297,"activeCount":101},[9298],{"nctId":9275,"briefTitle":9276,"status":158,"phases":9299,"primaryCompletion":9278,"completion":9279,"start":9280,"enrollment":726,"conditions":9300,"interventions":9301},[93],[1333],[9260,9283],{"intervention":9303,"totalTrials":204,"cells":9304},"Anti-TNF",{"EARLY_PHASE1":9305,"PHASE1":9307,"PHASE2":9309,"PHASE3":9311,"PHASE4":9313,"NA":9315},{"trials":9306,"activeCount":101},[],{"trials":9308,"activeCount":101},[],{"trials":9310,"activeCount":101},[],{"trials":9312,"activeCount":101},[],{"trials":9314,"activeCount":101},[],{"trials":9316,"activeCount":101},[9317],{"nctId":9318,"briefTitle":9319,"status":158,"phases":9320,"primaryCompletion":9321,"completion":7848,"start":9322,"enrollment":1176,"conditions":9323,"interventions":9326},"NCT02619552","Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease",[],"2018-06","2011-08",[9324,9325],"Crohn's Disease","IBD",[9303,9303,9327],"Steroids",{"intervention":9327,"totalTrials":204,"cells":9329},{"EARLY_PHASE1":9330,"PHASE1":9332,"PHASE2":9334,"PHASE3":9336,"PHASE4":9338,"NA":9340},{"trials":9331,"activeCount":101},[],{"trials":9333,"activeCount":101},[],{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[],{"trials":9341,"activeCount":101},[9342],{"nctId":9318,"briefTitle":9319,"status":158,"phases":9343,"primaryCompletion":9321,"completion":7848,"start":9322,"enrollment":1176,"conditions":9344,"interventions":9345},[],[9324,9325],[9303,9303,9327],{"intervention":9347,"totalTrials":204,"cells":9348},"Paliperidone",{"EARLY_PHASE1":9349,"PHASE1":9351,"PHASE2":9353,"PHASE3":9355,"PHASE4":9357,"NA":9359},{"trials":9350,"activeCount":101},[],{"trials":9352,"activeCount":101},[],{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[],{"trials":9360,"activeCount":101},[9361],{"nctId":9362,"briefTitle":9363,"status":733,"phases":9364,"primaryCompletion":3100,"completion":3100,"start":3100,"enrollment":101,"conditions":9365,"interventions":9366},"NCT01584466","Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study",[93],[16],[9347],{"intervention":9368,"totalTrials":204,"cells":9369},"Skin Prep Chlorhexidine",{"EARLY_PHASE1":9370,"PHASE1":9372,"PHASE2":9374,"PHASE3":9376,"PHASE4":9378,"NA":9380},{"trials":9371,"activeCount":101},[],{"trials":9373,"activeCount":101},[],{"trials":9375,"activeCount":101},[],{"trials":9377,"activeCount":101},[],{"trials":9379,"activeCount":101},[],{"trials":9381,"activeCount":101},[9382],{"nctId":9383,"briefTitle":9384,"status":158,"phases":9385,"primaryCompletion":7463,"completion":7463,"start":4907,"enrollment":9386,"conditions":9387,"interventions":9389},"NCT02510144","Skin Prep to Reduce Postoperative Shoulder Infection",[93],80,[9388],"Shoulder Infection",[9368,9390],"Skin Prep Benzoyl Peroxide",{"intervention":9390,"totalTrials":204,"cells":9392},{"EARLY_PHASE1":9393,"PHASE1":9395,"PHASE2":9397,"PHASE3":9399,"PHASE4":9401,"NA":9403},{"trials":9394,"activeCount":101},[],{"trials":9396,"activeCount":101},[],{"trials":9398,"activeCount":101},[],{"trials":9400,"activeCount":101},[],{"trials":9402,"activeCount":101},[],{"trials":9404,"activeCount":101},[9405],{"nctId":9383,"briefTitle":9384,"status":158,"phases":9406,"primaryCompletion":7463,"completion":7463,"start":4907,"enrollment":9386,"conditions":9407,"interventions":9408},[93],[9388],[9368,9390],{"intervention":9410,"totalTrials":204,"cells":9411},"Lopinavir\u002FRitonavir",{"EARLY_PHASE1":9412,"PHASE1":9414,"PHASE2":9416,"PHASE3":9418,"PHASE4":9420,"NA":9422},{"trials":9413,"activeCount":101},[],{"trials":9415,"activeCount":101},[],{"trials":9417,"activeCount":101},[],{"trials":9419,"activeCount":101},[],{"trials":9421,"activeCount":101},[],{"trials":9423,"activeCount":101},[9424],{"nctId":9425,"briefTitle":9426,"status":223,"phases":9427,"primaryCompletion":8438,"completion":9428,"start":3028,"enrollment":97,"conditions":9429,"interventions":9430},"NCT00344487","Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study",[93],"2009-09",[28],[9410],{"intervention":9432,"totalTrials":204,"cells":9433},"6 months of SAT",{"EARLY_PHASE1":9434,"PHASE1":9436,"PHASE2":9438,"PHASE3":9440,"PHASE4":9442,"NA":9444},{"trials":9435,"activeCount":101},[],{"trials":9437,"activeCount":101},[],{"trials":9439,"activeCount":101},[],{"trials":9441,"activeCount":101},[],{"trials":9443,"activeCount":101},[],{"trials":9445,"activeCount":101},[9446],{"nctId":9447,"briefTitle":9448,"status":733,"phases":9449,"primaryCompletion":252,"completion":1282,"start":9450,"enrollment":101,"conditions":9451,"interventions":9454},"NCT05495815","Proper Duration of Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention",[93],"2024-12",[9452,9453],"Periprosthetic Joint Infection","Antibiotic Suppression",[9432,9455,9456],"12 months of SAT","Indefinite SAT",{"intervention":9455,"totalTrials":204,"cells":9458},{"EARLY_PHASE1":9459,"PHASE1":9461,"PHASE2":9463,"PHASE3":9465,"PHASE4":9467,"NA":9469},{"trials":9460,"activeCount":101},[],{"trials":9462,"activeCount":101},[],{"trials":9464,"activeCount":101},[],{"trials":9466,"activeCount":101},[],{"trials":9468,"activeCount":101},[],{"trials":9470,"activeCount":101},[9471],{"nctId":9447,"briefTitle":9448,"status":733,"phases":9472,"primaryCompletion":252,"completion":1282,"start":9450,"enrollment":101,"conditions":9473,"interventions":9474},[93],[9452,9453],[9432,9455,9456],{"intervention":9456,"totalTrials":204,"cells":9476},{"EARLY_PHASE1":9477,"PHASE1":9479,"PHASE2":9481,"PHASE3":9483,"PHASE4":9485,"NA":9487},{"trials":9478,"activeCount":101},[],{"trials":9480,"activeCount":101},[],{"trials":9482,"activeCount":101},[],{"trials":9484,"activeCount":101},[],{"trials":9486,"activeCount":101},[],{"trials":9488,"activeCount":101},[9489],{"nctId":9447,"briefTitle":9448,"status":733,"phases":9490,"primaryCompletion":252,"completion":1282,"start":9450,"enrollment":101,"conditions":9491,"interventions":9492},[93],[9452,9453],[9432,9455,9456],{"intervention":9494,"totalTrials":204,"cells":9495},"Pramlintide acetate",{"EARLY_PHASE1":9496,"PHASE1":9498,"PHASE2":9500,"PHASE3":9502,"PHASE4":9504,"NA":9506},{"trials":9497,"activeCount":101},[],{"trials":9499,"activeCount":101},[],{"trials":9501,"activeCount":101},[],{"trials":9503,"activeCount":101},[],{"trials":9505,"activeCount":101},[],{"trials":9507,"activeCount":101},[9508],{"nctId":9509,"briefTitle":9510,"status":733,"phases":9511,"primaryCompletion":161,"completion":161,"start":2525,"enrollment":101,"conditions":9512,"interventions":9513},"NCT00732147","Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM",[93],[6552],[9494],{"intervention":9515,"totalTrials":204,"cells":9516},"CBSST + Oxytocin",{"EARLY_PHASE1":9517,"PHASE1":9519,"PHASE2":9521,"PHASE3":9523,"PHASE4":9525,"NA":9527},{"trials":9518,"activeCount":101},[],{"trials":9520,"activeCount":101},[],{"trials":9522,"activeCount":101},[],{"trials":9524,"activeCount":101},[],{"trials":9526,"activeCount":101},[],{"trials":9528,"activeCount":101},[9529],{"nctId":9530,"briefTitle":9531,"status":158,"phases":9532,"primaryCompletion":2749,"completion":2749,"start":3100,"enrollment":9533,"conditions":9534,"interventions":9535},"NCT01752712","Oxytocin and CBSST for People With Schizophrenia",[93],83,[16,19],[9515,9536],"CBSST + Placebo",{"intervention":9536,"totalTrials":204,"cells":9538},{"EARLY_PHASE1":9539,"PHASE1":9541,"PHASE2":9543,"PHASE3":9545,"PHASE4":9547,"NA":9549},{"trials":9540,"activeCount":101},[],{"trials":9542,"activeCount":101},[],{"trials":9544,"activeCount":101},[],{"trials":9546,"activeCount":101},[],{"trials":9548,"activeCount":101},[],{"trials":9550,"activeCount":101},[9551],{"nctId":9530,"briefTitle":9531,"status":158,"phases":9552,"primaryCompletion":2749,"completion":2749,"start":3100,"enrollment":9533,"conditions":9553,"interventions":9554},[93],[16,19],[9515,9536],{"intervention":9556,"totalTrials":204,"cells":9557},"123I-metaiodobenzylguanidine",{"EARLY_PHASE1":9558,"PHASE1":9560,"PHASE2":9562,"PHASE3":9564,"PHASE4":9566,"NA":9568},{"trials":9559,"activeCount":101},[],{"trials":9561,"activeCount":101},[],{"trials":9563,"activeCount":101},[],{"trials":9565,"activeCount":101},[],{"trials":9567,"activeCount":101},[],{"trials":9569,"activeCount":101},[9570],{"nctId":9571,"briefTitle":9572,"status":158,"phases":9573,"primaryCompletion":7848,"completion":7848,"start":4827,"enrollment":679,"conditions":9574,"interventions":9577},"NCT01250912","Imaging With a Radio Tracer to Guide VT Ablations",[93],[9575,9576],"Ventricular Tachycardia","Arrhythmia",[9556],{"intervention":9579,"totalTrials":204,"cells":9580},"Human recombinant growth hormone",{"EARLY_PHASE1":9581,"PHASE1":9583,"PHASE2":9585,"PHASE3":9587,"PHASE4":9589,"NA":9591},{"trials":9582,"activeCount":101},[],{"trials":9584,"activeCount":101},[],{"trials":9586,"activeCount":101},[],{"trials":9588,"activeCount":101},[],{"trials":9590,"activeCount":101},[],{"trials":9592,"activeCount":101},[9593],{"nctId":9594,"briefTitle":9595,"status":733,"phases":9596,"primaryCompletion":4972,"completion":4972,"start":9597,"enrollment":101,"conditions":9598,"interventions":9600},"NCT01614171","Growth Hormone for Osteoporosis Pseudoglioma Syndrome",[93],"2013-12",[9599],"Osteoporosis Pseudoglioma Syndrome",[9579],{"intervention":9602,"totalTrials":204,"cells":9603},"salsalate",{"EARLY_PHASE1":9604,"PHASE1":9606,"PHASE2":9608,"PHASE3":9610,"PHASE4":9612,"NA":9614},{"trials":9605,"activeCount":101},[],{"trials":9607,"activeCount":101},[],{"trials":9609,"activeCount":101},[],{"trials":9611,"activeCount":101},[],{"trials":9613,"activeCount":101},[],{"trials":9615,"activeCount":101},[9616],{"nctId":9617,"briefTitle":9618,"status":158,"phases":9619,"primaryCompletion":3664,"completion":8437,"start":9620,"enrollment":23,"conditions":9621,"interventions":9622},"NCT01182727","Salsalate for Insulin Resistance in Schizophrenia",[93],"2010-08",[16,4974],[9602],{"intervention":9624,"totalTrials":204,"cells":9625},"Darbepoetin alfa",{"EARLY_PHASE1":9626,"PHASE1":9628,"PHASE2":9630,"PHASE3":9632,"PHASE4":9634,"NA":9636},{"trials":9627,"activeCount":101},[],{"trials":9629,"activeCount":101},[],{"trials":9631,"activeCount":101},[],{"trials":9633,"activeCount":101},[],{"trials":9635,"activeCount":101},[],{"trials":9637,"activeCount":101},[9638],{"nctId":9639,"briefTitle":9640,"status":158,"phases":9641,"primaryCompletion":6637,"completion":6637,"start":5700,"enrollment":679,"conditions":9642,"interventions":9644},"NCT00883415","Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease",[],[3491,9643,2272],"Chronic Kidney Disease",[9624],{"intervention":9646,"totalTrials":204,"cells":9647},"IV fluid repletion",{"EARLY_PHASE1":9648,"PHASE1":9650,"PHASE2":9652,"PHASE3":9654,"PHASE4":9656,"NA":9658},{"trials":9649,"activeCount":101},[],{"trials":9651,"activeCount":101},[],{"trials":9653,"activeCount":101},[],{"trials":9655,"activeCount":101},[],{"trials":9657,"activeCount":101},[],{"trials":9659,"activeCount":101},[9660],{"nctId":9661,"briefTitle":9662,"status":158,"phases":9663,"primaryCompletion":820,"completion":820,"start":5775,"enrollment":1597,"conditions":9664,"interventions":9666},"NCT02930044","Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis",[93],[9665],"Diabetic Ketoacidosis",[9646],{"intervention":9668,"totalTrials":204,"cells":9669},"Pioglitazone",{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9676,"PHASE4":9678,"NA":9680},{"trials":9671,"activeCount":101},[],{"trials":9673,"activeCount":101},[],{"trials":9675,"activeCount":101},[],{"trials":9677,"activeCount":101},[],{"trials":9679,"activeCount":101},[],{"trials":9681,"activeCount":101},[9682],{"nctId":9683,"briefTitle":9684,"status":158,"phases":9685,"primaryCompletion":9686,"completion":9686,"start":5990,"enrollment":9687,"conditions":9688,"interventions":9689},"NCT01135394","Pharmacogenomics of Thiazolidinediones",[93],"2018-05-31",114,[6552],[9668],{"intervention":9691,"totalTrials":204,"cells":9692},"probenecid",{"EARLY_PHASE1":9693,"PHASE1":9695,"PHASE2":9697,"PHASE3":9699,"PHASE4":9701,"NA":9703},{"trials":9694,"activeCount":101},[],{"trials":9696,"activeCount":101},[],{"trials":9698,"activeCount":101},[],{"trials":9700,"activeCount":101},[],{"trials":9702,"activeCount":101},[],{"trials":9704,"activeCount":101},[9705],{"nctId":9706,"briefTitle":9707,"status":158,"phases":9708,"primaryCompletion":5262,"completion":7130,"start":9191,"enrollment":31,"conditions":9709,"interventions":9711},"NCT00690014","Evaluation of Renal Drug Transport in Healthy Volunteers",[93],[9710],"Kidney Disease",[9691],{"intervention":8693,"totalTrials":204,"cells":9713},{"EARLY_PHASE1":9714,"PHASE1":9716,"PHASE2":9718,"PHASE3":9720,"PHASE4":9722,"NA":9724},{"trials":9715,"activeCount":101},[],{"trials":9717,"activeCount":101},[],{"trials":9719,"activeCount":101},[],{"trials":9721,"activeCount":101},[],{"trials":9723,"activeCount":101},[],{"trials":9725,"activeCount":101},[9726],{"nctId":8687,"briefTitle":8688,"status":223,"phases":9727,"primaryCompletion":6186,"completion":6186,"start":3077,"enrollment":659,"conditions":9728,"interventions":9729},[93],[8691],[8693,8694],{"intervention":9731,"totalTrials":204,"cells":9732},"Clozapine",{"EARLY_PHASE1":9733,"PHASE1":9735,"PHASE2":9737,"PHASE3":9739,"PHASE4":9741,"NA":9743},{"trials":9734,"activeCount":101},[],{"trials":9736,"activeCount":101},[],{"trials":9738,"activeCount":101},[],{"trials":9740,"activeCount":101},[],{"trials":9742,"activeCount":101},[],{"trials":9744,"activeCount":101},[9745],{"nctId":9746,"briefTitle":9747,"status":158,"phases":9748,"primaryCompletion":9749,"completion":9749,"start":8238,"enrollment":9750,"conditions":9751,"interventions":9752},"NCT02404155","Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)",[93],"2021-10-26",274,[16],[9731],{"intervention":9754,"totalTrials":204,"cells":9755},"Daptomycin 6mg\u002Fkg\u002Fday",{"EARLY_PHASE1":9756,"PHASE1":9758,"PHASE2":9760,"PHASE3":9762,"PHASE4":9764,"NA":9766},{"trials":9757,"activeCount":101},[],{"trials":9759,"activeCount":101},[],{"trials":9761,"activeCount":101},[],{"trials":9763,"activeCount":101},[],{"trials":9765,"activeCount":101},[],{"trials":9767,"activeCount":101},[9768],{"nctId":9769,"briefTitle":9770,"status":158,"phases":9771,"primaryCompletion":5700,"completion":5700,"start":9772,"enrollment":253,"conditions":9773,"interventions":9777},"NCT00261807","Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections",[93],"2005-06",[9774,9775,9776],"Fasciitis, Necrotizing","Severe Necrotizing Skin and Soft Tissue Infections","Fournier's Gangrene",[9754],{"intervention":9779,"totalTrials":204,"cells":9780},"Optimal Medical Therapy",{"EARLY_PHASE1":9781,"PHASE1":9783,"PHASE2":9785,"PHASE3":9787,"PHASE4":9789,"NA":9791},{"trials":9782,"activeCount":101},[],{"trials":9784,"activeCount":101},[],{"trials":9786,"activeCount":101},[],{"trials":9788,"activeCount":101},[],{"trials":9790,"activeCount":101},[],{"trials":9792,"activeCount":101},[9793],{"nctId":9794,"briefTitle":9795,"status":158,"phases":9796,"primaryCompletion":8340,"completion":8340,"start":1485,"enrollment":4389,"conditions":9797,"interventions":9799},"NCT00119847","Electrophysiological Effects of Late PCI After MI",[93],[33,2402,3422,2403,9576,9798],"Ventricular Fibrillation",[9779],{"intervention":9801,"totalTrials":204,"cells":9802},"Norepinephrine",{"EARLY_PHASE1":9803,"PHASE1":9805,"PHASE2":9807,"PHASE3":9809,"PHASE4":9811,"NA":9813},{"trials":9804,"activeCount":101},[],{"trials":9806,"activeCount":101},[],{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[],{"trials":9812,"activeCount":101},[],{"trials":9814,"activeCount":101},[9815],{"nctId":9816,"briefTitle":9817,"status":158,"phases":9818,"primaryCompletion":9819,"completion":1433,"start":9820,"enrollment":9821,"conditions":9822,"interventions":9826},"NCT04497155","Prehospital Norepinephrine and Early Mortality in Traumatic Shock",[],"2018-12-31","2013-01-01",2164,[9823,9824,35,9825],"Traumatic Shock","Hemorrhagic Shock","Hypotension and Shock",[9801],{"intervention":8479,"totalTrials":204,"cells":9828},{"EARLY_PHASE1":9829,"PHASE1":9831,"PHASE2":9833,"PHASE3":9835,"PHASE4":9837,"NA":9839},{"trials":9830,"activeCount":101},[],{"trials":9832,"activeCount":101},[],{"trials":9834,"activeCount":101},[],{"trials":9836,"activeCount":101},[],{"trials":9838,"activeCount":101},[],{"trials":9840,"activeCount":101},[9841],{"nctId":8471,"briefTitle":8472,"status":733,"phases":9842,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":101,"conditions":9843,"interventions":9844},[93],[8477],[7180,8479,8480],{"intervention":8480,"totalTrials":204,"cells":9846},{"EARLY_PHASE1":9847,"PHASE1":9849,"PHASE2":9851,"PHASE3":9853,"PHASE4":9855,"NA":9857},{"trials":9848,"activeCount":101},[],{"trials":9850,"activeCount":101},[],{"trials":9852,"activeCount":101},[],{"trials":9854,"activeCount":101},[],{"trials":9856,"activeCount":101},[],{"trials":9858,"activeCount":101},[9859],{"nctId":8471,"briefTitle":8472,"status":733,"phases":9860,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":101,"conditions":9861,"interventions":9862},[93],[8477],[7180,8479,8480],{"intervention":9864,"totalTrials":204,"cells":9865},"Lithium",{"EARLY_PHASE1":9866,"PHASE1":9868,"PHASE2":9870,"PHASE3":9872,"PHASE4":9874,"NA":9876},{"trials":9867,"activeCount":101},[],{"trials":9869,"activeCount":101},[],{"trials":9871,"activeCount":101},[],{"trials":9873,"activeCount":101},[],{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[9878],{"nctId":9879,"briefTitle":9880,"status":158,"phases":9881,"primaryCompletion":2524,"completion":2524,"start":5261,"enrollment":3234,"conditions":9882,"interventions":9884},"NCT01108068","Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome",[93],[9883],"Osteoporosis Pseudoglioma",[9864],{"intervention":8312,"totalTrials":204,"cells":9886},{"EARLY_PHASE1":9887,"PHASE1":9889,"PHASE2":9891,"PHASE3":9893,"PHASE4":9895,"NA":9897},{"trials":9888,"activeCount":101},[],{"trials":9890,"activeCount":101},[],{"trials":9892,"activeCount":101},[],{"trials":9894,"activeCount":101},[],{"trials":9896,"activeCount":101},[],{"trials":9898,"activeCount":101},[9899],{"nctId":8306,"briefTitle":8307,"status":158,"phases":9900,"primaryCompletion":746,"completion":746,"start":5261,"enrollment":1597,"conditions":9901,"interventions":9902},[93],[8310],[2393,8312]]